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Abstract 
The human body defends itself from pathogen infections through very complicated 
processes. They include host innate, adaptive and cellular intrinsic immunities. Host innate 
and adaptive immunities have been studied extensively in past decades, and more detail is 
being continuously revealed to us. Cellular intrinsic immunity has been recognised in more 
recent decades and has attracted great interest among researchers. Many cellular proteins 
have been identified to repress viral infections such as HIV, Influenza and Herpes Viruses. 
One aspect of intrinsic immunity, or intrinsic resistance, to herpes virus infections was 
demonstrated to involve nuclear structures known as ND10 (nuclear domain 10). With 
accumulating evidence about ND10, many components of ND10 that are involved in 
intrinsic immunity were identified. In the early stage of infection, HSV-1 and HCMV 
genomes become associated with ND10 components, which include PML, Sp100 and the 
hDaxx-ATRX complex. All these proteins were identified to repress HSV-1 and HCMV 
infection and replication. Viral proteins that have been identified to interact with PML, 
Sp100 and the hDaxx-ATRX complex and that counteract their anti-viral activities include 
ICP0 from HSV-1 and IE1 and pp71 from HCMV. Furthermore, recently studies on EBV 
proteins identified BNRF1 to interact with the hDaxx-ATRX complex, while EBNA1 
appears to down regulate PML and EBNA-LP is involved in Sp100 dispersion from ND10. 
The evidence above raises the possibility that ND10 interacting proteins from different 
herpes viruses may be functionally interchangeable. 
IE1 interacts with ND10 to de-sumoylate and disperse PML and Sp100. There is also 
evidence of interaction between IE1 and hDaxx complex. pp71 was demonstrated to 
interact with and promote the degradation of hDaxx, and to disrupt the hDaxx-ATRX 
complex to stimulate HCMV infection and replication. For HSV-1, ICP0 was identified to 
degrade PML and Sp100, and counteract the effects of the hDaxx-ATRX complex on viral 
infection repression. Therefore, IE1 and pp71 were analysed for their ability to 
complement ICP0 null HSV-1, and they were demonstrated to stimulate ICP0 null HSV-1 
infection to a large extent. In this study, the reverse investigation was analysed. To extend 
the study, EBV proteins that interact with ND10 were also analysed in stimulating HSV-1 
and HCMV mutant viruses.  
The major findings in this thesis are summarised as follows: 
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1. IE1 and pp71 can separately and cooperatively stimulate ICP0 null HSV-1 
infection in HepaRG cells and human fibroblasts. 
2. The expression of IE1 and ICP0 in human fibroblasts can increase wt HCMV 
infection. 
3. ICP0 can complement pp71 null HCMV infection but not IE1 null HCMV. 
4. Two sequences that are essential for IE1 functions were identified and one IE1 
sequence was identified to be HCMV specific on promoting viral infection and 
replication. 
5. EBV proteins that interact with ND10 can stimulate ICP0 null HSV-1 and pp71 
null HCMV infection. 
The data in this thesis demonstrated that the combination of IE1 and pp71 is 
interchangeable with ICP0 in HSV-1 infection and EBV proteins that interact with 
ND10 partially complement ICP0 null HSV-1 infection. The results indicated that the 
integrity of ND10 is an important part of cellular intrinsic resistance to HSV-1 
infection. The observation on ICP0 complementing IE1 deletion HCMV indicated the 
HCMV specific role of IE1. ICP0, BNRF1 and pp71 are all involved in counteracting 
the hDaxx-ATRX complex repression on viral infection and replication. These three 
proteins were demonstrated to complement ICP0 null HSV-1 and pp71 null HCMV 
infection, which indicates the importance of the hDaxx-ATRX complex on repressing 
herpes viruses infection. Even though solid data in this thesis has confirmed the ND10 
repression on herpes virus infection and the herpes viruses from different subfamilies 
counteracting this repression through different viral proteins, more detail about this 
intrinsic resistance mechanisms still require extensive investigation. 
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1 Introduction 
Viruses are small infectious agents that can only replicate inside the living cells of hosts. 
Virus can infect all kinds of organisms, from animals and plants to bacteria and archaea. 
Viruses cause many kinds of human diseases, from colds, chickenpox and influenza to 
AIDS, hepatitis, SARS and several forms of cancer. Within the evolution process, 
organisms have developed a series of defence systems to prevent virus infections, 
including the innate immune system, the adaptive immune system and intrinsic anti-viral 
defences. The innate and adaptive immune systems have been well studied for many years. 
In contrast, the intrinsic anti-viral defence is a relatively recent concept and less is known 
about its function in the process of defence to virus infection. This thesis concentrates on 
HSV-1 (Herpes Simplex Virus type 1) and HCMV (Human Cytomegalovirus) infection, 
investigating the role of cellular nuclear sub-structures known as ND10 or PML nuclear 
bodies in the mechanism of intrinsic anti-viral defence. General reviews of many relevant 
aspects of these viruses can be found in (Knipe et al., 2006; Reddehase, 2013; Weller, 
2011). 
1.1 Herpesviridae family 
Herpesviridae are a large DNA virus family that cause diseases in mammals, birds, 
reptiles, amphibians, marine molluscs and fish. Eight human herpes viruses are identified 
currently, which are Herpes Simplex Virus type 1 (HSV-1), Herpes Simplex Virus type 2 
(HSV-2), Varicella Zoster Virus (VZV), Epstein Barr virus (EBV), Human 
Cytomegalovirus (HCMV), Human Herpesvirus type 6 (HHV-6), Human Herpesvirus type 
7 (HHV-7) and Kaposi's sarcoma herpesvirus (KSHV). Herpesviridae family includes 
three subfamilies, the Alphaherpesvirinae, the Betaherpesvirinae and the 
Gammaherpesvirinae. HSV-1 belongs to the  Alphaherpesvirinae, and it is neurotropic and 
establishes latency in neuronal ganglia. HCMV is included in the Betaherpesvirinae, and 
establishes latency in peripheral blood monocytes. Replication of HCMV is slow in cell 
culture and is restricted to a limited number of cell lines. EBV is a member of the 
Gammaherpesvirinae that has infected more than 90% of the population over the world. It 
infects and establishes latency in lymphocytes. HSV-1, HCMV and EBV share many 
properties such as gene expression strategy and host cell interaction targets (such as ND10) 
and some of these similarities will be investigated in this thesis. 
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1.1.1 Alphaherpesvirinae 
The herpes viruses in Alphaherpesvirinae replicate and reproduce more quickly than 
members of the other two subfamilies. Alphaherpesvirinae family members infect humans 
and animals such as pigs, bovines, horses, cats, chickens and turkeys. The 
alphaherpesviruses are further divided into four subfamilies, which are Simplexvirus, 
Varicellovirus, Mardivirus and Iltovirus. HSV-1, HSV-2 and VZV (also known as HHV-1, 
HHV-2 and HHV-3) are well studied human herpes viruses from the Alphaherpesvirinae. 
HSV-1 is one of the most comprehensively studied of the herpes viruses in Herpesviridae. 
HSV-1 infection in human is separated into latent and lytic stages. The primary infection 
of HSV-1 occurs in epithelial cells and keratinocytes at mucocutaneous sites including the 
mouth, eyes, and genitalia (Szostecki et al., 1990). Viral genome hides in sensory and 
autonomic ganglia of the nervous system to establish latent infections, which only express 
several latency related untranslated transcripts  without virus production (reviewed in 
(Bloom & Kwiatkowski, 2011; Efstathiou & Preston, 2005; Nicoll et al., 2012)).As 
described in more detail later, HSV-1 immediate early protein ICP0 was identified as an 
important protein in activating viral gene expression during lytic and latent infection 
(Everett, 1984; Gordon et al., 1990; Natarajan et al., 1991; Sacks & Schaffer, 1987; Stow 
& Stow, 1986). It has been extensively studied for its effects on cellular intrinsic resistance 
and virus-host interactions (reviewed in (Everett, 2011) and it was studied in different 
aspects in this thesis. 
1.1.2 Betaherpesvirinae 
One factor which distinguishes the members of the Betaherpesvirinae from other herpes 
virus family members is their slow reproduction time, at least in cultured cells. Members in 
this subfamily are further divided into Cytomegalovirus, Muromegalovirus, Proboscivirus 
and Roseolovirus. Betaherpesviruses infect humans, and animals including rats, elephants, 
African green monkeys, Rhesus monkeys, Chimpanzees, Orangutans and Night monkeys. 
They establish latency infection mostly in monocytes, which is different to 
Alphaherpesvirinae and Gammaherpesvirinae. Four members of the Betaherpesvirinae 
infect humans, they are Human cytomegalovirus (HCMV also known as human 
herpesvirus 5, HHV-5), Human herpesvirus 6A and 6B (HHV-6A and HHV-6B) and 
Human herpes virus 7 (HHV-7). In this thesis, two important proteins, IE1 and pp71, from 
HCMV were studied to contribute more detail about their roles in evading intrinsic 
resistance to HCMV infection.   
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1.1.3 Gammaherpesvirinae 
Gammaherpesvirinae reproduce at a variable rate compared to the other two subfamilies of 
Herpesviridae and viral infections in humans are mainly established in lymphocyte cells. 
The molecular phylogenetic analyses confirmed the close similarity of those viruses and 
distinguished this subfamily from Alpha and Beta herpesviruses. The Gammaherpesvirinae 
family is further divided into four genera, which are Lymphocryptovirus, Rhadinovirus, 
Macavirus and Percavirus. EBV (also known as HHV-4)  is a member of 
Lymphocryptovirus, and KSHV (also known as HHV-8)  is a member of Rhadinovirus. 
They are two viruses from Gammaherpesvirinae that can cause severe infections in 
humans and have attracted primary interest of scientists. Three EBV proteins, which are 
EBNA-1, BNRF1 and EBNA-LP, were studied in this thesis for their interactions with 
ND10 and their abilities to substitute for the functions of other viral proteins during HSV-1 
and HCMV infection.  
1.2 The virus particle structure of the Herpesviridae 
A typical Herpesviridae infectious virion particle includes the lipid bilayer envelope, 
tegument, capsid and double-stranded DNA (dsDNA) from the very outside to inside 
(Figure 1.1). The double stranded (ds) DNA inside the virion encodes the information for 
virus replication. Intracellular capsids can be found in three forms, A-capsids, which are 
empty, B-capsids that contain scaffolding proteins but no DNA, and C-capsids, which 
contain viral dsDNA. The tegument is between the inner surface of the lipid bilayer 
envelope and the outer surface of the capsid. The lipid in the envelope is host-cell derived 
and contains viral glycoproteins. 
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Figure 1.1 General structure of herpesvirus infectious virion particle. 
 
1.2.1 Virus genome structure of the Herpesviridae 
Herpesviridae genomes vary in size from the smallest at 124 kbp (Simian Varicella Virus) 
to the largest at 295 kbp (Koi Herpesvirus). The genomes of HSV-1 and HCMV are 152 
kbp and 235 kbp respectively. The genome structures of HSV-1 and HCMV have similar 
arrangements, consisting of the unique long (UL) region, the unique short (US) region, the 
terminal repeat long regions (TRL and IRL) and the terminal repeat short regions (TRS and 
IRS). At the 3’ and 5’ termini, and at the junction between the internal repeats (IRL and 
IRS), an additional repeat element the ‘a’ sequence is found. The ‘a’ sequence provides 
signals for cleavage and packaging of the replicated genomes. The arrangement of the 
different regions in HSV-1 and HCMV genomes is shown in Figure 1.2.  
 
 
Glycoprotein 
Lipid bilayer envelope 
Tegument 
Capsid 
Virus dsDNA genome 
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Figure 1.2 The similar Genome organization of HSV-1 and HCMV. 
The EBV genome structure is different to that of HSV-1 and HCMV (Straus et al., 1993). 
It consists of about 172000 base pairs of dsDNA organized in U1 to 5, IR1 to 4, and two 
TR regions (Figure 1.3). 
 
Figure 1.3 The Genome organization of EBV. 
Figure is taken from (Straus et al., 1993) 
1.2.2 Capsid 
Capsid-like structures were first observed in HSV-1 infected cells and further classified 
into A-, B-, and C-capsids (Gibson & Roizman, 1972). Later on, similar capsid structures 
were observed in HCMV infected cells (Gibson, 1996; Irmiere & Gibson, 1985). More 
recently, in Rhesus monkey rhadinovirus infected cells, the comparable chemical 
composition and structural features of the three types of capsid have been observed, which 
indicates that a similar manner of capsid assembly process may apply to 
gammaherpesvirus (O'Connor et al., 2003; Yu et al., 2003b). Of the three different kinds of 
capsids, A, B and C-capsids, only the C-capsid contains viral DNA (reviewed in (Conway 
& Homa, 2011)). The procapsid, which is another capsid type, has a distinctive spherical 
shape compared to A-, B-, and C-capsids under electron microscope observation (Rixon & 
McNab, 1999; Trus et al., 1996). Procapsids are transiently stable and undergo 
spontaneous structural rearrangement to form the stable polyhedral structure that is 
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characteristic of the other types of capsids (Heymann et al., 2003; Yu et al., 2005; Zhou et 
al., 1998). Capsid assembly starts with the formation of the procapsid in HSV-1. The 
procapsids spontaneously rearrange into particles resembling the B- capsid, which lacks 
the DNA inside of the structure. Proteolytic cleavage of the scaffolding protein and VP26 
recruitment into the capsid structure are required for B-capsid formation (Chi & Wilson, 
2000). Viral genome DNA packaging into the capsid structure is the last step of mature 
capsid formation. This process is believed to arise spontaneously, but, more investigation 
is still required (Yu et al., 2005). The proteins that constitute the outer shell of the HSV-1 
capsid are the major capsid protein (VP5/UL19), virion protein 26 (VP26/UL35), virion 
protein 23 (VP23/UL18) and virion protein 19C (VP19C/UL38) and the portal protein 
UL6. During virion DNA encapsidation, an additional component of HSV-1 premature 
capsid, VP24, functions as a protease which processes the internal capsid scaffold. HCMV 
has a similarly capsid structure. Five virion proteins constitute the HCMV capsid, the 
major capsid protein encoded by UL86, the minor capsid protein, the minor capsid protein 
binding protein, the portal protein (PORT) encoded by UL104 and the smallest capsid 
protein (SCP) encoded by UL48A. 
 
1.2.3 Tegument 
The inner nucleocapsid and the outer envelope are separated by the tegument. This is 
composed of multiple proteins, which enter the host cell along with the capsid, and at least 
some of which regulate early events of the virus infection. Many tegument proteins are 
phosphorylated, but the significance of this and other post-translational modifications to 
these proteins remains largely unexplored.  
The HSV-1 tegument includes at least 26 tegument proteins. Major components include 
VP1/2, VP11/12, VP13/14, VP16, VP22 and the virion-induced host shut-off protein 
(VHS)(Loret et al., 2008; Morrison et al., 1998).ICP0 is also present in the HSV-1 
tegument layer (Delboy et al., 2010; Yao & Courtney, 1992). Among these tegument 
constituents, the most studied are VP16, VP22, VHS and ICP0 (more detail is introduced 
in section 1.6.1.1). VP16 is encoded by UL48, with 490-amino acids in its sequence and an 
acidic C-terminal transcriptional activation domain. The association between VP16 and 
cellular proteins Host Cell Factor (HCF) and Oct-1 activates the Immediate Early (IE) gene 
transcription, and VP16 is also involved in virion assembly.  
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The HCMV tegument structure contains at least 76 tegument proteins and less than half of 
them have been determined and identified (reviewed in (Kalejta, 2008)). Proteins include 
pp65 (UL83), pp71 (UL82), pp150 (UL32) and largest tegument protein (LTP, UL48 gene 
product) . Some HCMV tegument proteins are not essential for virion structure, such as 
pp65 and pp71 (Bresnahan & Shenk, 2000; Reyda et al., 2014), but the deletion of pp71 
impairs the viral infection at low MOI infection (Bresnahan & Shenk, 2000).  
EBV tegument contains BNRF1, BPLF1, BOLF1, BBLF1, BGLF1, BGLF2 and BVRF1. 
BNRF1 was investigated to be one of the most abundant tegument proteins in the EBV 
structure (Johannsen et al., 2004). Although deletion of BNRF1 was initially reported to 
have no significant effect on viral infection and DNA replication (Feederle et al., 2006), 
more recent work has shown that it is important for stimulation of viral gene expression in 
the early stages of lytic infection (Tsai et al., 2011). 
 
1.3 Biology of herpesvirus infections 
1.3.1 Viral attachment and penetration into the host cell 
The entry process of Herpesviridae starts from virus attachment to non-specific cell 
surface molecules such as heparin sulphate, followed by binding to specific cell surface 
receptors, then the virus envelope fuses with the cellular membrane and endocytosis occurs 
(reviewed in (Eisenberg et al., 2011)). Many viral proteins and pathways interact to 
coordinate cellular signals during virus entry. In addition, the entry process can trigger 
multiple cellular processes including nuclear processes to facilitate virus entry or induce 
antiviral responses. HSV-1 entry is mediated by glycoproteins known as gB, gC, gD, gH 
and gL. There are other glycoproteins such as gE, gG, gI and gM that are components of 
the HSV-1 envelope but which are not directly involved in entry. Glycoproteins gB, gD, 
gH and gL are essential for HSV-1 infection in cell culture. Glycoproteins gB and gC bind 
to host cell surface molecules such as heparan sulphate during initial attachment to the host 
cell. The interaction between gD with one of three cellular receptors: herpes virus entry 
mediator (HVEM), nectin-1 or nectin-2, followed by the activity of the gB fusion protein 
and the gH/gI heterodimer, triggers the fusion of viral envelope with the cell membrane. In 
HCMV entry, EGFR, PDGFRαm and avb3 integrin have been proposed as specific 
receptor molecules. However, some study shows EGFR is not expressed on all HCMV-
permissive cell lines that are efficiently infected by HCMV (Compton & Feire, 2007; 
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Wang et al., 2003). The HCMV glycoproteins that are important for virus entry are known 
as gB, gO, gH, gM and gL (Compton & Feire, 2007). 
 
1.3.2 Capsid transport and DNA entry into the nucleus 
Fusion of the viral envelope with the cellular membrane releases the capsid and tegument 
proteins into the cytoplasm. The capsids are then transported on microtubules to the 
nuclear envelope, where they dock at nuclear pores and release the viral genome through 
the pore into the nucleus.  
 
1.3.3 Herpesvirus Gene Expression 
The gene expression of herpesviruses is classified into three stages, which are the 
Immediate-early (IE), Early and Late genes expression. Those viral genes are classified by 
the expression time during virus infection process. IE genes are the first expressed viral 
genes after primary infection on host cells, which is followed by Early gene transcription 
and finally the Late genes expression. IE genes are the only genes expressed when protein 
synthesis is inhibited, while the expression of other viral genes is activated by the products 
of the previously expressed genes, such as the initiation of Early and Late gene expression 
(Figure 1.4).  
 
 
Figure 1.4 Herpesvirus genes expression stimulation. 
IE genes are the first ones transcribed in host cell nucleus, and their products can both 
stimulate viral transcription and gene expression directly, and also inhibit the intrinsic anti-
viral defence of the host cell. The mechanism of IE protein inhibition of intrinsic anti-viral 
defence is introduced in more details in the next paragraphs. IE gene expression is 
followed by early (E) genes, which encode enzymes that are involved in nucleotide 
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metabolism and DNA replication. E genes contain two members, E or β1 genes and 
delayed-early (D-E) or β2 genes, which differ in expression time. The late (L) genes are 
expressed last, which principally encode the virion structural proteins. Two subclasses 
constitute the L genes, the early-late (E-L) or γ1 and true L or  γ2 genes, which divided by 
their strict dependence upon viral DNA replication. 
IE genes expression in HSV-1 is carried out by the host-cell transcription machinery but 
requires activation by the viral tegument protein VP16, which is assembled with cellular 
proteins to form enhancer core complex as illustrated in Figure 1.5 (Preston et al. 1988. 
Cell 52, 425-434.). 
 
 
Figure 1.5 The assemble of VP16 with cellular proteins to form enhancer core complex. 
VP16 in HSV-1 is responsible for the initiation of IE gene expression. Five IE genes are 
transcribed at the immediate early stage. They are distinguished from Early and Late genes 
by specific sequence in the upstream regions of IE promoters termed TAATGARAT 
sequences, which can be recognized by HSV-1 tegument protein VP16. During the primary 
HSV-1 infection, VP16 binds as part of a protein complex that contains two cellular 
factors, the POU-domain transcription factor Oct-1 and the cell-proliferation factor HCF, 
to transcriptionally activate expression of IE genes (Wysocka and Herr, 2003).  
The expression products of HSV-1 IE genes stimulate viral transcription directly (ICP4; 
(DeLuca, 2011)), promote gene expression at the post-transcriptional level (ICP27; 
(Sandri-Goldin, 2011)) and antagonize the intrinsic resistance and transfer the infection 
into the lytic stage (ICP0; (Everett, 2011)).  
HCMV infection is divided into latent and lytic stages as HSV-1. The Lytic infection of 
HCMV is also divided into three phases which are immediate early, early and late 
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(reviewed in (Fortunato & Spector, 1999)). Once the HCMV capsid enters host cells, the 
viral genome will transfer into the nucleus, where viral gene expression is established. 
Initial viral genome expression can be repressed in the nucleus by ND10 components and 
this may contribute to establishment of a latent infection, or HCMV IE genes are expressed 
and the cell enters into lytic infection. The activation of HCMV IE gene expression does 
not require de novo viral protein synthesis, but it depends on tegument protein pp71, which 
is delivered into host cells immediately after infection. Protein pp71 localizes to ND10 and 
interacts with hDaxx (Hofmann et al., 2002), which is a cellular repressor that silences IE 
gene transcription (Woodhall et al., 2006). HCMV IE genes express two important 
proteins, IE1 (IE72) and IE2 (IE86), which are stimulated by the MIEP (major immediate 
early promoter) (Boshart et al., 1985). hDaxx recruits ATRX in the nucleus to form the 
hDaxx-ATRX complex which mediates MIEP repression in the absence of pp71. ATRX is 
dispersed by pp71 prior to hDaxx dispersion (Lukashchuk et al., 2008) and the level of 
hDaxx is down regulated by pp71 (Saffert & Kalejta, 2006). The de-repressed MIEP 
stimulates IE gene transcription, and then IE proteins IE1 and IE2 stimulate the HCMV 
infection into the lytic stage (Figure 1.6). The deletion of pp71 or IE1 can severely impair 
the HCMV infection at low MOI, but this growth defect can be rescued by high MOI 
infection (Bresnahan & Shenk, 2000; Gawn & Greaves, 2002). IE2 deletion abolishes the 
mutant virus replication and infection, and the re-introducing IE2 gene into viral genome 
can rescue this growth defect (Sanders et al., 2008). HCMV early gene expression requires 
previously synthesized IE proteins and cellular proteins. In this stage of infection, early 
gene products are involved in viral replication, preparing the cells for viral DNA 
replication and repression of host immune responses. Late genes of HCMV are stimulated 
by viral genome replication. They encode proteins that assemble and constitute the 
complex virion. HCMV late genes are further divided into two broad classes which are 
leaky-late class genes and ‘true’ late genes. The leaky-late genes are expressed during the 
early stage of infection at a low level and are upregulated at a later stage after viral DNA 
replication has commenced. The ‘true’ late genes are expressed after the early time of 
infection and are highly dependent on viral DNA replication.  
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Figure 1.6 pp71 interacts with hDaxx-ATRX complex to de-repress MIEP. 
As for HSV-1 and HCMV, EBV infection is separated into latent and lytic stages. 
Furthermore, EBV infections on different cell lines exhibit different replication strategies. 
EBV infected epithelia cells always proceed to lytic infection after virus entry, whereas 
EBV infected B cells enter into a latent stage directly without lytic infection. In the latent 
stage, the EBV genome circularizes in the host cell nucleus and is copied by host cell DNA 
polymerase through a mechanism that requires the viral protein known as EBNA1 (Amon 
& Farrell, 2005). Two EBV latent related proteins interact with ND10 members, EBNA1 
and EBNA-LP, which will be investigated in this study. 
1.4 Herpesviruses and human disease 
The Herpesviruses family infects many kinds of species which include mammals, birds, 
reptiles, amphibians, marine molluscs and fish. Viruses from Herpesviruses three sub-
families can infect human cells. These are HSV-1, HSV-2 and VZV from the α-herpesvirus 
family, HCMV, HHV-6A, HHV-6B and HHV-7 from the β-herpesvirus and EBV and 
KSHV from the γ-herpesvirus family (reviewed in (Knipe et al., 2006). Because all these 
herpes viruses establish latent infection in humans, therefore individuals cannot eradicate 
the infection. This ensures the herpes viruses are maintained within infected individuals, 
and can transmit the virus to the individuals around them. In most cases the infections of 
herpes viruses are non-serious and asymptomatic, but they can still cause serious diseases, 
particularly the infection in new born and immunocompromised individuals.  
1.4.1 Alphaherpesviruses and human disease 
HSV-1, HSV-2 and VZV are three important members of the Alphaherpesviruses which 
have been well studied for causing lifelong infections in humans. HSV-1 and HSV-2 can 
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infect almost any part of the skin or mucosa on the human body. HSV-1 produces mostly 
facial cold sores and fever blisters. The virus hides in the cell bodies of neurons to evade 
the immune system and becomes latent for a long period. HSV-2 produces mostly genital 
infections and evades the immune system in the same way as HSV-1. HSV-1 tends to hide 
in the trigeminal ganglia, while HSV-2 tends to hide in the sacral ganglia. Some infected 
people experience sporadic episodes of viral reactivation or outbreaks after the primary 
infection. In the virus outbreak, the virus in a nerve cell becomes active and is transported 
via the axon to the skin causing new sores. Figure 1.7 shows the latent and lytic infection 
cycles of HSV-1 and HSV-2. HSV infects skin, eye, mucous membrane (SEM) and can 
cause disseminated infection and encephalitis in neonates. A considered diagnosis and 
timely treatment to HSV infected patients could relieve the SEM infection efficiently. HSV 
infections can cause life threatening diseases in central nervous system (CNS). HSV-1 is a 
major cause of severe viral encephalititis. If no proper treatment is applied to the patients 
with HSV-1 encephalitits, 70% of patients will die and the infection causes severe sequelae 
in almost all survivors. HSV infections in neonates and immune compromised hosts are the 
most severe and even life threatening. HSV infection in immunocompromised patients is 
slowly progressed and accompanied by extensive tissue damage and necrosis, but fatal 
infections are not common.  
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Figure 1.7 Latent and Lytic infection by HSV-1 and HSV-2.  
Figure modified from (Knipe & Cliffe, 2008). 
VZV causes varicella (chickenpox) on the human body in the primary infection and herpes 
zoster following reactivation. It evades the immune system in a similar manner as HSV by 
establishing latency in sensory ganglia. Most adults are immune to VZV infection because 
of childhood exposure, but immune compromised patients, pregnant women and newborns 
appear to be predisposed to severe infection. VZV infections in immunocompromised 
children are life threatening without proper treatment or if treatment is delayed. Acyclovir 
and its prodrug Valacyclovir are analogues of guanosine, which can selectively inhibit 
VZV and HSV replication. As an effective treatment to VZV infection, after administration 
acyclovir can spread throughout the human body, including the CNS, and can be well-
tolerated and rarely causes side-effects. A vaccine for VZV has been approved by the FDA 
in 1995 and is available in many countries over the world (Holmes, 1996). 
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1.4.2 Betaherpesviruses and human disease 
HCMV, HHV-6A, HHV-6B and HHV-7 are members of the Betaherpesviruses which 
have humans as their primary host. HHV-6A can be found in the patients with 
neuroinflammatory diseases. Primary infection of HHV-6B causes exanthem subitum in 
childhood. Furthermore, the reactivation of HHV-6B can cause encephalitis, bone marrow 
suppression and pneumonitis in transplant recipients and this makes the diagnosis of HHV-
6B vital for the patients. HHV-7 can also cause exanthema subitum, but it is not as 
important as HHV-6B.  
HCMV is the best known member in Betaherpesviruses family for its severe infection 
consequences. HCMV infection is recognized in a high proportion of the population over 
the world. It is much more common in developing countries for over 90% positive in the 
population, whereas this number is around 50% in developed countries (Fulop et al., 
2013). Most patients get the HCMV infection during childhood through exposure to the 
virus. HCMV maintains latency in CD34+ haematopoietic stem cells after the primary 
infection. HCMV can cause sensory impairment, retinitis, encephalitis, hepatitis, 
gastroenteritis and pneumonitis in immunocompromised hosts such as neonates, organ 
transplantation recipients and HIV positive patients. For bone marrow transplantation, as 
the severity of immunosuppression increases, so does the risk of HCMV infection. It is 
even fatal for bone marrow allograft recipients with a severe HCMV infection. The 
treatment for HCMV infection includes the competitive inhibitors of HCMV encoded 
DNA polymerase, immunoglobulin application, and adoptive transfer of immunity.  
Ganciclovir and Valganciclovir are competitive inhibitors of HCMV DNA polymerase but 
are not well tolerated by pregnant patients (Sullivan et al., 1992). Therefore 
immunoglobulin is an effective way for the treatment of pregnant patients.  
1.4.3 Gammaherpesviruses and human disease 
Gammaherpesviruses are distinguished by their tropism for lymphocytes and are divided 
into Lymphocryptoviridae and Rhadinoviridae. EBV, which is one of the best studied 
gammaherpesviruses belongs to the Lymphocryptoviridae. EBV infects T cells, B cells and 
epithelial cells in the human body, and it has been linked to Burkitt’s lymphoma, CNS 
lymphoma, post-transplant lymphoproliferative syndrome and HIV-associated hairy 
leukoplakia (Maeda et al., 2009). There is evidence that EBV is also associated with 
immune mediated diseases such as auto-immune diseases. An asymptomatic EBV 
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infection usually occurs in the early childhood and is spread by saliva. EBV establishes 
latency in lymphoid tissues to evade the immune system and is harboured in the host for 
the remainder of their life.  
KSHV (HHV-8) is another important member in gammaherpesvirus that belongs to the 
Rhadinoviridae. Primary target cells of KSHV are lymphocytes. It has been reported that B 
cells, T cells, monocytes and endothelial cells have been found positive for KSHV DNA. 
KSHV infection causes Kaposi’s sarcoma, primary effusion lymphoma and some types of 
multicentric Castleman’s disease (Boshoff & Weiss, 2002b; Cesarman et al., 1995).  
1.5 Host immunity and cellular defence to viral infection 
During evolution, the human body has adapted several complicated defence systems to 
prevent virus infection, which include the innate immune system, the adaptive immune 
system and intrinsic immunity. The innate and adaptive immune systems have been 
extensively studied from many different aspects, whereas intrinsic immunity is a relatively 
recent concept (Bieniasz, 2004; Kerscher et al., 2006; Michaelson & Leder, 2003; Pertel et 
al., 2011; Yan & Chen, 2012).  
1.5.1 Innate immune system 
The innate immune system, also known as the first line of defence, plays the earliest role in 
anti-viral defence in the whole conventional immune system. It includes many cell types, 
cytokines and chemokines for defending the host from viral infection. On a cellular level, 
NK cells were identified to be important in controlling herpes virus infection with an 
efficient response to viral infection (reviewed in (Biron et al., 1999)). NK cells stimulate 
IFN-γ expression, which mediates many cellular pathways against viral infection. This 
response happens within the first several hours to several days, and this is more rapid than 
the adaptive immune response mediated by B and T lymphocytes that take over a week to 
develop. Helper T cells also respond to IFN-α/β that is produced by infected cells, and the 
activated helper T cells mediate cytotoxicity to infected host cells and stimulate the 
adaptive immune response to virus infection. 
Some aspects of intrinsic resistance also respond to innate immunity signalling in viral 
infection. Several components of ND10 are induced by IFN I/II to increase antiviral 
infection by repressing virus gene expression, notably by PML, hDaxx, ATRX and Sp100 
(Everett & Chelbi-Alix, 2007; Tavalai & Stamminger, 2008). For example, HSV-1 
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infection triggers the innate immunity immediately to control the infection and lysis of the 
infected cells. This process also facilitates the adaptive immune response to HSV-1 
infection. In brief, pathogen-associated molecular patterns (PAMPs, examples including 
lipopolysaccharide, peptidoglycan and double-stranded RNA) interact with the invading 
HSV-1, and then are recognized by toll-like receptors (TLRs). Activated TLRs trigger the 
inflammatory signals that including TLR-mediated Type I IFN-α/β production. In response 
to the IFN-α/β production, the cellular Janus/Just another kinase (JAK) - signal transducers 
and activators of transcription (STAT) signalling pathway is activated that induce 
phosphorylation and formation of the STAT1/STAT2 complex which is then imported into 
the nucleus. The STAT1/STAT2 complex binds to IFN-stimulated response elements 
(ISRE) located on interferon-stimulated genes (ISGs) to stimulate ISGs transcription. One 
of the many ISG transcription products that represses HSV-1 replication is PKR (protein 
kinase RNA-activated). PML expression in this process is increased in response to IFN-α/β 
(Chelbi-Alix et al., 1995; Lavau et al., 1995; Regad & Chelbi-Alix, 2001) and it further 
represses viral infection and replication (more detail will be introduced in section 1.5.3). 
 
1.5.2 Intrinsic resistance to viral infection 
1.5.2.1 Intrinsic resistance to herpes virus infection 
Intrinsic resistance to virus infection is located at the front line of the intracellular host-cell 
defence system. It is conferred by constitutively expressed cellular proteins that restrict 
viral infection. In herpes virus infection, such as HSV-1, HCMV and EBV, components of 
ND10 have been identified by many groups to restrict viral infection. Meanwhile, the 
relative viral proteins that repress the host cell intrinsic resistance were also identified 
(some examples are listed in Table 1.1) (Ahn et al., 1998; Ahn & Hayward, 1997; 2000; 
Amon et al., 2006; Bell et al., 2000; Everett et al., 1998; Everett & Murray, 2005; Glass & 
Everett, 2013; Maul et al., 2000; Tavalai et al., 2011; Tavalai et al., 2006; Tavalai & 
Stamminger, 2009; Tsai et al., 2014).  
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Table 1.1 ND10 components and the viral proteins that interact with them. 
Herpes virus Viral protein ND10 interaction 
components 
HSV-1 ICP0 (Everett, 2000; Everett 
et al., 1998) 
PML, Sp100 
HCMV IE1 (Ahn et al., 1998; Ahn 
& Hayward, 1997) 
PML, Sp100 
pp71(Baldick et al., 1997; 
Ishov et al., 2002; 
Lukashchuk et al., 2008; 
Tavalai et al., 2008a) 
hDaxx, ATRX 
EBV EBNA1(Sivachandran et al., 
2010; Sivachandran et al., 
2008; Stenberg et al., 1985) 
PML 
EBNA-LP(Echendu & Ling, 
2008; Ling et al., 2005) 
Sp100 
BNRF1(Feederle et al., 
2006; Tsai et al., 2014; Tsai 
et al., 2011) 
hDaxx, ATRX 
 
1.5.2.2 Intrinsic resistance to retroviral infection 
The concept of intrinsic resistance as a term to describe the antiviral effects of 
constitutively expressed cellular proteins was first developed in relation to the restriction of 
retrovirus infection (Bieniasz, 2004). Cellular proteins, such as APOBEC3G/F and 
TRIM5α, have been demonstrated to restrict HIV replication (reviewed in (Ishov et al., 
2004; Nisole et al., 2005; Sokolskaja et al., 2006)). APOBEC3G (apolipoprotein B 
mRNA-editing enzyme catalytic polypeptide 3G or A3G, initially known as CEM-15) is a 
member of cytidine deaminase family that can catalyse the mutation of viral DNA. It was 
identified as a cellular protein that represses the replication of Vif (viral infectivity factor) 
gene mutants of HIV-1 (Sheehy et al., 2002). A3G catalyses the hydrolysis of cytidines (C) 
in the negative sense single-stranded DNA that reverse transcribed into uridine residues 
(U) (Harris et al., 2003; Yu et al., 2003a). As a consequence, it leads to guanine (G) to 
adenine (A) changes in the positive sense strand of proviral DNA. These mutations lead to 
potential damage to viral genome expression and regulatory genetic elements (Figure 1.8). 
Vif protein of HIV counteracts A3G by targeting A3G to ubiquitylate it, and leads to the 
degradation of A3G by proteasomes. In the absence of Vif during viral genome expression, 
A3G is packaged into progeny virions and leads to mutation during progeny virion gene 
reverse transcription, therefore impairing HIV viral replication (Sheehy et al., 2003; Yu et 
al., 2003a). 
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Figure 1.8 Hydrolysis of cytidine catalysed by A3G. A3G changes C to U during reverse 
transcription.  
Thus, the HIV genes structure and its expression are damaged.  
TRIM5α is one member of tripartite motif-containing (TRIM) superfamily, whose 
structural characteristics include a RING domain near the N-terminal region, one or two B-
box domains and a coiled-coil domain in the C-terminal region of the motif . TRIM5α was 
first identified as an inhibitor of HIV-1 replication in rhesus monkey cells (Hatziioannou et 
al., 2004; Keckesova et al., 2004; Perron et al., 2004; Stremlau et al., 2004; Yap et al., 
2004). It has a C-terminal PRY/SPRY domain that includes viral recruitment motifs 
(Nisole et al., 2005; Yap et al., 2005). The PRY/SPRY domain recognizes the shape of 
sensitive retroviral capsids, then recruits the TRIM5 enzyme to the incoming virions to 
repress the viral infection (Stremlau et al., 2004). TRIM5α deficient cells were 
demonstrated to be more susceptible to infection, further confirming its repression function 
on HIV infection (Stremlau et al., 2004). The detailed mechanisms of A3G and TRIM5α 
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repression on HIV infection are still not clear and other repressors still wait to be identified, 
therefore, further research work is still ongoing. However these two examples illustrate the 
some of the core principles of intrinsic resistance proteins, in that they are constitutively 
expressed and in some cases are targeted by viral proteins that counteract their activities. 
1.5.3 ND10 and its components  
ND10, also known as PML Nuclear Bodies (PML-NBs) were first described in connection 
with Herpesvirus infection over 20 years ago(Maul et al., 1993), although these electron 
dense punctuate structures in the nucleus of human cells had first been noted much earlier. 
ND10 are tightly bound to the nucleus matrix (Stuurman et al., 1992) and electron 
microscopy studies have shown a ring-like protein structure that apparently in normal 
circumstances contains no nucleic acids in the centre (Boisvert et al., 2000; Dellaire & 
Bazett-Jones, 2004). ND10 have many functions in cell biology that have been well 
studied, such as transcriptional regulation, DNA damage response, regulation of cellular 
senescence, regulation of neoangiogenesis and apoptosis (reviewed in (Bernardi & 
Pandolfi, 2003; 2007; Borden, 2002; Eskiw & Bazett-Jones, 2002; Negorev & Maul, 2001; 
Zhong et al., 2000b)). In recent years, ND10 have been linked to the restriction of 
replication of both DNA and RNA virus infection (Boutell & Everett, 2013; Michaelson & 
Leder, 2003; Rivera-Molina et al., 2013; Tavalai & Stamminger, 2008). For instance, 
accumulating data have shown that ND10 components re-localize to invading viral 
genomes during HSV-1 infection (Everett & Murray, 2005; Everett et al., 2008; 
Lukashchuk & Everett, 2010). Knock down of ND10 components has been shown to 
increase HCMV infection (Lukashchuk et al., 2008; Tavalai et al., 2011; Tavalai et al., 
2006; Tavalai et al., 2008b), and the absence of ATRX in ND10 increased EBV gene 
expression (Tsai et al., 2014). 
ND10 undergo significant changes in size, number and location in the nucleus indicating 
their dynamic nature (Dellaire & Bazett-Jones, 2004; Muratani et al., 2002). One of the 
main components is the promyelocytic leukaemia (PML) tumour suppressor protein, which 
is essential for the formation of ND10 (Gareau & Lima, 2010; Ishov et al., 1999). The 
deletion of PML has been demonstrated to disturb the localization of Sp100 and hDaxx to 
ND10 (Everett et al., 2006). Other important ND10 members in intrinsic immunity include 
Sp100, hDaxx and ATRX. Sp100 was demonstrated to localize within ND10 by the 
interaction with PML through SUMO (Small Ubiquitin-like Modifier) modification 
(Negorev et al., 2001). It also contributes to the repression of herpes virus infections such 
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as HCMV and HSV-1 (Everett et al., 2008; Glass & Everett, 2013; Negorev et al., 2006; 
Tavalai et al., 2011). hDaxx is another important member of ND10, which recruited to 
ND10 through its SUMO interaction motif (SIM) (Ishov et al., 1999). It also contributes to 
viral infection repression, especially in immediate early stage of viral infection (Cantrell & 
Bresnahan, 2006; Lukashchuk & Everett, 2010; Reeves et al., 2010; Tavalai et al., 2008b). 
ATRX is recruited by hDaxx and predominantly found in ND10 and heterochromatin 
(Baumann et al., 2008; Berube et al., 2008; Everett et al., 2007; Kerscher et al., 2006; 
Ritchie et al., 2008; Tang et al., 2004; Xue et al., 2003). ATRX has many features that 
suggest a role in chromatin structure and control of gene expression (Tang et al., 2004). 
Recent studies on ATRX have demonstrated its repression function on HCMV and EBV 
infection and replication, and this repression could be counteracted by viral tegument 
proteins (Lukashchuk et al., 2008; Tsai et al., 2014; Tsai et al., 2011). 
The formation and structure of ND10 is illustrated in Figure 1.9 (adapted from (Bernardi & 
Pandolfi, 2007)). In brief, PML interacts with itself or other PML isoforms to form the 
major part of ND10, and PML/PML interaction includes direct interactions involving the 
coiled-coil element of the TRIM and indirect interactions through SUMO and the SIM 
(reviewed in (Bernardi & Pandolfi, 2007)). The recruitment of hDaxx to ND10 is through 
the SIM site on hDaxx, which was proved by mutations in the hDaxx SIM motif that 
impaired hDaxx localization to ND10 (Ishov et al., 1999; Lin et al., 2006). ATRX interacts 
with hDaxx through the N-terminal PAH domain of hDaxx and is recruited to ND10 by 
hDaxx (Tang et al., 2004). Sumoylated Sp100 locates to ND10 by the interaction with 
sumoylated PML through its SIM (Cuchet-Lourenco et al., 2011). Many other gene 
regulation proteins can be recruited to ND10, such as ISG20, LYSP100, NDP55, SUMO 
family members and so on, whose functions and roles in intrinsic immunity (if any) have 
not been studied (Dent et al., 1996; Gongora et al., 1997; Maul et al., 1995). Thus, in this 
thesis, the investigation will concentrate on PML, Sp100, hDaxx and ATRX. 
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Figure 1.9 A model for the assembly of promyelocytic leukaemia nuclear bodies (ND10). 
Figure modified from (Bernardi & Pandolfi, 2007) 
1.5.3.1 PML 
PML is a tumour suppressor protein that is encoded by the PML gene and it is steadily 
expressed in most human cell lines. The PML gene is a member of tripartite motif (TRIM) 
family located on chromosome 15q22 that spans ~53,000 bases and nine exons (as 
indicated in Figure 1.11). PML gene C-terminal exons splicing leads to the expression of 
seven major isoforms of PML, I-VII (Bernardi & Pandolfi, 2007). Most isoforms (I-VI) 
predominantly localize within the nucleus due to the nuclear localization signal (NLS) 
located in exon 6. As Figure 1.11 shows, all PML isoforms contain exons 1-3, which 
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encode the TRIM/RBCC motif. The TRIM motif contains a zinc-finger structure (RING 
motif, R), two additional zinc-finger motifs (B-boxes, B) and a coiled-coil domain (CC). 
The RING domain was shown to be important for PML post-translational modification by 
SUMO (Meroni & Diez-Roux, 2005; Shen et al., 2006), which is an ubiquitin-like protein 
(UBL). B-box domains in other TRIM proteins (TRIM5α and TRIM15) were demonstrated 
to contribute to intrinsic resistance to HIV infection (Brass et al., 2008; Li et al., 2007). 
The CC domain following the B-box domains is responsible for homomeric and 
heteromeric interactions among TRIM family members (Cuchet-Lourenco et al., 2011; 
Lewis et al., 2010; Mische et al., 2005). The whole TRIM motif is required for PML I 
mediated restriction of HSV-1 infection (Cuchet et al., 2011). 
PML proteins were reported to repress VSV, HSV-1, HCMV and influenza A virus 
infection and replication (Chelbi-Alix et al., 1998; Everett et al., 2006; Ishov & Maul, 
1996; Kang et al., 2006; Kyratsous & Silverstein, 2009; Maul et al., 1996; Reichelt et al., 
2011; Tavalai et al., 2008b; Wang et al., 2011). Many herpes viral proteins, such as ICP0 
from HSV-1, IE1 from HCMV and EBNA1 from EBV, were reported to interact with 
PML for de-repression of the viral genes expression (Everett et al., 2006; Kang et al., 2006; 
Lee et al., 2004; Muller & Dejean, 1999; Stenberg et al., 1985). In ND10 structure, PML is 
the major component protein and indispensable for maintaining ND10 structure (Gareau & 
Lima, 2010; Ishov et al., 1999). Knock down of PML by siRNA severely damaged the co-
localization of Sp100 and hDaxx, and as a consequence, leads to increased viral infection 
(Everett et al., 2008; Glass & Everett, 2013).  
The difference between the PML isoforms is mainly due to alternative C-terminal exons 
(as indicated in Figure 1.10). PML VII lacks the NLS, thus leading to its spread in the 
cytoplasm but not mainly in nucleus (Jensen et al., 2001). This PML isoform has been 
shown to regulate the transforming growth factor-β signal pathway (Newhart et al., 2013). 
Other PML isoforms have different binding interfaces and functional specificity in nucleus 
and during herpes virus infection. PML isoform I binds to transcription factor AML1 to 
stimulate AML1-induced transcription (Abb, 1985). PML III interacts with Aurora A and 
regulates its kinase activity, which implicates a role of PML III in centrosome duplication 
and genome stability (Bostikova et al., 2014). PML VI binds to p53 to induce premature 
senescence (Bischof et al., 2002; Newhart et al., 2012). PML IV is the preferentially 
interaction target of EBV protein EBNA1, which down regulates PML and stimulate lytic 
infection (Stenberg et al., 1985). Construction of cell lines that lack wild type PML 
isoforms and reintroduction of different PML isoforms provided convenient tools to study 
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each single PML isoforms’ function in HSV-1 infection (Cuchet et al., 2011). The PML I 
or PML II expression in endogenous PML depletion cells can partially reverse ICP0 null 
HSV-1 infection increase (Cuchet et al., 2011). The same study also showed that each 
individual PML isoform is capable of recruiting Sp100 into ND10 and to be sumoylated 
(Cuchet et al., 2011). 
Similar to many proteins expressed in a cell, PML is post-translational modified., There are 
two major types of modification of PML that have been identified, phosphorylation and 
sumoylation. PML is phosphorylated after translation at Tyr and Ser residues (Chang et al., 
1995). This process has been demonstrated to be important for lung cancer development 
(Scaglioni et al., 2006). The most important post-translational modification of PML that 
has been studied is sumoylation. Mutation of PML sumoylation sites abolished the 
recruitment of Sp100 and hDaxx to ND10 (Ishov et al., 1999; Zhong et al., 2000a). Three 
sumoylation sites of PML have been identified, which are K65, K160 and K490 (Boddy et 
al., 1996; Duprez et al., 1999; Kamitani et al., 1998). Nevertheless, the expression of PML 
I isoform in the cells that had been depleted of wt PML identified K616 but not K65 as a 
sumoylation site in PML I (Cuchet-Lourenco et al., 2011), which might indicate the 
sumoylation of PML is partially isoform dependent. 
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Figure 1.10 PML protein isoforms.  
The figure is modified from (Bernardi & Pandolfi, 2007). Key domains of PML 
isoforms showing the RBCC location in the protein sequence and the NLS sequence 
location. The SIM is located in exon 7a.  
 
Different herpes viruses interact with PML by different mechanisms to release PML’s 
repression of viral replication. HSV-1 IE protein ICP0 degrades PML to stimulate HSV-1 
lytic infection (Boutell et al., 2011; Cuchet-Lourenco et al., 2012; Everett, 2011; Everett et 
al., 1998; Muller & Dejean, 1999; Perusina Lanfranca et al., 2013). IE1 from HCMV de-
sumoylates sumoylated PML and disperses the PML in nucleus to counteract the intrinsic 
immunity (Kang et al., 2006; Kim et al., 2011b; Lee et al., 2004; Muller & Dejean, 1999; 
Tavalai et al., 2011). EBV protein EBNA1 was demonstrated to down regulate PML in 
host cells through interacting with casein kinase 2 (CK2) and ubiquitin specific protein 7 
(USP7) (Sivachandran et al., 2010; Sivachandran et al., 2008). Details about the above 
interactions between PML and viral proteins will be discussed in section 1.6.  
PML depleted cells have been widely studied to analyse the effects of PML on herpes virus 
infection by different labs to support the notion of PML mediated intrinsic immunity. PML 
knock down cells have been demonstrated to increase ICP0 null HSV-1 infection (Everett 
et al., 2006). PML depletion was also shown to increase IE gene expression and the plaque 
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formation efficiency of wt HCMV. In the same experiment, IE gene expression of several 
mutant HCMVs, in which the IE1 gene, the pp71 gene were deleted or the MIEP (major 
immediate-early promoter) sequence was altered, was also increased in PML depleted 
fibroblast cells (Tavalai et al., 2008b). Therefore, the above reports demonstrated the 
repression function of PML in α and β herpes virus infection. It is important to note 
however that depletion of PML did not restore replication of these mutant viruses to wt 
levels. For example, depletion of PML increases ICP0 null mutant HSV-1 plaque 
formation by about 10-fold, whereas the defect of the mutant virus in the parental cell line 
is 500- to 1000-fold. Therefore although PML is involved in regulating HSV-1 infection, 
other factors must also be important. 
1.5.3.2 Sp100 
Sp100 is another important ND10 component involved in viral gene expression regulation 
(Negorev et al., 2006; Negorev et al., 2009). It was originally identified by the presence of 
anti-Sp100 auto-antibodies in the sera of primary biliary cirrhosis patients (Szostecki et al., 
1990) and was the first protein identified in the ND10 structure (Negorev et al., 2001; 
Negorev & Maul, 2001). The human Sp100 gene was originally reported to locate on 
chromosome 2 and encode a protein of calculated molecular mass of 53 kDa. The sequence 
of Sp100 reported has an acidic region that leads to a highly aberrant electrophoretic 
mobility in SDS-PAGE which resolves at the molecular weight near 100 kDa (Szostecki et 
al., 1990; Szostecki et al., 1987). Sp100 is a single-copy gene that encodes four spliced 
isoforms, Sp100A, Sp100B, Sp100C and Sp100 HMG (high mobility group, HMG) 
(Amon & Farrell, 2005). The genome structure of Sp100 isoforms is shown in Figure 1.11. 
The shortest and most abundantly expressed isoform, Sp100A, which shares 477 amino 
acids with the other three isoforms, was reported to promote transcription (Negorev et al., 
2006; Negorev et al., 2009; Sullivan et al., 1992). Sp100B, Sp100C and Sp100 HMG 
isoforms contain a SAND domain (named after Sp100, AIRE-1, NucP41/45 and DEAF-1) 
that binds DNA composed of un-methylated CpG (-C-phosphate-G-) sites (Fulop et al., 
2013; Holmes, 1996). The mutation at W655Q in the Sp100B SAND domain was reported 
to abolish the interaction with DNA, and then promote transcription (Holmes, 1996; 
Negorev et al., 2006; Negorev et al., 2009). This might indicate the SAND domain 
possesses transcription repression activity. Sp100C contains a PHD (plant homeo-domain) 
and Bromo-domain that in some cases are involved in binding to methylated lysines in 
histones and acetylation of lysines respectively (Baker et al., 2008; Boshoff & Weiss, 
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2002a). Sp100HMG has a HMG-1/2 family homologous domain that may possess DNA-
binding potential (Seeler et al., 1998).  
 
 
Figure 1.11 Sp100 protein isoforms. 
This figure is modified from (Guldner et al., 1999). Key structural features are 
shown, including the PML/ND10 targeting region near the N- terminal end, the SAND 
domain location in Sp100B, Sp100C and Sp100HMG, the PHD and Bromo domains in 
Sp100C, and the HMG domains in Sp100HMG. 
 
In herpes virus infection studies, Sp100 has been identified to regulate HSV-1, HCMV and 
EBV infection and replication (Bell et al., 2000; Echendu & Ling, 2008; Everett et al., 
2008; Ling et al., 2005; Tavalai et al., 2011). Many herpes viral proteins target Sp100 to 
stimulate virus infection and gene expression, such as ICP0 from HSV-1, IE1 from HCMV 
and EBNA-LP from EBV (further details will be discussed in section 1.6) (Chelbi-Alix & 
de The, 1999; Echendu & Ling, 2008; Everett et al., 2008; Ling et al., 2005; Muller & 
Dejean, 1999). Sp100 is also sumoylated as PML, but this post translational modification is 
not essential for its localization to ND10 (Sternsdorf et al., 1997). PML has been shown to 
be important for Sp100 sumoylation (Everett et al., 2008). Further investigation 
demonstrated Sp100 recruitment to ND10 dependent on its SIM motif. In the same study, 
the SIM motif, but not sumoylation, has been shown to be important for Sp100A 
recruitment to invading ICP0 null HSV-1 genomes (Cuchet-Lourenco et al., 2011).  
1.5.3.3 hDaxx 
hDaxx (human Daxx) is an important ND10 component involved in intrinsic resistance to 
virus infection. It was first identified as a modulator of apoptotic signalling (Rowe et al., 
1956). hDaxx is mainly located to chromatin and ND10, where it is involved in chromatin 
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assembly and remodelling, transcription, apoptosis regulation and viral gene repression 
(reviewed in (Maeda et al., 2009)). hDaxx is expressed in most human tissues (Rowe et al., 
1956). Its structure contains 740 amino acids and several major domains were identified in 
the primary work, they include two N-terminal paired amphipathic helices (PAHs), a 
coiled-coil domain, an acidic region and a C-terminal serine/proline/threonine (S/P/T) rich 
region (Rowe et al., 1956). hDaxx was reported to interact with numerous proteins, and 
many of them are related to intrinsic resistance to viral infection and apoptosis (reviewed 
in (Maeda et al., 2009)). The interaction between hDaxx and FAS, which is a widely 
expressed cell death receptor that is important to the regulation of the immune system and 
tissue homeostasis, was originally reported to activate apoptosis (Rowe et al., 1956). Then, 
it was reported to interact with PML in yeast two-hybrid screening and co-localize with 
ND10 in immunofluorescence assays (Ishov et al., 1999; Zhong et al., 2000c). The 
interactions of hDaxx with chromatin components and modifiers, such as H2A, H2B, H3, 
H4 and HDAC II were also reported (Hollenbach et al., 2002). After that, hDaxx was 
identified to interact with ATRX and form a complex in ND10 in 2003 and 2004 (Tang et 
al., 2004; Xue et al., 2003). Furthermore, the hDaxx-ATRX complex was reported to form 
mainly in the S phase of cell cycle, and this complex is separated during G2 phase. In cells 
that lacked hDaxx, S phase is accelerated which leads to the formation of binucleated cells 
(Kerscher et al., 2006). HCMV infection interferes with the formation of the hDaxx-ATRX 
complex, and also leads to the formation of binucleated cells (Cantrell & Bresnahan, 2006; 
Foster & Jack, 1971; Ishov et al., 2002; Lukashchuk et al., 2008). 
Due to the large number proteins that interact with hDaxx, it is involved in many signaling 
pathways and cell functions. Some of the reports about hDaxx were not consistent with its 
function in apoptosis, which indicates its complicated mechanisms of interaction with other 
proteins. hDaxx was firstly reported to promote apoptosis through the interaction with Jun-
N-terminal kinase (JNK), which leads to downstream events and finally apoptosis (Rowe 
et al., 1956). hDaxx also interacts and activates the JNK upstream kinase Apoptosis signal-
regulating kinase 1 (ASK1) that activates JNK after activation (Pluta et al., 1998). 
Furthermore, TGF-β treatment stimulates the phosphorylation of hDaxx by nuclear kinase 
HIPK2, which is required for TGF-β induced apoptosis and JNK signalling. This indicates 
the HIPK2 and hDaxx are involved in the nuclear pathways that activate JNK and 
apoptosis upon TGF-β (Pertel et al., 2011). Thus, hDaxx was initially identified as a factor 
that promotes apoptosis. However, researchers also observed anti-apoptotic roles of hDaxx. 
A Daxx knock out mouse embryo model (Daxx-/-) increased apoptosis (Mehle et al., 2004). 
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The similar apoptosis increase also observed in Daxx knock out embryonic stem cells 
(Mehle et al., 2004). The apoptosis increase in hDaxx knockdown by RNAi in cells was 
also observed by other group (Michaelson & Leder, 2003). Furthermore, hDaxx 
knockdown cells are more sensitive to FAS, UV or tumour necrosis factor α (TNF-α) 
induced apoptosis (Michaelson & Leder, 2003). Thus, the above studies indicated the 
complexity of hDaxx in apoptosis, and whether this is related to its interactions with ND10 
is as yet un-clear. 
 
 
Figure 1.12 The hDaxx protein map. 
Figure adapted from (Boshart et al., 1985). The main protein interaction regions are 
shown as indicated. 
 
hDaxx was reported to be sumoylated by SUMO-1 and to interact with Ubc9 (Everett & 
Murray, 2005; Ryu et al., 2000). Mutations at K630 and K631 abolished the sumoylation 
of Daxx. Furthermore, the same study also indicated that the sumoylation of Daxx is not 
essential for its co-localization with PML (Everett & Murray, 2005). A SIM domain was 
also reported in the hDaxx sequence. By generating different hDaxx mutation, the SIM site 
was identified between 733-740 amino acids. Furthermore, the hDaxx-SUMO interaction 
was reported important for its SUMO conjugation (Lin et al., 2006). The extent of 
sumoylation of hDaxx under normal circumstances is unclear as, unlike PML and Sp100, 
modified forms of hDaxx consistent with sumoylation are not readily detectable in whole 
cell lysates. 
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In virology, hDaxx performs anti-viral infection functions in many instances. In RNA 
viruses, integrase from Avian Sarcoma virus (ASV) and HIV-1, DENV C from dengue 
virus (DENV) and PUUV-N from Puumala virus (PUUV) were reported to modulate 
hDaxx, and for DNA viruses, BNRF1 from EBV, pp71 from HCMV, protein VI from 
Adenovirus type 5 and L2 from HPV were reported to interact with hDaxx during viral 
infection (reviewed in (Schreiner & Wodrich, 2013)). Furthermore, ICP0 from HSV-1 was 
reported to antagonize hDaxx-ATRX complex repression of viral gene expression although 
there was no evidence of a direct interaction (Lukashchuk & Everett, 2010). In this study, 
the interactions between hDaxx and pp71 and BNRF1 will be introduced in more detail in 
section 1.6. 
1.5.3.4 ATRX 
ATRX forms a strong complex with hDaxx that accumulates in ND10 (Tang et al., 2004; 
Xue et al., 2003). Its name came from the mutation in X-linked α-thalassemia/mental 
retardation syndrome (Gibbons et al., 1995). The ATRX gene contains about 11,000 
nucleotides, of which the major ATRX isoform cDNA is approximately 7,500 nucleotides 
(Brasch & Ochs, 1992; Gibbons et al., 1995). The structure of ATRX includes a 
SWI/SNF2-type ATPase/helicase motif, a plant homeodomain-like (PHD) zinc finger, a 
HP1 binding region and hDaxx interaction domain and PxVxL sequence (Amon et al., 
2006; Argentaro et al., 2007; Chelbi-Alix et al., 1995; Lechner et al., 2005; Tang et al., 
2004). Mutations in ATPase/Helicase domains and PHD zinc finger motif causing a severe 
mental retardation syndrome, which is associated with urogenital abnormalities, facial 
dysmorphisms, and frequently α-thalassaemia (the ATR-X syndrome as described above) 
(Brasch & Ochs, 1992; Gibbons et al., 1995). The structure of ATRX is shown in Figure 
1.13. 
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Figure 1.13 The ATRX protein map.  
Key structural features showing: PHD zinc finger, HP1 binding domain, hDaxx 
interaction domain, helicase domains and SNF2 homology region. 
 
ATRX was identified to possess a PHD zinc finger that indicates its potential function in 
chromatin remodelling. The ATRX PHD zinc finger domain is of the C4HC3 type (four 
cysteines-one histidine-three cysteines) that coordinates two zinc ions to stabilize the 
protein fold. Sequence data base searches revealed that DNA methyltransferase DNMT3A, 
DNMT3B and DNMT3L share the same PHD zinc finger domain structure with ATRX 
(Meroni & Diez-Roux, 2005). Therefore, this unique domain in ATRX was named the 
ADD domain (Aapola et al., 2000). The studies on DNMTs indicate the potential of 
interaction between DNMTs with histones (Dent et al., 1996), and DNMT3L was reported 
to recognize the H3K4 (lysine 4 on histone H3) methylation status through its ADD 
domain (Gongora et al., 1997). Accordingly, the above studies suggest the potential 
interaction between ATRX with histones, and furthermore, it is involved in transcription 
regulation.  
Accumulating evidence demonstrated that ATRX interacts with hDaxx to predominantly 
locate at ND10 and heterochromatin (Baumann et al., 2008; Berube et al., 2008; Everett et 
al., 2007; Kerscher et al., 2006; Ritchie et al., 2008; Tang et al., 2004; Xue et al., 2003). In 
recent report, hDaxx and ATRX were identified in H3.3 immunoprecipitations (Brass et al., 
2008). Further investigation indicated the hDaxx is a specific histone chaperone for H3.3, 
and the interaction between ATRX and hDaxx is essential for H3.3 incorporation at 
telomeres (Lewis et al., 2010). Thus, it is likely that ATRX cooperates with hDaxx to 
interact with H3.3 for transcription regulation. More recently, the hDaxx-ATRX-H3.3 
complex was reported to be a BNRF1 interaction target for stimulating lytic stage infection 
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(Tsai et al., 2014). It indicates the hDaxx-ATRX complex interaction with histones 
involves an anti-viral infection process in host cells. 
ATRX interacts with HP1 to perform gene expression regulation (Rivera-Molina et al., 
2013), and is recruited to ND10 by hDaxx (Tang et al., 2004; Xue et al., 2003). ND10 
have been reported to perform intrinsic immunity functions during viral infection (Ahn et 
al., 1998; Ahn & Hayward, 1997; 2000; Amon et al., 2006; Bell et al., 2000; Everett et al., 
1998; Everett & Murray, 2005; Glass & Everett, 2013; Maul et al., 2000; Tavalai et al., 
2011; Tavalai et al., 2006; Tavalai & Stamminger, 2009; Tsai et al., 2014). Therefore, it 
was reasonable to predict that ATRX is involved in viral gene regulation. Recent reports 
have indicated the repression function of ATRX in herpes virus infection, which includes 
examples of herpes viruses from the α, β and γ herpes virus subfamilies (Lukashchuk & 
Everett, 2010; Lukashchuk et al., 2008; Tsai et al., 2014). Meanwhile, viral proteins that 
counteract the hDaxx-ATRX repression during viral infection were identified in parallel, 
and more detail will be introduced in section 1.6.  
1.5.3.5 SUMO family 
Small ubiquitin-like modifier (SUMO) proteins are a family of small proteins that become 
covalently bound to other proteins at lysine residues to provide post translational 
modification. Sumoylation (SUMO modification) alters the interaction patterns between 
proteins, changes the proteins localization in the cell and changes the activities of the 
sumoylated proteins (Boddy et al., 1996; Gareau & Lima, 2010; Hay, 2005; Kamitani et al., 
1997; Mahajan et al., 1997; Matunis et al., 1996; Shen et al., 1996). This post translational 
modification is involved in many cellular processes like the stress response, nuclear-
cytosolic transport, apoptosis, transcriptional regulation, protein stability and progression 
through the cell cycle (Bergink & Jentsch, 2009; Gareau & Lima, 2010; Hay, 2005). In 
ND10, SUMO modifies PML, Sp100 and hDaxx and it is important for maintaining ND10 
structure (as indicated in Figure 1.9) (Bernardi & Pandolfi, 2007; Cuchet-Lourenco et al., 
2011; Shen et al., 2006). The SUMO protein 3D structure is similar to ubiquitin (as its 
name indicates), and the covalently attachment on substrates of SUMO and ubiquitin also 
occur through similar enzymatic cascades that involves an E1 activating enzyme, an E2 
conjugating enzyme and an E3 protein ligase (Capili & Lima, 2007; Kerscher et al., 2006). 
The SUMO modification pathway is shown in Figure 1.14. 
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Figure 1.14 The SUMO conjugation cycle.  
This figure is adopted from (Everett et al., 2013b; Gareau & Lima, 2010). 
 
SUMO proteins are translated as immature precursors first, then the immature SUMO 
proteins are modified by Ulps (ubiquitin-like protein-specific protease, Ulp, in yeast) or 
SENPs (sentrin-specific protease, SENP, in human) to generate the mature form of SUMO, 
which has a C- terminal di-glycine motif for efficient adenylation (Biron et al., 1999). 
Adenylated SUMO proteins are attacked by HS- group from the active site Cys on the E1 
activating enzyme complex and the -GG of SUMO is covalently conjugated to the Cys on 
the E1 activating enzyme, which contains SUMO activating enzyme subunit1 (SAE1) and 
SUMO activating enzyme subunit2 (SAE2) (in yeast the E1 complex is formed by Aos1 
and Uba2) (Drane et al., 2010; Nevels et al., 2011), to form the E1~SUMO thioester 
(chemical groups that have a C-S-CO-C structure). The E2 conjugating enzyme also has a 
conserved active site Cys residue, and UBC9 (ubiquitin-like conjugating enzyme 9) is the 
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predominant E2 enzyme that has been identified (Adler et al., 2011; Everett, 2006a; 
Kerscher et al., 2006; Preston & Nicholl, 2006). Therefore, the E1~SUMO complex 
transfers SUMO to UBC9 to form the UBC9~SUMO thioester. Following the above 
conjugation, UBC9~SUMO can directly interact with some SUMO substrates to form 
covalent bond between SUMO-GG and a Lys residue on the substrates, or alternatively, E3 
protein ligases facilitate the conjugation between SUMO with its substrates. In many cases, 
SUMO substrates have a SUMO conjugation consensus motif that has been characterized 
as ψKXE. The ψKXE site contains a large hydrophobic amino acid (isoleucine, leucine or 
valine) which is represented by ψ, a lysine (K) residue for modification, an X residue 
represents any amino acid and a glutamic acid (E) (Dimitropoulou et al., 2010). 
Sumoylated proteins can be de-conjugation by Ulps/SENPs to release the SUMO back into 
the SUMO conjugation cycle (reviewed in (Everett et al., 2013b; Gareau & Lima, 2010)). 
Sumoylated proteins interact with SIM sites on its binding partners. SIM sites are 
characterized by a short group of hydrophobic amino acids, such as (V/I)X(V/I)(V/I), that 
is flanked by acidic residues (Gareau & Lima, 2010). 
The SUMO family has 4 members, which are SUMO1, SUMO2, SUMO3 and SUMO4, 
encoded by different genes. The molecular weight of SUMO1-3 is about 12 kDa. SUMO1 
shares about 50% sequence with SUMO2/3, it uses the same E1 complex and Ubc9 
(Kerscher et al., 2006). SUMO2 and SUMO3 share 97% sequence identity in their 
structure, which leads to use of the term SUMO2/3 to represent both of them. Different to 
other SUMOs, the function of SUMO4 remains unclear in protein modification (Baumann 
et al., 2008; Berube et al., 2008). SUMO1 and SUMO2/3 may have different conjugation 
substrates and also differ in SUMO chain formation. For instance, SUMO2/3 has the 
potential to form SUMO chains in sumoylation of PML and other substrates but this 
property is not shared by SUMO1 (Kyratsous & Silverstein, 2009; Ritchie et al., 2008). 
Sumoylation is also involved in the regulation of viral infections, and more detail about 
this will be introduced in section 1.6. 
1.6 Herpes virus ND10 interaction proteins 
As introduced above, ND10 restrict several different virus infections (Boutell & Everett, 
2013; Tavalai & Stamminger, 2008). During evolution, viruses have developed 
complicated mechanisms to counteract host cell defences that are imparted by ND10. 
Several major viral ND10 interaction proteins from different herpes viruses are listed in 
53 
 
Table 1.1. This chapter will introduce more detail about the interactions between viral 
proteins and ND10 components, and furthermore the mechanisms of stimulating viral 
infection through the above interactions. 
1.6.1 HSV-1 protein ICP0 interacts with ND10 
HSV-1 infects the majority of the population and establishes a life-long latent infection in 
sensory neurones. The reactivation of HSV-1 infection can cause life threatening diseases 
in immune compromised patients and neonates (introduced in section 1.4.1). ND10 
components were reported to restrict HSV-1 infection, and in parallel, viral proteins that 
counteract ND10 repression were also identified (Everett et al., 2008; Everett et al., 2009; 
Everett et al., 1991; Everett et al., 2006; Everett & Zafiropoulos, 2004; Glass & Everett, 
2013; Harris et al., 1989; Lukashchuk & Everett, 2010; Maul & Everett, 1994; Natarajan et 
al., 1991; Wilcox et al., 1997).  
1.6.1.1 HSV-1 ICP0 protein 
The viral protein identified to interact with ND10 for stimulating HSV-1 infection is ICP0 
(Cuchet-Lourenco et al., 2012; Everett, 1987; 1988b; Everett & Maul, 1994; Everett et al., 
2006; Glass & Everett, 2013; Harris et al., 1989). ICP0 is expressed by HSV-1 in the IE 
stage of infection, during which 5 viral proteins are expressed, they are ICP4 (Kim et al., 
2011a), ICP27 (Kutluay & Triezenberg, 2009), ICP22 (Lilley et al., 2011; Rice et al., 
1995), ICP47 (Lukashchuk et al., 2010) and ICP0. Once ICP0 is expressed, it localizes to 
ND10 and causes their disruption (Maul & Everett, 1994; Maul et al., 1993). The 
association of ICP0 with ND10 degrades PML , abrogates sumoylation of Sp100 and 
disperses Sp100, hDaxx and ATRX from ND10 (Boutell et al., 2011; Boutell et al., 2002; 
Everett et al., 1998; Everett et al., 2009; Lukashchuk & Everett, 2010; Muller & Dejean, 
1999; Parkinson & Everett, 2000).  
ICP0 is encoded by the IE-1 gene, which has two copies, within the TRL and IRL regions 
of the genome (herpes virus genome structure is shown in Figure 1.2). ICP0 contains 775 
amino acids with a predicted molecular weight about 80 kDa (Perry et al., 1986). The ICP0 
molecular weight indicated on polyacrylamide gels is approximately 110 kDa, therefore, 
ICP0 was referred to as Vmw110 in earlier reports. In the ICP0 structure, several 
functional groups have been identified (indicated in Figure 1.15). They are the RING 
finger domain, 3 major phosphorylation sites, a nuclear localization sequence (NLS), the 
USP7 (ubiquitin-specific processing protease 7) interaction motif (Daubeuf et al., 2009; 
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Everett et al., 1997; Saffert & Kalejta, 2007) and a region required for ND10 localization 
(reviewed in (Everett, 2006b)). Studies on ICP0 mutants indicated that the N-terminal half 
of ICP0 is important for its function on transcription activation for viral promoters (Cai & 
Schaffer, 1989; Everett, 1987; 1988a; Perry et al., 1986). The RING finger domain is 
important for ICP0 to perform its E3 ligase activity (Barlow et al., 1994; Boutell et al., 
2002). The USP7 interaction motif, as indicated, is responsible for the interaction between 
USP7 and ICP0, which is important for stabilization of ICP0 and innate response 
modulation (Daubeuf et al., 2009; Saffert & Kalejta, 2007).  
 
Figure 1.15 A map of the ICP0 protein sequence.  
Figure adapted from (Everett, 2006b). Key structures are indicated as a RING 
finger domain, 3 phosphorylation sites, a nuclear localization sequence (NLS), USP7 
interaction motif and ND10 localization signal region. 
 
The RING finger domain in ICP0 was firstly identified as “C3HC4” sequence motif located 
in the N-terminal third of the protein that binds to two Zn2+ atoms (Barlow et al., 1994). 
Many RING finger domain containing proteins perform E3 ubiquitin ligase activities in 
diverse cellular functions and processes, for instance, the cell cycle, signalling, 
transcription, DNA repair and apoptosis (Joazeiro & Weissman, 2000). ICP0 also performs 
E3 ubiquitin ligase activity through RING finger domain (Boutell et al., 2002), which is 
essential for ICP0 induced PML degradation (Boutell et al., 2003; Chelbi-Alix & de The, 
1999; Everett et al., 1998; Everett et al., 2009; Parkinson & Everett, 2000). Mutations 
within the RING finger domain of ICP0 inactivate its ubiquitin conjugation activity and 
completely impair its ability to stimulate lytic infection and the reactivation of quiescent 
viral genomes (Boutell et al., 2002; Everett et al., 1995; Everett, 1987; Everett et al., 2009; 
Lium & Silverstein, 1997; O'Rourke et al., 1998). Studies on ICP0 mutants demonstrated 
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that the RING finger domain is not required for ICP0 localization to ND10 but is important 
for efficient viral infection (Everett et al., 2009). 
The ubiquitin conjugation pathway is similar to the SUMO conjugation pathway (Figure 
1.15) which requires an E1 ubiquitin activation enzyme, an E2 conjugation enzyme and an 
E3 ubiquitin ligase. In brief, monomeric ubiquitin is activated by an ATP dependent 
reaction and covalently conjugated to the E1 activation enzyme by a thioester bond. Then, 
the activated ubiquitin is transferred to E2 ubiquitin conjugation enzyme, and finally, the 
ubiquitin in the E2-ubiquitin thioester is mediated by E3 ligase to transfer to its substrates 
by covalently attachment to the lysine residues on its substrates. Unlike the SUMO 
conjugation pathway in which there is only one known E2 (Ubc9), there are 20-30 
different E2 enzymes and hundreds of E3s (Deshaies & Joazeiro, 2009; Pickart & Eddins, 
2004). The ubiquitin chains which have more than 4 ubiquitin monomers are recognized by 
26S proteasome. Therefore, the ubiquitin attached substrate is degraded by the proteasome 
and the monomeric ubiquitin is released back to the ubiquitinization cycle by ubiquitin-
specific protease (USP) enzymes (Everett, 2013). 
ICP0 interacts with USP7 (or HAUSP, herpesvirus-associated ubiquitin-specific protease) 
to perform several important functions (Daubeuf et al., 2009; Everett et al., 1997; Saffert 
& Kalejta, 2007; Shih et al., 2007). This interaction protects ICP0 from auto-ubiquitination 
in vitro, and prevents RING finger-dependent and proteasome-dependent ICP0 degradation 
during HSV-1 infection in U2OS osteosarcoma cells (Shih et al., 2007). In converse, ICP0 
mediates the ubiquitination of USP7 in a RING finger-dependent manner and induces the 
proteasome-dependent degradation of USP7 during low MOI HSV-1 infection (Saffert & 
Kalejta, 2007). In the same study, it was also reported that the binding of ICP0 to USP7 is 
not important for PML degradation that is induced by ICP0. Furthermore, reducing the 
expression level of USP7 had a negative effect on HSV-1 gene expression at low MOI, 
probably because this reduced the stability of ICP0 and therefore its rate of accumulation 
(Saffert & Kalejta, 2007). The ICP0 and USP7 interaction is also involved in innate 
immune response repression. USP7 was identified to repress the TLR-mediated NF-κB 
response, and this property is usurped by ICP0 through the interaction with USP7 during 
HSV-1 infection (Daubeuf et al., 2009).  
ICP0 was reported to repress the interferon response to increase HSV-1 infection 
(Jamieson et al., 1995b; Smith et al., 2011). Melroe et al .(2004) demonstrated that HSV-1 
infection reduces IFN-β production by monitoring mRNA accumulation and IFN-β 
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secretion levels. Then ICP0 was identified to prevent IFN regulatory factor-3 (IRF-3) 
nuclear accumulation, and thereafter reduce the IFN-β production (Jamieson et al., 1995b). 
ICP0 deletion mutant HSV-1 was reported to induce interferon-stimulated genes (Everett 
et al., 2010; Preston & Nicholl, 2005). Eidson et al. observed that cells infected with HSV-
1 mutant d109, which expresses ICP0 but not the other four IE proteins during infection, 
reduced the interferon-stimulated gene expression and a similar result was also repeated by 
expressing ICP0 in adenovirus (Smith et al., 2011). In addition, the studies on E3 ligase 
function of ICP0 and cellular proteasomal activity indicated the above activities are 
important for inhibiting toll-like receptor 2 (TLR-2) dependent inflammatory responses 
and NF-κB signalling (van Lint et al., 2010). 
ICP0 interacts with PML isoform I via sequences encoded in the isoform I specific exon 
and it also targets sumoylated PML and Sp100 through its SIM sites. The SIMs of ICP0 
are also important for stimulating HSV-1 lytic infection and reactivation from quiescence 
(Boutell et al., 2011). Furthermore, a recent study on sequences related to SIMs of ICP0 
indicated these motifs cooperatively stimulate viral infection (Roizman et al., 2006).  
In addition to degrading PML, ICP0 has been found to degrade a number of other cellular 
proteins, including RNF8, RNF168, CENP-A, CENP-B, CENP-C, CENP-I, CENP-H, 
CENP-N, USP7, USP7β, IκBα, IFI16 and E2FBP1 (reviewed in (Boutell & Everett, 
2013)). This accumulating evidence indicates the multifunctional roles of ICP0 in HSV-1 
infection and replication, which require further investigation on this important viral protein. 
1.6.2 HCMV proteins that interact with ND10 
HCMV is an important member of the β-herpesvirus subfamily. It infects the majority of 
the human population especially in developing countries. Similar to HSV-1, the infection 
of HCMV is separated into latent and lytic stages. The lytic infection is further divided into 
IE, E and L phases (Hancock et al., 2010; Smith et al., 2013). The two viral proteins that 
have been identified to interact with ND10 members for stimulating viral infection are 
tegument protein pp71 and IE protein IE1 (Ahn et al., 1998; Ahn & Hayward, 1997; 2000; 
Baldick et al., 1997; Cantrell & Bresnahan, 2006; Everett et al., 2013a; Gawn & Greaves, 
2002; Greaves & Mocarski, 1998; Hofmann et al., 2002; Homer et al., 1999; Hwang & 
Kalejta, 2007; Ishov et al., 2002; Kang et al., 2006; Kim et al., 2011b; Korioth et al., 1996; 
Lee et al., 2007; Lee et al., 2004; Lukashchuk & Everett, 2010; Lukashchuk et al., 2008; 
Tavalai et al., 2011). 
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1.6.2.1 HCMV IE1 protein 
IE1 is a 491 amino acid phosphoprotein that is expressed within the first 2 h of HCMV 
infection in the host cell nucleus. The predict molecular weight of IE1 is about 64 kDa 
(Wang & Dasso, 2009), whereas IE1 migrates to 72 kDa in SDS-PAGE (Foster & Jack, 
1971; Gareau & Lima, 2010; Torok & Etkin, 2001; Yap et al., 2005), therefore, IE1 was 
also known as IE72. IE1 is encoded by the UL123 open reading frame which is located at 
the abundantly transcribed major IE (MIE) region. The MIE also encodes another 
important IE protein, IE2 (encoded by UL122) (reviewed in (Scherer & Stamminger, 
2014)). IE1 and IE2 share the first 85 amino acids that are encoded by exon 2 and exon 3 
(Sobol & Mossman, 2011; Stenberg et al., 1985). MIE expression is stimulated by the MIE 
enhancer promoter (MIEP), which is one of the most efficient transcriptional enhancers 
known to date (Sheehy et al., 2002; Sheehy et al., 2003; Sokolskaja et al., 2006). The 
MIEP is repressed by the hDaxx-ATRX complex in ND10, and during the very early 
stages of infrection tegument protein pp71 interacts with hDaxx-ATRX to release the 
MIEP from hDaxx-ATRX complex repression (Cantrell & Bresnahan, 2006; Hofmann et 
al., 2002; Lukashchuk et al., 2008). The functions of pp71 will be introduced in more 
detail in the next section. IE1 was identified to de-sumoylate PML and Sp100 and interact 
with hDaxx (Ahn et al., 1998; Ahn & Hayward, 1997; Korioth et al., 1996; Lee et al., 2004; 
Muller & Dejean, 1999; Reeves et al., 2010; Tavalai et al., 2011). Mutant HCMVs that are 
deleted for IE1 cannot perform efficient infection of cultured cells at low MOI, but this 
defect can be rescued in high MOI infections (Gawn & Greaves, 2002; Greaves & 
Mocarski, 1998). 
The IE1 protein structure contains four important regions (Figure 1.16), they are the 
nuclear localization signal (NLS, aa 1-24) (Lee et al., 2007; Wilkinson et al., 1998), a 
globular core domain (aa 25-382), a highly acidic region (373-475) (Huh et al., 2008; 
Paulus et al., 2006) and chromatin tethering domain (CTD) (Shin et al., 2012). In Figure 
1.16, two special amino acids are indicated, K450 and L174. K450 was identified to be a 
sumoylation site of IE1 (Xu et al., 2001) and L174 is essential for the interaction with 
PML and targeting ND10 (Lee et al., 2004; Muller & Dejean, 1999). The IE1 NLS motif 
was identified by expressing fusion proteins that combine IE1 residues 1-24 to the N-
terminal end of β-galactosidase (Wilkinson et al., 1998) or EGFP (Lee et al., 2007) in 
human fibroblast cells. The globular core domain is involved in many protein interactions, 
and this will be introduced in more detail later. The acidic region of IE1 is important for 
the interaction with STAT2, which involves in the IFN pathway (Huh et al., 2008; Paulus 
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et al., 2006). The CTD domain was reported to be involved in the interaction between IE1 
and core histones, which leads to the association of IE1 with chromosomes during cell 
mitosis (Lafemina et al., 1989; Reinhardt et al., 2005; Scherer et al., 2014). 
 
Figure 1.16 The IE1 protein sequence.  
Key motifs are indicated as NLS (aa 1-24), globular domain (aa 25-382), acidic 
region (aa 373-475) and CTD (aa 476-491). Figure is adapted from (Scherer & 
Stamminger, 2014). 
 
The IE1 globular domain is important for many of the protein’s interactions and activities. 
Sequence deletions within this region were demonstrated to abrogate the transactivation 
activity of IE1 (Hayhurst et al., 1995; Lee et al., 2004; Malone et al., 1990). The deletion 
of exon 3 or exon 4 sequences in IE1 was reported to damage the IE1 and IE2 synergistic 
stimulation of HCMV early promoter activity (Malone et al., 1990). Exon 3 of IE1 was 
also identified to be important for TATA less DNA polymerase α promoter activation. In 
the same study, the deletion of aa 105-139 and aa 267-286 were also observed to similarly 
damage activation of this promoter. In addition, deletion of aa 6-85, which cover exon 2 
and exon 3, was observed to abolished nucleus localization of IE1 (Hayhurst et al., 1995). 
Several mutations within the IE1 globular domain abolished the activities of IE1 on PML 
de-sumoylation and ND10 disruption. Deletion of aa 132-274, aa 290-320 and aa 232-491 
in IE1 were observed to be unable to de-sumoylate PML, whereas a sequence deletion in 
acidic domain didn’t have the same effect (Lee et al., 2004). In the same study, an HCMV-
BAC clone containing the aa 290-320 deletion, which is the smallest deletion in the study, 
was unable to perform infectious activity (Lee et al., 2004). Researchers also tried to 
identify the sequence region in globular domain that interacts with PML in yeast two-
hybrid assays. The results showed that the deletion in globular region, such as deletion of 
aa 132-274, or in converse, expression the deleted region, such as aa 132-274, all abolished 
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the interaction with PML (Ahn et al., 1998). The above studies indicated that the globular 
domain is important for IE1 transactivation activity and interaction with ND10, it was also 
noticed that this region is very sensitive to mutation (Hayhurst et al., 1995; Lafemina et al., 
1989). Therefore, point mutation is a better way than sequence deletion to study the 
properties of this region.  
More recently, Scherer et al. reported the 3D structure of the core region of IE1 from 
rhesus CMV (Scherer et al., 2014), which is highly related to the human CMV protein. The 
IE1 region responsible for the interaction with PML was identified as a coiled-coil region 
that is represented by helixes H1, H2 and H3 in Figure 1.17. Furthermore, this globular 
domain of IE1 was also identified to interact with TRIM5α, which implies the potential 
mechanism of IE1 interacting with TRIM family proteins through structural mimicking 
(Scherer et al., 2014).  
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Figure 1.17 3D structure of the rhesus CMV IE1 globular domain.  
It represents aa 42-392 of rhesus CMV IE1 which corresponding to aa 27-379 of 
HCMV IE1. This figure is adapted from (Scherer et al., 2014).  
 
IE1 was reported to repress the IFN response through its acidic domain (Huh et al., 2008; 
Krauss et al., 2009; Paulus et al., 2006; Reinhardt et al., 2005). Primary HCMV infection 
stimulates the accumulation of many IFN-stimulated mRNAs, and eventually disarms this 
antiviral response (Kamitani et al., 1997; Kerscher et al., 2006; Mahajan et al., 1997; 
Matunis et al., 1996; Scherer & Stamminger, 2014; Shen et al., 1996). By comparing the 
IFN-responsive transcripts that accumulate to substantially increased levels in IE1 null 
HCMV and wt HCMV, IE1 was identified to be responsible for this IFN-response 
repression. The observation was also confirmed using IFN treated IE1 expressing 
fibroblast cells (Paulus et al., 2006). Meanwhile, the same study also confirmed the 
colocalization and physical interaction of IE1 with STAT1/STAT2 (Paulus et al., 2006). 
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There after the acidic domain of IE1 was identified to be responsible for the interaction 
between IE1 and STAT2, and furthermore, the STAT2 interaction domain of IE1 is 
separated from the sequences required for ND10 disruption (Huh et al., 2008; Krauss et al., 
2009). Even though the sumoylation of IE1 is not essential for IE1 disrupting the ND10 
structure and de-sumoylation of PML, it is important for IE1 to interact with STAT2, 
which further implies the potential role of IE1 in regulating the IFN response (Huh et al., 
2008). In addition, IE1 was reported to disrupt inerleukin-6 (IL-6) signalling by 
sequestering STAT3, which indicated the complexity of IE1 interacting with cellular 
pathways to regulate HCMV gene expression (Grant et al., 2012). 
IE1 disrupts ND10 to stimulate HCMV infection (Ahn et al., 1998; Korioth et al., 1996; 
Lee et al., 2004; Tavalai et al., 2011; Xu et al., 2001). This process is proteasome 
independent, which means that IE1 interacts with sumoylated PML and de-sumoylates it 
instead of degrading PML like ICP0 (Lee et al., 2004; Xu et al., 2001). In the study of Xu 
et al., the K450 was identified to be essential for IE1 sumoylation, but this point mutation 
didn’t abolish or damage IE1 mediated ND10 disruption (Xu et al., 2001). Other studies on 
K450 confirmed the dispensable role of this amino acid for IE1 and PML interaction, but 
the same study observed a reduced HCMV growth kinetics by generating site mutation at 
this site. These results indicated that the sumoylation of IE1 contributes to efficient HCMV 
replication (Nevels et al., 2004a). IE1 was also reported to de-sumoylate Sp100 in a similar 
manner to that found for PML (Tavalai et al., 2011). Four Sp100 isoforms were de-
sumoylated and dispersed in the presence of IE1, and furthermore the down regulation of 
Sp100 by siRNA was shown to stimulate wt HCMV infection, which supported the notion 
that the interaction between IE1 and Sp100 contributes to the HCMV infection (Tavalai et 
al., 2011). IE1 directly interacts with hDaxx to activate a putative latency-associated 
transcript (LUNA) promoter, which indicated the multifunctional role of IE1 during 
HCMV infection (Reeves et al., 2010). 
1.6.2.2 HCMV tegument protein pp71  
The tegument protein pp71 from HCMV was originally termed as VP8, which is due to its 
identification as the eighth largest viral protein (Compton & Feire, 2007). It is encoded by 
the UL82 gene, and as its name indicates, it is a 71 kDa phosphoprotein (Chee et al., 1990; 
Wang et al., 2003). The UL82 gene is expressed at the early-late stage of HCMV infection, 
and the newly synthesised protein also localizes to nucleus (Pickart & Eddins, 2004). Early 
work identified pp71 as being required to stimulate the MIEP (Liu & Stinski, 1992). More 
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recently, pp71 was reported to be involved in many viral and cellular process, such as 
inducing the degradation of hDaxx, degradation of members of the Rb family, stimulating 
IE gene expression, stimulating cell cycle progression, and MHC expression inhibition 
(Bresnahan & Shenk, 2000; Homer et al., 1999; Kalejta et al., 2003; Kalejta & Shenk, 
2003b; Saffert & Kalejta, 2006; Yongxu Lu, 2014). This thesis will concentrate on the 
study of interaction between pp71 and hDaxx-ATRX complex in ND10 (Figure 1.6) 
(Cantrell & Bresnahan, 2006; Lukashchuk et al., 2008). 
pp71 was reported to increase HCMV DNA infectivity and expression (Baldick et al., 
1997). The co-transfection of HCMV DNA with pp71 expressing plasmids was observed 
to cause a 30-80 fold increase in plaque forming efficiency (Baldick et al., 1997). pp71 
was also observed to increase late gene expression, virus spread and promote plaque 
development in the same study (Baldick et al., 1997). In addition, Baldick et al. also 
reported that the expression of IE1 and IE2 slightly increased HCMV DNA plaque 
formation, and IE1 and IE2 together can amplify the pp71 stimulation on HCMV DNA 
transfection (Baldick et al., 1997). The same study and others reported that pp71 activates 
the MIEP (Baldick et al., 1997; Liu & Stinski, 1992). The ND10 protein hDaxx, as 
previous introduced, performs transcriptional repression at ND10, where other viral 
infection repressors also accumulate. It recruits ATRX to form heterodimeric complex to 
repress HCMV infection (Hofmann et al., 2002; Ishov et al., 2002; Lukashchuk et al., 
2008; McFarlane & Preston, 2011; Saffert & Kalejta, 2006; 2007). Accumulating evidence 
indicates that the MIEP of the HCMV genome is involved in the assembly of higher order 
chromatin structure, which represents the cellular regulation of viral genomes (Lecossier et 
al., 2003; Yu et al., 2003a). hDaxx interacts with histones and histone deacetylase enzymes 
(HDACs), which are involved in the regulation of chromatin structure (introduced in 
section 1.5.4.4). Therefore, the study of hDaxx demonstrated its repression of the HCMV 
MIEP (Woodhall et al., 2006), and pp71 was identified to interact with hDaxx-ATRX 
complex to rescue the repression of the MIEP (Everett et al., 2013a; Hofmann et al., 2002; 
Ishov et al., 2002; Lukashchuk et al., 2008; Saffert & Kalejta, 2006). Figure 1.18 shows 
the pp71 localization and function in HCMV latent and lytic infection. During latent 
infection, pp71 is located in the cytoplasm, therefore, it is incapable to interact with hDaxx 
and release the viral genome from repression (Saffert & Kalejta, 2007). In lytic infection, 
pp71 transfers into the nucleus and displaces ATRX from hDaxx-ATRX complex, and 
then induces the degradation of hDaxx to release the viral genome from repression 
(Lukashchuk et al., 2008; Saffert & Kalejta, 2006; 2007). 
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Figure 1.18 pp71 localization and function in HCMV latent and lytic infection.  
Figure adapted and modified from (Hayhurst et al., 1995) 
 
Isolation of a pp71 null mutant of HCMV was reported in 2000 (Bresnahan et al., 2000). 
Meanwhile, Bresnahan and Shenk observed that knock down of UL82 leads to severe 
impairment of HCMV infection and replication at low MOI, such as 0.01. This damage to 
HCMV infection efficiency could be at least partially rescued at high MOI infection, such 
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as 3 pfu per cell (Bresnahan & Shenk, 2000). This observation shares similarities with IE1 
null HCMV and ICP0 null HSV-1, which perform impaired infection at low MOI but 
replicate to similar levels as wt virus in high MOI infections (Greaves & Mocarski, 1998; 
Sacks & Schaffer, 1987; Stow & Stow, 1986). This might indicate cellular intrinsic 
resistance to HCMV and HSV-1 infection can be overcome by high doses of virus. 
pp71 also involves in the evasion of HCMV from innate immunity. It was reported to limit 
cell surface MHC class I complex accumulation in glioblastoma cells (Yongxu Lu, 2014). 
In addition, pp71 induces proteasome-dependent degradation of retinoblastoma family 
proteins (Rb), which is a tumor suppressor protein that inhibits several major cancers 
(Kalejta et al., 2003). In this respect, pp71 shares properties with other DNA virus proteins, 
such as adenovirus E1A, simian virus 40T and papillomavirus E7, on the interaction with 
Rb, which indicates the similarities of different DNA virus interactions with the host cell. 
1.6.3 EBV proteins that interact with ND10  
EBV is a member of the γ-herpesvirus subfamily. It has a different genome structure and 
replication kinetics compared with HSV-1 and HCMV (introduced in section 1.3). ND10 
were reported to be dispersed during EBV lytic infection (Bell et al., 2000). Therefore, 
viral proteins that may be responsible for ND10 interactions attracted researchers’ attention. 
Recently, EBV nuclear antigen 1 (EBNA1), EBNA-leader protein (EBNA-LP) and BNRF1 
were reported to interact with ND10 components (Echendu & Ling, 2008; Ling et al., 2005; 
Sivachandran et al., 2010; Tsai et al., 2014; Tsai et al., 2011). In this section, details about 
these proteins will be introduced. 
1.6.3.1 EBV EBNA1 protein 
EBNA1 is one of the six EBV nuclear antigens that may be expressed in latent infections 
(the other five are EBNA 2 ,3A, 3B, 3C and -LP). It is expressed in most EBV infected 
cells and EBV associated tumours (Cesarman et al., 1995). EBNA1 is also responsible for 
the maintenance and replication of the episomal EBV genome (reviewed in (Young & 
Rickinson, 2004)). The EBNA1 primary structure is separated by a Gly-Ala repeat region 
in the middle of the sequence. This repeat region was originally suggested to be involved 
in immune evasion (Guldner et al., 1999), but further studies indicated that it is important 
for mature protein stabilization (Szostecki et al., 1990; Szostecki et al., 1987).  
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EBNA1 was reported to disrupt ND10 (Sivachandran et al., 2010; Sivachandran et al., 
2008). It was also reported that EBNA1 degrades at least one isoform of PML to stimulate 
lytic infection (Stenberg et al., 1985). The disruption of ND10 by EBNA1 in latent 
infection is due to the degradation of PML. This process was indicated to involve USP7 
and casein kinase 2 (CK2) (Holowaty et al., 2003; Sivachandran et al., 2010; Sivachandran 
et al., 2008). USP7 is involved in the regulation of ubiquitination (introduced in section 
1.6.1.1) and interacts with another PML interacting protein, ICP0. CK2 regulates several 
cellular processes by phosphorylation of cellular proteins, including PML (Hatziioannou et 
al., 2004; Scaglioni et al., 2006). EBNA1 interacts with CK2 to increase phosphorylation 
of PML, then stimulates the multiubiquitylation and finally degradation of PML 
(Hatziioannou et al., 2004; Scaglioni et al., 2006; Sivachandran et al., 2010). Further 
studies demonstrated that each single PML isoform is capable to suppress EBV lytic 
reactivation. In the same study, PML IV was identified to be the primary degradation target 
of EBNA1 (Stenberg et al., 1985). 
1.6.3.2 EBV EBNA-LP protein 
EBV infection of human B cells leads to B cell immortalization (Loret et al., 2008; Yap et 
al., 2004). This process requires several EBV proteins, and EBNA-LP is one important 
member of them (Keckesova et al., 2004; Perron et al., 2004). EBNA-LP acts as a 
coactivator with EBNA2, another nuclear antigen that can be expressed in the latent stage 
infection, to stimulate the immortalization of B cells (Kalejta, 2008; Kempkes et al., 1995).   
Recently, EBNA-LP was reported to interact with Sp100 in ND10 and disperse Sp100 and 
heterochromatin protein 1α (HP1α) from ND10 (Ling et al., 2005). The interaction 
between EBNA-LP and Sp100 was confirmed by immunoprecipitation, and 
immunofluorescence studies indicated the dispersion of Sp100 and HP1α by EBNA-LP. 
The study also identified that the ND10 targeting domain of Sp100 is the EBNA-LP 
interaction motif. Furthermore, an Sp100 mutant deleted of the ND10 targeting domain is 
able to coactivate EBNA2 (Ling et al., 2005). Later studies from the same group reported 
the Sp100A dimerization domain is highly overlapping with the EBNA-LP interaction 
domain, which is located within ND10 localization motif. The result also demonstrated that 
interferon-β is unable to inhibit EBNA-LP function, which indicates the potential function 
of EBNA-LP in EBV evasion of antiviral responses (Echendu & Ling, 2008). 
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1.6.3.3 EBV tegument protein BNRF1  
BNRF1 is one of the most abundant proteins in the EBV tegument (Johannsen et al., 2004). 
It contains 1319 amino acids with a molecular weight about 140 kDa (Boshoff & Weiss, 
2002b; Stenberg et al., 1985). 
The interaction between BNRF1 and hDaxx was reported by (Tsai et al., 2011). The 
hDaxx interaction motif in BNRF1 was identified as aa 360-600 in this study, which also 
indicated that BNRF1 co-localizes with hDaxx in ND10 and disperses ATRX to disrupt the 
hDaxx-ATRX complex (Tsai et al., 2011). Different to pp71, another hDaxx interaction 
protein, BNRF1 didn’t induce the degradation of hDaxx in the above study. More recently, 
Tsai et al. (2014) reported more details about the relationship between BNRF1 and hDaxx-
ATRX. They observed that BNRF1 disperses and replaces ATRX in the hDaxx-ATRX 
complex to form a ternary complex of BNRF1-hDaxx-H3.3-H4. The complex further 
enhanced EBV gene expression in the early stages of infection (Tsai et al., 2014). The 
study also compared the difference between ATRX and hDaxx on regulating EBV gene 
expression. ATRX and hDaxx knock down cell lines were prepared to study the BNRF1 
null EBV gene expression. By measuring the immediate early and lytic early protein 
expression, both ATRX and hDaxx knockdown increased the mutant EBV gene expression. 
This study further confirmed the repression function of the hDaxx-ATRX complex on 
EBV.  
BNRF1 null EBV was generated and applied in the study of EBV infection on B cells in 
vitro (Feederle et al., 2006). This study didn’t observe significant impairment of viral DNA 
replication and progeny virus production, but the BNRF1 null EBV that was cultivated and 
collected showed about a 20-fold decrease of infection ability at MOI 10. Furthermore, the 
study also indicated the importance of BNRF1 for nuclear entry of the EBV genome 
(Feederle et al., 2006). The above properties of BNRF1 indicated the similarities with pp71. 
Both proteins interact with the hDaxx-ATRX complex and disperse ATRX from ND10. 
Mutant viruses that are deleted for BNRF1 or pp71 are able to infect hDaxx and ATRX 
depleted cells more efficiently (Lukashchuk et al., 2008; Tavalai et al., 2008b; Tsai et al., 
2014). Therefore, in chapter 5 in this thesis, the BNRF1 and pp71 were compared in 
several assays. 
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1.7 Aims and objectives of the study 
Cellular proteins were identified to restrict viral infections. For herpes viruses, ND10 was 
demonstrated to be important in viral infection regulation. Viral proteins that interact with 
ND10 to counteract the viral infection restriction were investigated and identified by 
extensive studies. These viral proteins were considered possible functional counterparts to 
each other, but only limited information was provided by existing research reports, and 
little detail about the direct interchangeability among them has been reported (such as 
ICP0, pp71, IE1, EBNA1, EBNA-LP and BNRF1).  The main aim of this project was to 
analyse the ability of proteins from the different herpesviruses to substitute for each other 
functionally. Previous work in the Everett lab had demonstrated that the functional 
requirement of ICP0 to HSV-1 can be largely replaced by the combination of IE1 with 
pp71. Furthermore, SIM sequence of ICP0 was demonstrated to be essential for the 
interaction with PML and Sp100. Therefore, the identification of SIMs in IE1 suggested 
that they could play a role in stimulating ICP0 null HSV-1 infection.  
Another important question that rose from previous work is whether ICP0 can replace IE1 
or pp71 in HCMV infection. Furthermore, γ herpes viruses are also restricted by ND10 
during viral infection. To extend the study, ND10 interaction proteins from EBV were also 
examined for their ability to stimulate other herpes virus infection, such as HCMV and 
HSV-1. In the result section, six herpes viral proteins were analysed in ND10 interaction 
and complementation of mutant herpes viruses that deleted relevant viral genomes. 
Therefore, the presentation of the results is introduced in three parts, which were 
concentrated in: (1) Complementation of ICP0 null HSV-1 infection by IE1 and IE1 
mutants. (2) Complementation of IE1 null HCMV and pp71 null HCMV by ICP0. (3) 
Stimulation of ICP0 null HSV-1 and pp71 null HCMV by EBV proteins which had been 
identified to interact with ND10. To investigate more detail about IE1, several IE1 mutants 
were prepared in this study based on IE1 sequences analysis.  
The data presented in this study provided evidence of the interchangeable role of ND10 
interaction proteins from different herpes virus subfamilies. It was also identified that IE1 
has HCMV specific functions that ICP0 cannot replace. Furthermore, a HCMV specific 
region of IE1 was identified in this study. But the mechanism of how this HCMV specific 
region in IE1 interact with other viral proteins and its functions in other viral and cellular 
processes are still required further investigation. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Cells 
All cells were grown in a humidified incubator at 37 oC in the presence of 5% CO2. 
2.1.1.1 HEK 293T cells  
Originally from HEK 293 cells (Human Embryonic Kidney 293 cells; (Ahn et al., 1998)), 
these cells (obtained from BD Biosciences) additionally express the Large T antigen of 
SV40, which can bind to several proteins that inhibit the cell cycle. HEK 293T cells also 
have neomycin resistance as a result of introducing the Large T antigen into them 
(DuBridge et al., 1987). 
2.1.1.2 HepaRG (HA) cells 
This cell line was derived from differentiated human hepatoma cells (Gripon et al., 2002). 
It can differentiate into two distinct liver cell types. Half the cells differentiate into 
hepatocyte-like cells and another half of the cells differentiate into biliary-like cells. For 
the experiments in this thesis they were used without differentiation because they can be 
readily manipulated while, unlike many permanent laboratory cell lines, they restrict ICP0-
null mutant HSV-1 efficiently (Everett et al., 2008). 
2.1.1.3 HA-TetR cells 
HepaRG cells transduced with a lentivirus vector expressing the EGFPnlsTetR fusion 
protein and neomycin (G418) resistance (Everett et al., 2009). 
2.1.1.4 HFT Cells 
This cell line is an immortalized version of limited passage diploid human fibroblasts, 
constructed by the method of (Smith et al., 2013) and provided by Dr Chris Boutell. 
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2.1.2 Cell culture media 
2.1.2.1 DMEM 
Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Life Technologies 
(DMEM, high glucose, pyruvate, Catalogue number: 41966-029, 500ml). It was 
supplemented with 10% foetal calf serum and 100 U/ml penicillin, 100µg/ml streptomycin, 
and was used for the growth of HEK 293T and HFT cells. 
2.1.2.2 William's Medium E 
William’s Medium E is a commercial product from Life Technologies (William's E 
Medium, no glutamine, Catalogue number: 22551-022) and was used for the growth of 
HepaRG cells. It was supplemented with 5 ml L-Glutamine-200 mM (100X, Life 
Technologies, Catalogue number: 25030-24), 10% foetal calf serum (Life Technologies, 
Catalogue number: 10270-106), 100 U/ml penicillin, 100 µg/ml streptomycin (Life 
Technologies, Catalogue number: 15140-122), 5 µg/ml insulin and 0.5 µM hydrocortisone. 
The insulin and hydrocortisone maintain the cells in the undifferentiated condition (Gripon 
et al., 2002). 
2.1.2.3 Cell culture solutions 
Versene: This medium is for washing cells before trypsin digestion. It is made of 0.6 mM 
EDTA with 0.002% phenol red in phosphate buffered saline (PBS).  
Trypsin: 10X Trypsin solution was purchased from Life Technologies (Sigma, Catalogue 
number: T4549-100 ml) and was diluted 1 in 10 in Versene before use.  
2.1.3 Yeast strains 
2.1.3.1 AH109 yeast strain  
The yeast 2 hybrid assay used in the work presented in this thesis was based on the 
Matchmaker 3 system (Clontech). The yeast strain AH109 uses three reporter genes to 
eliminate false positive results. These are genes ADE2, HIS3 and MEL1 (or lacZ) which 
are under the control of promoters that incorporate GAL4 upstream activating sequences 
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(UAS) and TATA boxes, and thus are only expressed in cells expressing GAL4 DNA 
binding domain and activation domain fusion proteins that interact. 
2.1.3.2 Y187 yeast strain 
Yeast strain Y187 contains the lacZ reporter gene under control of a promoter the GAL1 
UAS. The yeast strains AH109 and Y187 were purchased from Clontech. 
2.1.4 Viruses 
2.1.4.1 HSV-1 strains 
The wild type (wt) HSV-1 strain used in this  laboratory is strain 17 syn+, known as 17+ 
for short (Hollenbach et al., 2002). The ICP0 deletion mutant derivative of 17+ is dl1403 
(Stow & Stow, 1986). Mutant dl1403/CMV lacZ (herein termed ∆ICP0) includes the lacZ 
gene under the control of HCMV promoter/enhancer and was kindly provided by Dr Chris 
Preston. This virus can be titrated conveniently by detection of β-galactosidase activity 
(blue plaque assay, section 2.2.5.2) (Jamieson et al., 1995a). The ∆ICP0 HSV-1 virus 
stocks were grown in BHK cells and titrated on U2OS cells, and aliquots for use in the 
work for this thesis were provided by Anne Orr.  
2.1.4.2 HCMV strains 
HCMV strain Towne wt (TNwt): 
TNwt was a gift from Dr. Michael Nevels. TNwt was derived from a bacmid of strain 
Towne, and it includes a SV40-driven EGFP marker gene inserted into a non-essential 
region of the Us segment of the viral genome (Marchini et al., 2001). The TNwt used in 
this thesis was grown and titrated on HFT.IE1 cells (see below). 
AD169: 
This virus is an alternative and commonly used laboratory HCMV strain (Chee et al., 
1990; Rowe et al., 1956). AD169 stocks used in this thesis were cultivated and titrated in 
HFT.IE1 expression cells. In this way, the virus titre increased and cultivation time could 
be reduced to 7 days. 
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HCMV stain TBE40 wt (TBwt): 
TBwt, also a laboratory strain but more closely related to clinical HCMV strains, with 
fewer deletions and other mutations compared to strains Towne and AD169, was also a gift 
from Dr. Michael Nevels (Bernardi & Pandolfi, 2007). 
IE1 deleted mutant HCMV strains: 
A derivative of TNwt with a deletion of the IE1 specific coding sequences (TNdlIE1) was 
a gift from Dr. Michael Nevels and it was derived from the same bacmid as TNwt 
(Knoblach et al., 2011). The TNdlIE1 used in this study was grown and titrated on 
HFT.IE1 cells. The TBE40 IE1 deletion mutant TBdlIE1 and its revertant version 
TBrvIE1were gifts from Dr. Michael Nevels (Zalckvar et al., 2013). Stocks of these 
viruses were titrated on HFT-IE1 cells. 
pp71 deleted mutant HCMV:  
AD169subUL82 (herein named ∆pp71) was kindly provided by Steven McFarlane (Chris 
Boutell’s laboratory). It was originally made in Thomas Shenk’s laboratory by deleting the 
UL82 gene which encodes the pp71 protein in AD169 genome. This mutant also expresses 
enhanced green fluorescent protein as a marker (Bresnahan et al., 2000).  
2.1.5 Bacteria 
2.1.5.1 DH5α Chemically Competent E. coli 
This is a commercial product from Invitrogen (Catalogue Number: 18265-017). These 
bacteria were used for routine plasmid transformation, DNA manipulation and for large 
scale plasmid preparation. 
2.1.5.2 Stbl3 Chemically Competent E. coli 
Commercial product of Invitrogen (Catalogue Number: C7373-03). These bacteria were 
necessary for the construction of lentivirus vectors expressing IE1 as such plasmids were 
very unstable in DH5α bacteria. 
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2.1.6 Plasmids 
Table 2.2 lists the lentiviral vector plasmids used in this study. Where a reference is given, 
the plasmid was provided by others for use in this work (usually from the group of 
Professor R.D. Everett). Those for which notes on the construction are given in the 
‘source’ column were constructed by the author during the course of this work. Further 
details on the construction, structure and functions of these plasmids are given in the 
relevant results chapters. 
Table 2.1 List of plasmids used in this study. 
Plasmid Source Application 
pLKOneo.EGFPnlsTetR (Everett et al., 2013a) Expresses 
EGFPnlsTetR in 
target cell line. 
pLDT.IE1 (Everett et al., 2013a) Expresses IE1 in 
target cell line in 
an inducible 
manner. The 
transduced cells 
were selected by 
puromycin. 
pLDT.IE1.YL1-YL7 Replacement of the wt IE1 
sequence in pLDT.IE1 by 
IE1 mutant segments 
including mutations YL1 to 
YL7. Constructed by the 
author (Everett et al., 
2013a). 
Each expresses an 
IE1 YL series 
mutant protein in 
target cell line in 
an inducible 
manner.  
pLDT.IE1 K450R Replacement of the wt IE1 
sequence in pLDT.IE1 by 
IE1 mutant segment 
K450R. Constructed by the 
author (Everett et al., 
2013a). 
Expresses IE1 
mutant K450R in 
target cell line in 
an inducible 
manner.  
pLDT.myc.pp71 (Everett et al., 2013a) Expresses myc 
tagged pp71 in 
target cell line in 
an inducible 
manner. The 
transduced cells 
were selected by 
blasticidin. 
pLDT.myc.EBNA1 The EBNA1 sequence was 
a kind gift from Dr. Joanna 
Wilson. A myc tag is 
attached on the 5’ end of the 
EBNA1 DNA sequence 
Express myc 
tagged EBNA1 in 
target cell line in 
an inducible 
manner. The 
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(Cerboni et al., 2000). 
Constructed by the author. 
transduced cells 
were selected by 
puromycin. 
pLDT.FLAG.BNRF1.puro Provided by the Everett 
laboratory (unpublished). 
The FLAG-tagged BNRF1 
sequence was provided by 
Paul Lieberman (Tsai et al., 
2011). The BNRF1 coding 
sequence was inserted into a 
pLDT lentivirus vector. 
Expresses FLAG 
tagged BNRF1 in 
target cell line in 
an inducible 
manner. The 
transduced cells 
were selected by 
puromycin. 
pLDT.FLAG.BNRF1.bla Replacement of the 
myc.pp71 sequence in 
pLDT.myc.pp71 by the 
FLAG.BNRF1 segment. 
Constructed by the author. 
Expresses FLAG 
tagged BNRF1 in 
target cell line in 
an inducible 
manner. The 
transduced cells 
were selected by 
blasticidin. 
pLDT.FLAG.EBNA-LP.neo The FLAG tagged EBNA-
LP sequence was a kind gift 
from Dr. Paul D. Ling (Ling 
et al., 2005). This sequence 
was inserted into an pLDT 
vector expressing neomycin 
(G418) resistance. 
Constructed by the author. 
Expresses FLAG 
tagged EBNA-LP 
in target cell line 
in an inducible 
manner. The 
transduced cells 
were selected by 
neomycin. 
pLDT.EYFP.TetR.IRES.P This plasmid was gift from 
Dr. Chris Boutell. The 
backbone is termed a 
‘single inducible vector’ as 
it incorporates both the 
inducible gene of interest 
and expression of the TetR 
repressor. Puromycin 
resistance is expressed from 
the TetR transcription unit 
by an internal ribosome 
entry site (IRES).  
Expresses EYFP 
in target cell line 
in an inducible 
manner after a 
single 
transduction. The 
transduced cells 
were selected by 
puromycin. 
pLDT.ICP0.TetR.IRES.P The EYFP segment in 
pLDT.EYFP.TetR.IRES.P 
was replaced by the cICP0 
sequence. Constructed by 
the author. 
Expresses ICP0 in 
target cell line in a 
single inducible 
manner.  
pLDT.IE1.TetR.IRES.P The EYFP segment in 
pLDT.EYFP.TetR.IRES.P 
was replaced by wt IE1 
sequence. Constructed by 
the author. 
Expresses IE1 in 
target cell line in a 
single inducible 
manner.  
pLDT.IE1.YL1.TetR.IRES.P 
and related plasmids 
incorporating the YL2, YL3, 
YL4, YL7 and K450R mutant 
EYFP segment in 
pLDT.EYFP.TetR.IRES.P 
was replaced by IE1 YL and 
K450R mutant segments. 
Express IE1 
mutant proteins in 
target cell line in a 
single inducible 
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forms of IE1. Constructed by the author. manner.  
pLDT.myc.EBNA1.TetR.IRES.P A single inducible vector 
version for the expression 
of myc tagged EBN1, 
derived from the 
mycEBNA1 vector 
described above. 
Constructed by the author. 
Expresses myc 
tagged EBNA1 in 
target cell line in a 
single inducible 
manner. The 
transduced cells 
were selected by 
puromycin. 
pLKO.shPML1 (Everett et al., 2008) Expresses an 
shRNA that 
targets all 
isoforms of PML. 
The transduced 
cells were selected 
by puromycin. 
pLNGY.PML.I (Cuchet et al., 2011) Expresses EYFP 
tagged PML 
isoform I in target 
cell line. The 
transduced cells 
were selected by 
neomycin. 
pLBG.myc.PML.VI Constructed by the author. Express myc 
tagged PML 
isoform VI in 
target cell line. 
The competent 
cells were selected 
by blasticidin. 
pCMV.DR.8.91 A gift from Prof. Didier 
Trono 
Expresses the 
lentivirus helper 
functions. 
pVSV-G BD Biosciences Expresses G 
protein of the 
Vesicular 
Stomatitis 
Virus (VSV-G) 
envelope gene. 
pGBK.ICP0 (Cuchet-Lourenco et al., 
2012) 
Used as a vector 
backbone for 
expressing BD 
fusion proteins in 
yeast. 
pGBK.IE1 The cICP0 sequence in 
pGBK.ICP0 was replaced 
by the IE1 sequence. 
Constructed by the author. 
Expresses a BD-
IE1 fusion protein 
in yeast cells. 
pGBK.IE1.YL3, YL4 and 
K450R 
The cICP0 sequence in 
pGBK.ICP0 was replaced 
by IE1 YL3, YL4 or K450R 
sequences. Constructed by 
the author. 
Expresses BD-IE1 
YL3, YL4 and 
K450R fusion 
proteins in yeast 
cells. 
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pGBK.PML.I (Cuchet-Lourenco et al., 
2012) 
Expresses a BD-
PML isoform I 
fusion protein in 
yeast cells. 
pGBK.SUMO1 (Vanni et al., 2012) Expresses a BD-
SUMO1 fusion 
protein in yeast 
cells. 
pGAD.PML.I Constructed by Delphine 
Cuchet. 
Expresses an AD-
PML.I fusion 
protein in yeast 
cells. 
pGAD.PML.VI Constructed by Delphine 
Cuchet. 
Expresses an AD-
PML.VI fusion 
protein in yeast 
cells. 
pGAD.PML.I ∆BB1, ∆BB2, 
∆CC, ∆RING 
The PML.I ∆BB1, ∆BB2, 
∆CC, and ∆RING mutations 
in PML.I lentivirus vector 
plasmids (Cuchet et al., 
2011) were inserted into 
pGAD.PML.I. Constructed 
by the author. 
Express AD-
PML.I ∆BB1, 
∆BB2, ∆CC, 
∆RING fusion 
proteins in yeast 
cells. 
pGAD.SUMO1 (Vanni et al., 2012) Expresses an AD-
SUMO1 fusion 
protein in yeast 
cells. 
pGAD.empty Clontech Negative control 
pGBK.empty Clontech Negative control 
 
 
2.1.7 Primers 
All primers were purchased from Sigma-Aldrich. Primers were provided as lyophilised 
solids and re-suspended in distilled water to a final concentration of 100 µM. 
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Table 2.2 List of primers. 
 
Primer Sequence Application 
IE1 YL1 
Forward 
5’-
TCCTCTGCCAAGAGAAAGATGGACCCTGATAA
TGGTGACGGGGGCCCTTCCTCCAAGGTG-3’ 
Generating IE1 
YL1 mutant 
vector 
IE1 YL1 
Reverse 
5’-GCGCAGAATTCTTACTGGTCAGCCTTGCTTC 
-3’ 
Generating IE1 
YL1 mutant 
vector 
IE1 YL2 
Forward 
5’-
CAGCTGAGTCTGGGAGCACCGGCAGCTCCAGA
GTTGGCCGAA-3’ 
Generating IE1 
YL2 mutant 
vector 
IE1 YL2 
Reverse 
5’-
TTCGGCCAACTCTGGAGCTGCCGGTGCTCCCA
GACTCAGCTG-3’ 
Generating IE1 
YL2 mutant 
vector 
IE1 YL3 
Forward 
5’-
CAGAATGCCGGAGATGGCGGAGATAAGGTTC
AT-3’ 
Generating IE1 
YL3 mutant 
vector 
IE1 YL3 
Reverse 
5’-
AACCTTATCTCCGCCATCTCCGGCATTCTGCAA
-3’ 
Generating IE1 
YL3 mutant 
vector 
IE1 YL4 
Forward 
5’-
CTGTGCTGCGGTGGCGGAGAGGAGACTAGT-3’ 
Generating IE1 
YL4 mutant 
cell line 
IE1 YL4 
Reverse 
5’-AGTCTCCTCTCCGCCACCGCAGCACAGCAC-
3’ 
Generating IE1 
YL4 mutant 
vector 
IE1 YL5 
Forward 
5’-
TGCTGCTATGTCTTAGCGGCGACTAGTGTGAT
GCTG -3’ 
Generating IE1 
YL5 mutant 
vector 
IE1 YL5 
Reverse 
5’-CTCCTCAGCTCCGGCTCCTAGGTCATCCAC-
3’ 
Generating IE1 
YL5 mutant 
vector 
IE1 YL6 
Forward 
5’-
CTGTCCTCAGGAGGTGGGGCTGAGAACAGT-3’ 
Generating IE1 
YL6 mutant 
vector 
IE1 YL6 
Reverse 
5’-GTTCTCAGCCCCACCTCCTGAGGACAGAGG-
3’ 
Generating IE1 
YL6 mutant 
vector 
IE1 YL7 
Forward 
5’-
ATATAGTCGACCCCATGGAGTCCTCTGCCAAG
AG 3’ 
Generating IE1 
YL7 mutant 
vector 
IE1 YL7 
Reverse 
5’-
GCGCAGAATTCTTAGCTCTTGCCTCCAGAGGC
GGTGGGTTCCTC-3’ 
Generating IE1 
YL7 mutant 
vector 
IE1 
K450R 
Forward 
5’-
GACACTGTGTCTGTCAGATCTGAGCCAGTGTC
TG-3’ 
Generating IE1 
K450R mutant 
cell line 
IE1 
K450R 
Reverse 
5’-
CAGACACTGGCTCAGATCTGACAGACACAGTG
TC-3’ 
Generating IE1 
K450R mutant 
vector 
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myc-
EBNA1 
Forward 
5’-
CGTGGGTCGACCCATGGCATCAATGCAGAAGC
TGATCTCAGAGGAGGACCTGCTTATGGCCATG
TCTGACGAGGGGCCAGGTACAGGACCTGGAA
ATGGC-3’ 
Generating 
myc tagged 
EBNA1 vector 
myc-
EBNA1 
Reverse 
5’-
CGTGAGAATTCTCACTCCTGCCCTTCCTCACCC
TCATCTCCATCACC-3’ 
Generating 
myc tagged 
EBNA1 vector 
 
2.1.8 Antibodies 
2.1.8.1 Primary Antibodies 
Table 2.3 List of primary antibodies 
Antibody Origin Application Source 
IE1 (1B12) Mouse IF/WB Thomas Shenk 
lab (Zhu et al., 
1995) 
IE1+ IE2 (E13) Mouse IF/WB Serotec 
IE2 (5A8.2) Mouse IF/WB Millipore 
ICP0 (11060) Mouse IF/WB (Everett et al., 
1993) 
pp71 (UL82) Mouse WB Thomas Shenk 
lab (Bresnahan 
& Shenk, 2000) 
myc (9E10) Mouse IF/WB Santa Cruz 
myc (Ab9106) Rabbit IF/WB Abcam 
FLAG (M2) Mouse IF/WB SIGMA 
pp52 (UL44, Sc-
56971) 
Mouse IF/WB Santa Cruz 
pp28 (5C3) Mouse IF/WB Abcam 
EGFP (ab290) Rabbit WB Abcam 
PML (A301-167A) Rabbit IF/WB Bethyl 
Laboratories 
PML (5E10) Mouse WB Gift from Roel 
van Driel 
(Stuurman et 
al., 1992). 
Tubulin (DM1A) Mouse WB Abcam 
 
2.1.8.2 Secondary antibodies 
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Table 2.4 List of secondary antibodies 
Antibody Application Source 
Sheep anti-mouse IgG hrp 
conjugated antibody (A4416) 
WB Sigma 
Goat anti-rabbit IgG hrp 
conjugated antibody (A0545) 
WB Sigma 
Donkey anti-mouse Alexa 555 
conjugated antibody (A31570) 
IF Invitrogen 
Goat anti-rabbit Alexa 633 
conjugated antibody (A21071) 
IF Invitrogen 
Goat anti-mouse Alexa 633 
conjugated antibody (A21050) 
IF Invitrogen 
Donkey anti-rabbit Alexa 555 
conjugated antibody (A31572) 
IF Invitrogen 
 
2.1.9 Restriction endonucleases 
All restriction endonucleases and the respective buffers in this study were ordered from 
New England Biolabs. 
2.1.10 General Solutions 
Lauria-Bertani (LB) broth: 10 g NaCl, 10 g Bactopeptone, 5 g yeast 
extract in 1 L water, pH 7.5 
Phosphate buffered saline (PBS):  170 mM NaCl, 3.4 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.2 
SDS-PAGE loading buffer:  50 mM Tris-HCl, pH 6.8, 2.24% SDS (w/v), 
11.1% (v/v) glycerol, 666.6 mM β-
mercaptoethanol 
STET:  8% (w/v) sucrose, 5% (v/v) Triton-X 100, 50 
mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0 
40×TAE:  40 mM Tris, 1 mM EDTA, 5 mM sodium 
acetate, glacial acetic acid to pH 7.6  
Tris-EDTA (TE): 10 mM Tris-HCl, pH 8.0, 1 mM EDTA 
Versene:     0.6 mM EDTA in PBS, 0.02% phenol red 
X-gal solution:  5 mM potassium ferrocyanide, 5 mM 
potassium ferricyanide, 2 mM magnesium 
chloride, 0.01% NP 40, in PBS; X-gal in 
DMSO (40 mg/ml) added to a final 
concentration of 2.4 mM 
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2.2 Methods 
2.2.1 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was used for making mutations in the IE1 sequence, 
using Phusion DNA polymerase (Thermo Scientific, catalogue number: F-530S) and 
buffers supplied by the manufacturer. 
2.2.1.1 Standard PCR reaction mixtures 
Standard PCR mixtures were prepared as follows: 
 
 
 
 
 
 
Table 2.5 Reagents for PCR  
Reagent Quantity 
Template DNA 50 ng 
Primer 1 1 µl (10 µM stock) 
Primer 2 1 µl (10 µM stock) 
5x HF Phusion Buffer (Thermo Scientific, 
catalogue number: F-518) 
10µl 
dNTPs (New England Biolabs, catalogue 
number: N0447S) 
1 µl 
Phusion polymerase 1 µl 
dH2O to 50 µl 
 
2.2.1.2 Standard PCR cycling conditions 
Standard PCR cycling programmes were set up as follows: 
Initial denaturation at 98℃ for 30 seconds 
Cycle number set up for 25-30 times repeat of the following: 
98℃ for 30 seconds 
60℃ for 30 seconds (this temperature was adjusted for annealing temperatures of primers 
used) 
72℃ for 30 seconds 
Final elongation: 
72℃ for 5 min 
Holding process: 
80 
 
4℃ hold 
 
2.2.1.3 Purification of PCR products 
PCR products were isolated using 1.2% agarose gels, then purified using a commercial 
PCR fragment purification kit (Dundee Cell Products). 
2.2.1.4 PCR fragment digestions 
Purified PCR fragments were treated by restriction endonuclease digestion to create 
suitable 5' - and 3' ends for ligation.  
DNA fragment digestion conditions: 
Table 2.6 Reagents for DNA fragment digestion 
Reagent Quantity 
PCR fragment 5-10 µl (depending on the concentration of 
fragment) 
Restriction endonuclease 1 µl 
10X restriction endonuclease 
buffer (New England Biolabs) 
3 µl 
dH2O to 30 µl 
 
The DNA digestion mixture was incubated at 37℃ for 1-2 h, and then the fragments were 
separated and isolated by DNA agarose electrophoresis. The fragments were purified again 
using the commercial PCR fragment purification kit. 
2.2.1.5 PCR fragment ligations 
The PCR products and vector fragments for ligation were isolated by 1.2% DNA agarose 
gel electrophoresis and purified using commercial DNA purification columns. Generally, 
vector fragments were prepared by digesting 10 µg of plasmid DNA. Purified DNA 
segments were eluted from the columns in 30 µl elution buffer. 
The PCR segments were digested by the same enzymes used to cut the plasmid vectors, by 
virtue of the appropriate recognition sequences within the primers used to generate the 
PCR fragments.  
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Ligation mixtures: 
Table 2.7 Reagents for DNA ligation 
Reagent Quantity 
PCR fragment (enzyme digested) 5 µl 
Plasmid vector fragment 5 µl 
10x Ligase buffer (New England Biolabs, 
Catalogue number: B0202S) 
3 µl 
T4 DNA Ligase (New England Biolabs, 
Catalogue number: M0202S) 
1 µl 
dH2O to 30 µl 
 
 
Control ligation mixture: 
 
Table 2.8 Reagents for DNA ligation control 
Reagent Quantity 
Plasmid vector 5 µl 
10x Ligase buffer (New England Biolabs, 
Catalogue number: B0202S) 
3 µl 
T4 DNA Ligase (New England Biolabs, 
Catalogue number: M0202S) 
1 µl 
dH2O to 30 µl 
 
The ligations were done at RT for 8 h or overnight.  
 
2.2.2 DNA manipulation  
2.2.2.1 Small scale DNA purification 
Boiling method 
This method is a home-made plasmid extraction method for small scale E. coli cultures. 
Plasmid quality obtained by this method is not as clean as that using a commercial kit, but 
it is quicker and cheaper. This method is suitable for testing ligation products purified from 
the transformed colonies.  
Transformed E. coli cultures were plated on selective plates and incubated at 37℃ 
overnight. The following day, single colonies were inoculated into 5 ml liquid broth 
containing appropriate selection antibiotics, then incubated at 37℃ overnight. On the next 
day, 1.3 ml of the culture was transferred into 1.5 ml Eppendorf tubes, and then the 
bacteria were pelleted by centifugation at 13,000 rpm for 1 min. If growth of the cultures 
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was poor (often the case with lentiviral vector plasmids) a pipette was used to take out the 
supernatant and add an extra 1.3 ml of the E. coli culture medium, and the centrifugation 
was repeated. The supernatant was removed, then 200 µl STET (10 mM Tris-HCl pH 8.0, 
1 mM EDTA, 100 mM NaCl, and 5% Triton™ X-100 (v/v)) buffer was added. The pellet 
was vortexed to re-suspend the bacteria, then 5 µl of 10 mg/ml lysozyme (freshly made, 
dissolved in STET buffer) was added to the re-suspended bacteria, then vortexed to mix. 
The Eppendorf tubes were immediately transferred into a boiling water bath for 50 sec, 
then the mixture was centrifuged at 13,000 rpm for 15 – 30 min. 180µl of the supernatant 
was transferred to a new Eppendorf tube, supplementing the volume with fresh STET if 
necessary, then  165 µl of isopropanol was added. After vortexing, the mixture was 
centrifuged at 13,000 rpm for 2 min. At this stage, the precipitate was usually visible in the 
bottom or on the sides of the Eppendorf tube. The supernatant was removed, and then 200 
µl of 80% ethanol was added before another centrifugation for 30 sec. The supernatant was 
removed and the tube centrifuged for another 30 sec so that the last of the supernatant 
could be removed. The pellet was air dried then dissolved in 30 µl dH2O or TE buffer. 
This is an economical method to test DNA ligations to identify the required clone. The 
DNA purified by this method is not suitable for transformation and needed to be further 
purified using the commercial PCR fragment isolation kit for further application.  
2.2.2.2 Large scale DNA purification 
Once suitable clones were identified, large scale plasmid DNA preparations were made by 
inoculating a single colony from a fresh transformation plate into 300 ml liquid bacterial 
medium containing selection antibiotics. After incubation at 37℃ with shaking (180 rpm) 
for 12 h or overnight, a Plasmid Xtra Midiprep Kit (MACHEREY-NAGEL, ref. 
740410.100) was used for plasmid extraction. All protocols were according to the 
manufacturer’s instructions. 
2.2.2.3 DNA sequencing 
DNA sequencing in this study was performed by the Dundee Sequencing Service. Primers 
used for DNA sequencing were purchased from Sigma-Aldrich. All protocols for plasmid 
and primer preparation were as advised by Dundee Sequencing Service. 
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2.2.2.4 DNA agarose gel electrophoresis 
DNA segments were separated using electrophoresis on 1% or 1.2% (w/v) agarose gels in 
1 X TBE buffer) at 100 V. DNA gels were stained by incubation in ethidium bromide (EB, 
0.5 µg/ml) for 30 min, then gels were photographed using a GelDoc (BioRad) imager 
under UV light. For DNA fragment isolation, the gels were examined using a long wave 
UV transilluminor, then the DNA segments were cut from the gel and purified using 
commercial kits (Dundee Cell Products). 
2.2.2.5 Bacterial transformation  
Commercial chemically competent DH5α and Stbl3 E.coli strains were aliquoted and 
stored in a -70℃ freezer to maintain viability. Before transformation, the competent cells 
were thawed on ice for 15 mins and then 3-5 µl of ligation mixture (or 0.5 µg of plasmid 
DNA) was added to 30 µl competent cells. The plasmid was incubated with the cells on ice 
for 30 min, then the mixture was heat shocked for 45 sec in a 42℃ water bath before 
returning to ice for 1 min. Then 300 µl of liquid bacteria medium was added to the heat-
shocked cells which were then incubated at 37℃ with shaking (200 rpm). After 1 h of 
incubation, the whole culture was plated on bacterial agar plates with selection antibiotics, 
which were then incubated at 37℃ overnight. 
2.2.3 Generating lentivirus transduced cell lines 
2.2.3.1 Transfection of HEK-293T cells 
1.5x106 HEK-293T cells were seeded into 60 mm plates with 4 ml DMEM medium 
(DMEM with 10% FCS, 0.1% P/S). On the next day, the HEK-293T cells were 50-70% 
confluent and ready for transfection.  
The production of lentivirus requires co-transfection of three plasmids as follows: a pLKO-
based lentivirus vector plasmid, pVSV-G to provide the envelope protein, and pCMV-
DR8.91 to provide lentiviral helper functions. 3µg of each plasmid was used for each 
transfection. 
In the first step of transfection, a mixture of 8 µl Lipofectamine PLUS reagent, 250 µl 
serum-free DMEM medium and 3µg of each plasmid was made then incubated at RT for 
15 min. In the second step, 12 µl lipofectamine reagents was added to 250 ul of serum-free 
DMEM, mixed, and then added to the plasmid-containing mixture that was made in the 
first step. This was then incubated at RT for 15 min. During the incubation time in the 
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second step, the HEK-293T cells that had been seeded one day before were washed with 
serum-free DMEM medium twice. In the third step of the transfection, 850 µl serum-free 
DMEM medium was added to each DNA/PLUS/lipofectamine mixture. Then this final 
mixture was added to the pre-washed HEK-293T cells. After incubation of the cells for 3 h 
at 37℃, 3 ml DMEM complete medium with 30% FCS was added to each plate and 
incubated at 37℃ overnight or 12 h.  
After this primary incubation, the plasmids should have gained entry into the HEK-293T 
cells. The mixture was removed and replaced with 4 ml of fresh DMEM medium 
containing 30% FCS. 
24h later, the supernatant was collected and another 4 ml of fresh DMEM medium 
containing 30% FCS was added to the cells. On the next day, the supernatant was collected 
again and added to the previously collected medium. This lentivirus containing medium 
was centrifuged at 1500 rpm (Sorvall bench top centrifuge) and then filtered through a 45 
micron sterile filter to remove debris and dead cells. The lentivirus supernatant was then 
ready for use, or alternatively it could be stored at 4℃ for 24 h before use. 
2.2.3.2 Lentivirus infection 
HepaRG or HFT cells were set up the day before lentivirus infection at 6x105 cells in each 
60 mm dish. When infecting the cells, 1.5 ml lentivirus containing medium was added to 
each plate with 1.5 µL polybrene at 5 µg/ml. The plate was then agitated every 10 min at 
37℃ (for giving a better lentivirus attachment) and after 1h the supernatant was 
removed and add another 1.5 mL of lentivirus medium with polybrene was added. The 
plate was then incubated at 37℃ for 1 h without shaking. Infection with lentivirus-
containing medium was then repeated for a third time before finally the remaining 
lentivirus medium with the same concentration of polybrene was added for overnight 
infection. On the next day, the medium was changed and the appropriate antibiotic was 
added to select for the transduced cells.   
The selection antibiotics used in this study were G418 (used at 500µg/ml), puromycin 
(used at 1 µg/ml) and blasticidin (used at 1 µg/ml). 
2.2.3.3 Inducing protein expression  
In this study, Tet-ON control system was used for making inducible cell lines. The 
induction of cell lines to express proteins from the genes inserted into the lentiviral vectors 
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was achieved by adding doxycycline (100 ng/ml for final concentration) to the cell culture, 
usually 24 h before further experimentation. Details of the expression system and other 
aspects of the lentiviral vectors used in this study are explained in sections 3.3 and 4.2.1. 
2.2.4 Western blot analysis  
Western blotting buffers 
Western blotting was conducted on standard Tris-glycine gels using the following buffers 
and reagents: 
Table 2.9 List of western blot butters and components 
Buffers and solutions Components 
Resolving buffer (RGB) 181.5 g/L Tris-HCl pH 8.8, 4 g/l SDS 
Stacking buffer (SGB) 59 g/L Tris-HCl pH 6.8, 4 g/l SDS 
Running buffer 6.32 g/L Tris base, 4 g/l  glycine, 1 g/l  
SDS 
Transfer buffer (TOWBIN) 20% methanol, 25 mM Tris, 192 mM 
glycine, pH 8.3 
Blocking solution 5% (w/v) skimmed milk in PBST 
Stripping buffer 2% SDS, 62.5 mM Tris-HCl, 100 mM β-
mercaptoethanol, pH 6.7 
Washing buffer (PBST) PBS with 0.1%Tween 20 
 
PBS solution was made by diluting 10X PBS, which was provided by Sigma-Aldrch, with 
dH2O. 
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Table 2.10 List of western blotting reagents 
Reagents Source 
Acrylamide :(N,N′-methylene-bis  
acrylamide) (30:1 w/w), 30% solution 
BioRad 
Ammonium  Persulphate (AP), made up to 
10% w/v with dH2O 
BioRad 
TEMED (N,N,N',N'-
tetramethylethylenediamine) 
Sigma-Aldrich 
Rainbow markers Invitrogen 
Photographic film Kodak Ltd 
Hybond (H+) nylon membrane GE Healthcare (cat. #10600015) 
ECL Western Blotting Detection Reagents  Perkin-Elmer (cat. # NEL 
101001EA) 
ECL Plus Western Blotting Detection 
Reagents  
Perkin-Elmer (cat. # NEL 
103001EA) 
ECL Prime Western Blotting Detection 
Reagent 
GE Healthcare (cat. # RPN2236) 
 
2.2.4.1 Protein sample preparation 
The composition of the 3X sample loading buffer was as follows: 1 ml SGB, 1 ml 20% 
SDS, 1 ml glycerol, 0.5 ml 14 M β-mercaptoethanol, bromophenol blue dye. Stored at –
20℃. Diluted to 1X loading buffer by addition of water.  
For cells in 24-well plates, 70µl of 1X loading buffer was added to each well to prepare 
whole cell protein samples, which were boiled the samples for 5 min and then centrifuged 
for 1 min before 10-30 µl aliquots were loaded on a gel. 
2.2.4.2 Preparation of the resolving gel 
For the preparation of 7.5% acrylamide gels, 5 ml dH2O, 2.5 ml RGB, 2.5 ml acrylamide 
solution (30:1) were mixed, then 80µl 10% APS and 8µl TEMED were added to catalyse 
polymerisation. For 10% polyacrylamide gels the mixture contained 4.2 ml dH2O, 2.5 ml 
RGB, 3.3 ml acrylamide, 80µl 10%APS, and 8µl TEMED. The resolving gel solution was 
poured immediately into glass gel plate sandwiches, and then dH2O was carefully overlaid 
on top of the resolving gel solution. The stacking gel solution was prepared while the gel 
set. 
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2.2.4.3 Preparation of the stacking gel 
For all gels, the stacking gel solution contained 1.4 ml dH2O, 0.6 ml SGB, 0.4 ml 
acrylamide (30:1), 20µl 10%APS, and 6µl TEMED. 
The water on the top of the resolving gel was poured off after the gel had set, then the 
stacking gel solution was added on top before fixing the gel the gel comb in place. The gel 
was then left to set firm before the comb was gently removed and the wells washed with 
dH2O before the completed gel sandwich was placed in the electrophoresis apparatus. 
2.2.4.4 Gel running and transfer 
A BioRad MiniProtean II kit was used for gel electrophoresis and western blot transfer. 
The protein samples were loaded on the gel and electrophoresis performed at a constant 
100 V for 2 h (10% resolving gels) or 1 h (7.5% resolving gels), or until the bromophenol 
blue dye reached the bottom of the gel. After electrophoresis had been completed, the gel 
was removed from the gel plates and placed in a sandwich between filter papers with a 
nitrocellulose filter in contact, while immersed in transfer buffer. This sandwich was then 
inserted into a transfer holder with nylon pads, and the proteins were transferred to the 
nitrocellulose membranes by electrophoresis for 2-3 hours at a constant 250m Amps in 
transfer buffer (TOWBIN). 
2.2.4.5 Membrane blocking and antibody blotting  
After the Western Blot transfer, the nitrocellulose membrane was washed in PBST, placed 
into 20 ml PBST with 5% dried milk and blocked by incubating the membrane at 4℃ 
overnight or for 2 h at RT with shaking. Subsequently, the primary antibody dilution was 
added to the membrane and incubated at RT for 2 h with shaking. Alternatively, the 
primary antibody incubation could be done at 4℃ with overnight shaking. Then the 
membrane was washed at least three times with PBST within 20 min before the secondary 
antibody dilution was added to the membrane. Incubation was continued at RT for 1-2 h 
before the membrane was again washed at least three times with PBST in 20 min prior to 
the ECL reaction. Membranes soaked in ECL detection reagent were exposed to X-ray film 
for a range of times before the films were developed in a Konica X-Omat machine. 
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2.2.5 Herpes Virus infection and Cultivation 
2.2.5.1 HSV-1 infection 
HSV-1 was used to infect HepaRG and HFT cell lines in this study. Where necessary, the 
relevant cell lines were induced to express inserted genes by addition of doxycycline (100 
ng/ml final concentration) for 24 h before infection. Virus dilutions were prepared in 
culture medium in order to infect the cells at the required multiplicity of infection (moi). 
Leaving 100 µl of cell culture medium in the wells of 24-well plates to ensure the cells did 
not dry out during virus adsorption, 100 µl of HSV-1 dilution was added to each well and 
the plate was shaken every few min to mix the virus dilution with the cell culture in the 
first hour. After 3h incubation, the mixture was removed from cells and 0.5 ml of fresh cell 
culture medium was added.  
For plaque assays, this overlay included 1% human serum and also doxycycline to 
maintain induction of protein expression when required. Doxycycline was omitted for 
uninduced cells. The human serum prevents virus released into the medium from one cell 
infecting other cells, which means the virus can only transmit by cell-cell contact. HSV-1 
virus used in this study could form plaques that were clearly detected by staining for the β-
galactosidase marker gene within 24 h. The next day, the cell culture medium was removed 
from cells,  then the cells were washed, fixed with glutaraldehyde and stained for β-
galactosidase activity (see ‘blue plaque’ assay method, Section 2.2.5.2). 
2.2.5.2 Titration of HSV-1 – ‘blue plaque’ assay 
The titre of stocks of ICP0 null HSV-1 mutant dl1403CMVlacZ (∆ICP0) was determined 
on U2OS cells, and aliquots of these stocks for use in the work of this thesis were kindly 
provided by Anne Orr. For titration in other cell lines of interest, the mutant HSV-1 has a 
lacZ marker gene whose activity can be detected by blue plaque assay, as follows: 
In the first step, cell medium was removed  from the infected cells (infection processes 
were introduced in section 2.2.5.1) and they were washed with PBS for one time. 
Then, 1% glutaraldehyde in PBS was prepared. The stock glutaraldehyde was warmed 
to 37℃ before dispensing. The steps involving glutaraldehyde were done in the fume 
hood with the fan on, and all glutaraldehyde solutions were disposed down the drain in 
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the fume hood. Pipette tips were rinsed under the tap in the fume hood before 
discarding. 
In the next step, 0.5ml PBS/1% glutaraldehyde was added to each well on 24-well 
plates. The plates were then incubated in the fume hood with the lid on at room 
temp for 20-40 min. 
Then, the PBS/1% glutaraldehyde fix solution was removed from the cells, and the 
fixed cells were washed with PBS for two times. The following steps were done on  
normal bench. 
Blue plaque assay reagent solution (0.5ml for each well on 24-well plate) was 
prepared as follows: 
Table 2.11 HSV-1 blue plaque assay reagents 
Reagent Solution Composition 
5 mM potassium ferrocyanide 1 ml stock 100 mM solution (in fridge) 
5 mM potassium ferricyanide 1 ml stock 100 mM solution (in fridge) 
2 mM MgCl2 0.4 ml 100 mM solution 
0.01% NP40 2 ml 0.1% solution 
PBS to required volume 15.6 ml for prepare 20 ml reagent solution. 
 
Reagent solution was pre-warmed in 37℃ water bath. 
Then, 40 mg/ml X-gal (Melford) in DMSO (Sigma-Aldrich) (20 mg in 500 ul for 
20 ml reagent solution) was prepared. Also warm X-gal solution to 37℃. This 
solution was prepared freshly for each experiment. 
In the next step, the X-gal solution was added drop-wise while vortexing and 
swirling to mix. This step reduces the formation of X-gal crystals.  
Then, the final reagent mix was filtered through a 45 micron filter. This step was 
done immediately before dispensing the reagent mix. In the following step,  the 
PBS wash solution was removed from the cells, and 0.5ml of the final reagent mix 
was added immediately. 
Then, fixed cells were incubated with the final reagent mix at 37℃ for 30-120 min. 
When a good blue colour had developed, the plates were washed with water and 
left on the bench to dry. 
In the final step, the blue plaque numbers were counted and  the virus titre was 
worked out. 
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X-gal is digested by lacZ gene product, which is β-galactosidase, and the digestion product 
dimerizes and oxidizes into an indigo coloured molecule. The reaction is illustrated as 
follows (Figure 2.1). 
 
Figure 2.1 Digestion of X-gal by lacZ gene expression protein (β-galactosidase). 
 
 
2.2.5.3 HCMV infection 
Three HCMV wt strains and various mutants were used in this thesis (see section 2.1.5). 
Histological staining using an antibody against the UL44 Early HCMV protein was used to 
detect the plaques formed on immortalized human fibroblast cell lines and modified to 
express different inserted genes. The infection by HCMV was similar to HSV-1 infection 
after induction of protein expression using doxycycline. In the infection process, the virus 
dilution was prepared first and then the cell culture medium was removed from the cells, 
leaving 100 µl of medium in each well of a 24-well plate. Then the virus dilution was 
added to each well and the plate shaken to mix it. As the HCMV replication cycle is longer 
than HSV-1, the virus inoculum could be left on the cells for 24 h but no longer than 48 h. 
After the primary infection, the virus was removed from the cells and fresh cell culture 
medium with 1% human serum and doxycycline (where required) was added. The HCMV 
plaques were allowed to develop during 7 to 10 days of incubation. During the incubation 
time, it was necessary to add fresh medium or change the medium once or twice. 
2.2.5.4 Cultivating HCMV  
Stocks of HCMV strains and mutants TNwt, TNdlIE1, AD169 and AD169sub82 (∆pp71) 
HCMV were grown on modified HFT cells as follows. TNwt, TNdlIE1 and AD169 were 
grown on HFT.IE1 cells while ∆pp71HCMV was grown on HFT.ICP0 cells. As described 
in the results section, ICP0 and IE1 can increase the infection of HCMV on HFT cells, but 
these cells cannot tolerate ICP0 expression for extended time periods. HFT cells can 
however tolerate IE1expression, which makes the HFT.IE1 cell line a better host for 
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cultivating both wt HCMV and the IE1 mutant TNdlIE1. As pp71 is required for HCMV to 
express immediate early genes, the ∆pp71 HCMV mutant is severely impaired for HCMV 
infection and gene expression. Expression of ICP0 in host cells can complement the mutant 
virus infection (see the relevant Results sections), therefore stocks of ∆pp71 HCMV were 
grown on HFT.ICP0 cells. In all cases, cell monolayers were infected at moi=1 then the 
cells were cultivated for 15 days before the virus-containing supernatant was collected. 
2.2.5.5 HCMV plaque assay 
Immunostaining of HCMV plaques 
The titres of stocks of HCMV TNdlIE1, TNwt and AD169 were determined on HFT.IE1 
cells while that ∆pp71 HCMV was tested on HFT.pp71 cells and HFT.ICP0 cells. 
Infections in subsequent experiments were performed at multiplicities based on these titres, 
for reasons that will be explained in the Results sections. Plaques were detected by 
histological staining for UL44 expression, as follows: 
Cells were seeded in 24-well plates at 1x105 /well, then the next day, doxycycline (100 
ng/ml) was added for induction when necessary. After a further 24 h, the cells were 
infected with HCMV, as described above. After 7 to 10 days of incubation, the cell 
monolayers were washed twice with 0.5 ml PBS and simultaneously fixed and 
permeabilized (F/P)  with F/P solution (F/P solution contains 16 ml PBS, 1 ml 10% NP40 
and 3 ml methanol buffered formaldehyde (37% solution) for 10 to 20 min. The cells were 
then washed twice with 0.5 ml PBST before incubation with 0.5 ml 5% skimmed milk in 
PBST for 30 min at RT on a table shaker. The block solution was removed then the 
primary antibody dilution (anti-UL44, 1:250) was added to the cells at 0.3 ml/well. 
Following incubation at RT for 2 h with horizontal shaking, the primary antibody solution 
was removed and stored for re-use. The cells were washed with 1 ml PBST three times, 
and then the secondary antibody solution (horseraddish peroxidase conjugated antibody in 
5% milk in PBST) was added to the cells at 0.5 ml/well and incubated at RT for 1 h. The 
secondary antibody solution was removed and the cells were washed with 0.5 ml PBST 
three times.  In the final step, 200 µl TRUE BLUE peroxidise stain (KPL, Lot No. 140590, 
Product Code: 50-78-02) was added to each well. The plates were then incubated at RT for 
5-10 min for development of the blue colour. When the blue plaques had formed clearly, 
the TRUE BLUE solution was removed and the cells were washed with water. The plaques 
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were counted soon after staining as the colour fades quite rapidly, and when necessary the 
plates were also scanned to record the data. 
2.2.6 Yeast 2 hybrid assay 
2.2.6.1 Yeast Growth supplements, media and cultures 
All Y2H strains detail is specified in section 2.1.3. The commercial Y2H analysis reagents, 
application and sources are described in Table 2.12.  
Table 2.12 List of yeast growth supplements and media.  
Reagent Preparation Purpose 
YPD broth/medium 
(Sigma-Aldrich) 
Add 50 g of YPD broth to 1 L of 
deionized H2O, then Mix to 
dissolve. Autoclave at 121 °C for 
15 min. Store autoclaved medium 
at room temperature. 
Liquid yeast incubation 
culture including essential 
amino acids. 
Adenine 
supplement 
(Clontech) 
Added to normal YPD medium or 
agar as required to make YPDA 
culture medium or selection plates. 
Added at 55 ℃ after autoclaving 
the YPD agar. 
Prevents yeast strains 
harbouring ADE1 and ADE2 
mutations and enhances 
growth of Y187 with ade2-
101 mutation 
YPD agar (Sigma-
Aldrich) 
Resuspend 65 g YPD agar in 1 L 
medium. Then autoclave and keep 
at 55 ℃ water bath for adding 
medium supplements. YPD agar 
containing 15 g/L agar. 
Agar medium base including 
essential amino acids. 
Drop-out Medium 
Supplements 
(DOBA) (Sigma-
Aldrich) 
1.92 g will supplement 1 L of 
medium. 
Drop-out agar medium base 
lacking essential amino acids 
DO growth 
supplement -Leu (-
L) (Clontech) 
0.69 g will supplement 1 L of 
medium. 
Yeast selection supplement 
for LEU2 expression (pGAD 
plasmid transformed strains) 
DO growth 
supplement -Trp (-
W) (Clontech) 
0.74 g will supplement 1 L of 
medium. 
Yeast selection supplement 
for TRP1 expression (pGBK 
plasmid transformed strains) 
DO growth 
supplement -Leu-
Trp (-L-W) (Sigma-
Aldrich) 
1.54 g will supplement 1 L of 
medium. 
Yeast selection supplement 
for both TRP1 and LEU2 
expression (pGAD and 
pGBK plasmids contained 
strains) 
DO growth 
supplement -Leu-
Trp-His (-L-W-H) 
(Clontech) 
0.62 g will supplement 1 L of 
medium. 
Yeast selection supplement 
for both TRP1, LEU2 and 
HIS3 interaction reporter 
gene expression (mated yeast 
strains selection) 
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Polyethylene glycol 
3350 (PEG) 
Store at room temperature. Increase the binding of 
plasmid DNA to the surface 
of intact yeast cells during 
transformation. 
5-bromo-4-chloro-
3-indolyl-β-D-
galactopyranoside 
(X-gal) (Melford) 
Store at room temperature.  Analysis reagent for lacZ 
gene expression. 
1 M 3AT Added to -L-W-H agar as required. 
Autoclave the 3AT separately with 
the agar. 1mM and 5mM 3AT used 
as final concentration in the -L-W-
H agar plate. 
Eliminate background 
expression of HIS3 gene 
 
2.2.6.2 Reviving glycerol stocks 
Yeast strains were stored in glycerol solution at -70 ℃. It was important to avoid frequent 
thaw of the yeast strain stocks as the transformation efficiency goes down dramatically 
after each time the stock were thawed. A sterile yellow tip was used to pick up an aliquot 
of the frozen stock and this was streaked onto a pre-warmed YPDA plate. The thawed 
yeast strain could be grown on the plate for a maximum of 3 days before re-streaking onto 
a fresh YPDA plate. 
2.2.6.3 Preparation of Yeast Strain Stocks 
A single colony on a YPDA plate was picked and inoculated into 1 ml YPDA media in an 
Eppendorf tube , then this was cultivated the inoculated media at 30 ℃ overnight. On the 
next day, 100 µl 80% glycerol was added into 400 µl of the yeast culture, then the mixture 
was vortexed and frozen down immediately on dry ice. The yeast strain stocks were stored 
at -70 ℃ and could be maintained for 1 year. 
2.2.6.4 Preparation of the parental yeast strains for transformation 
To maintain high transformation efficiency, it was important to re-streak the parental yeast 
strains on YPDA plates at least twice after reviving from the glycerol stocks. Several 
parental yeast strain colonies with 1-2 mm size were selected from a freshly streaked plate 
and inoculated into a 3 ml YPDA yeast media before being cultivated overnight at 30 ℃ 
with shaking. Strain AH109 was used for pGAD plasmid transformations (cultivated in 
medium lacking leucine (-L)) and strain Y187 was used for pGBK plasmid transformations 
(cultivated in medium lacking tryptophan (-W)).  
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2.2.6.5 Transformation of parental yeast strains 
Transformation buffers 
50X TE: 25 ml 1 M Tris-HCl pH 8.0, 10 ml 0.25 M EDTA pH 8.0, made up to 50 ml with 
dH2O (final concentrations 500 mM Tris-HCl pH 8.0, 50 mM EDTA). 
10X TE: 100 mM Tris-HCl pH 8.0, 10 mM EDTA, autoclaved. 
10X LiAc: 1.02 g/ml Lithium acetate, autoclaved. 
50% PEG: 40 g polyethylene glycol (PEG 3350) dissolved in 40 ml dH2O, autoclaved. 
TE/LiAc solution: 1ml 10X TE, 1ml 10X LiAc, 8 ml dH2O. 
TE/ LiAc /PEG solution: 0.5 ml 10X TE, 0.5 ml 10X LiAc, 4 ml 50% PEG. 
Transformation of parental yeast stains was performed by following the manufacturer’s 
instructions. In brief, the protocols are as follows: 
In the first day, 3-5 single colonies from AH109 and Y187 yeast strains were picked up to 
inoculate 750 µl yeast culture. Then the yeast was incubated overnight. In the following 
day, 750 µl parental yeast culture was added to 15 ml fresh YPDA medium and incubated 
for 4 h at 30 ℃ with constant shaking at 200 rpm (final OD600 is about 0.7). In the third 
day, yeast cells were harvested by centrifugation at 3.5 k/min for 5 min. Then, yeast cells 
were washed twice by 2 ml dH2O and two times by 2 ml 1x TE/LiAc solution. In the next 
step, the yeast cells were re-suspended in 75 µl 1x TE/LiAc solution. 50 µl yeast 
suspension, 25 µg denatured herring tested carrier DNA and 1-2 µg plasmid DNA are used 
for each transformation. The transformation mix was incubated in room temperature for 15 
min. And 150 µl TE/LiAc/PEG solution was added to the transformation mix (mix gently). 
In the next step, the transformation mix was incubated for 1 h at 30 ℃ with shaking at 200 
rpm. After the incubation, the transformation mix was heat-shocked at 42 ℃ for 20 min. In 
the following step, 700 µl dH2O was added to the transformation mix and mixed gently. 
The mixture in the last step was centrifuged at 6 K rpm for 1 min. The supernatant was 
discarded and the yeast cell pellet was re-suspended in 400 µl pre-warmed medium. 
AH109 yeast strain was re-suspended in -L medium and Y187 was re-suspend in -W 
medium. In the next step, 200 µl re-suspend yeast cells was plated out onto the appropriate 
pre-warmed -L or -W drop-out agar plates. Then, the transformed yeast strains were 
incubated at 30 ℃. After 4 days incubation, 2 mm diameter yeast colonies were selected 
and re-streaked onto fresh –L or –W drop-out agar plates. 
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2.2.6.6 Mating single transformed yeast strains 
The haploid yeast strains used in this Y2H system could be mated with each other to form 
diploids. The mating between transformed AH109 and Y187 strains formed a diploid strain 
which expressed both AD fusion and BK fusion proteins and which were able to grow in 
the absence of both leucine and tryptophan.  
Several colonies of 2-3 mm diameter of the relevant single transformed yeast strains were 
picked from fresh yeast plates, noting that the size and the number of the colonies from 
two single strains should be keep consistent for getting a maximum mating rate. The 
colonies were inoculated into 0.5 ml YPDA medium and incubated overnight at 30℃ with 
shaking (200 rpm). On the next day, 200 µl of the mating culture was plated onto pre-
warmed -L-W plates. The mated yeast diploids were grown to form colonies during 
incubation at 30℃ over the next 3days. The plates could then be stored at 4℃ for 2 months, 
but it was better to proceed directly to the 3AT growth phenotype assay in order to obtain 
the most reliable data. 
2.2.6.7 3AT based growth phenotype interaction assay 
Diploids in which the BD and AD fusion proteins interact are able to activate expression of 
two reporter genes, one which enables growth in the absence of histidine and the other that 
imparts β-galactosidase activity (lacZ gene product). The presence of 3AT decreases the 
growth of false positive yeast clones. Therefore diploids initially selected on -L-W plates 
could be screened for interactions by patching onto -L-W-H plates in the presence of 3AT, 
then the strength of the interaction could be assessed by staining for β-galactosidase 
activity. The protocols for this assay are as follows. 
In the first day, 10 diploid colonies of 2 mm diameter were picked up from -L-W agar 
plates into 0.5 ml -L-W medium. Then the colonies were mixed by vortexing. Mixed yeast 
was incubated over night at 30 ℃ with constant shaking at 200 rpm for 16 h. In the 
following day, OD600 of the yeast culture was measured and the yeast culture was diluted to 
OD600=0.2 by fresh -L-W medium. In the next step, 7 µl dilutions was applied onto -L-W 
and -L-W-H agar plates containing 0, 1, and 5 mM 3-AT. Agar plates in the last step were 
incubated at 30℃ for positive yeast cells growth. (The reporter genes expression enable the 
yeast cells to grow on -L-W-H plates with 3-AT) 
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2.2.6.8 X-gal staining assay 
X-gal staining solutions 
K2HPO4 solution: 68.5 g K2HPO4(3H2O) dissolved in 300 ml dH20, pH 10 (with HCl) 
(final concentration 1 M), filter sterilised with vacuum pump.  
KH2PO4 solution: 40.8 g KH2PO4 dissolved in 300 ml dH2O, pH 5.5-6.0 (final 
concentration 1 M), and filter sterilised with vacuum pump.  
1M Phosphate buffer solution: 61.5 ml K2HPO4 solution, 38.5 ml KH2PO4 solution, heated 
to 50℃ before use. 
1% agarose: 1% (w/v) agarose dissolved by autoclaving and then kept at 50℃ in a water 
bath before use. 
20% SDS (w/v): dissolve SDS in dH2O. 
40% X-gal solution: 0.16 g X-gal power dissolved in 400 µl DMF. 
The protocol for this assay is as follows: 
Yeast colonies grow on -L-W-H agar plates indicating the successfully mated diploid yeast 
strains. Whereas the -L-W-H agar plates with 3-AT repress back ground growth of diploid 
yeast strains. Another reporter gene in Y2H assay system is the lacZ gene, which is tested 
by X-gal staining. The protocols for X-gal staining are as follows. 
In the first step of this protocol, all buffers were pre-warmed in 50℃ water bath. Then, 5 
ml KPO4 with 600 µl DMF, 50 µl 20% SDS and 40% X-gal solution in DMF were mixed 
for preparing the reactivation solution. In the next step, 5 ml 1% agarose (in dH2O) was 
added to the mixture. Then, the mixture was pipetted above to the yeast agar plates 
immediately and gently. Agar plates were incubated over night at 37℃. In the next day, the 
agar plates were imaged. 
                                       
2.2.6.9 Y2H analysis of protein-protein interaction based on His3/lacZ 
reporter gene expression 
Mated yeast strains were selected on -L-W medium, and then -L-W-H medium. To 
eliminate background growth on -H medium, 1 or 5 mM 3-AT was added into the selection 
medium. The principle of Y2H assay used in this assay is illustrated in Figure 2.2.  
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Figure 2.2 Principles of Y2H analysis for protein/protein interaction.  
The X-gal digestionby lacZ protein (β-galactosidase) was introduced in section 
2.2.5.1. 
 
The GAL4 transcription factor is divided into two domains, which are the DNA binding 
domain (BK) in plasmid pGBK (plasmid information in section 2.1.6) and the activating 
domain (AD) in plasmid pGAD (detailed in section 2.1.6). Target proteins are expressed as 
fusion proteins with the above two transcription factor domains in yeast strains. The pGBK 
plasmids are transformed into Y187 yeast strain and the pGAD plasmids are transformed 
into AH109 yeast strain. Mated yeast strains are selected by -L-W, and then incubated in -
L-W-H medium to select the interaction between BK fusion protein (BK+Bait) and AD 
fusion protein (AD-Prey). 3AT eliminates the back ground growth of mated yeast strains 
on -L-W-H agar. Furthermore, protein/protein interactions between BK+Bait and AD-Prey 
is visualized by X-gal staining. 
2.2.7 Immunofluorescence and confocal microscopy 
2.2.7.1 Preparation of coverslips 
Commercial 13 mm round coverslips were autoclaved in a beaker before using.  
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2.2.7.2 Seed cells on the coverslips 
For observing protein expression in cells, and for virus infection, HepaRG and HFT cells 
were seeded at 1x105 cells per well, resulting in cells at about 50% confluence on the next 
day.  
2.2.7.3 HCMV infection on coverslips 
When infecting cells on the coverslips, most of the medium was removed to leave 100 µl 
medium on the coverslips. Then 100 µl of virus dilution was added and the cells incubated 
for 3 h, after which all medium was removed from the coverslips and replaced with cell 
culture medium with 1% human serum.  
2.2.7.4 Fixing 
20 ml of fixing solution contains 19 ml PBS, 1 ml 37% formaldehyde and 0.4 g sucrose. 
The cell culture medium was removed and the coverslips washed twice with PBS before 
0.5 ml fixing solution was added in a fume hood. After 5 min of treatment with the fix at 
RT, the coverslips were washed twice with PBS. At this stage, the coverslips could be used 
directly in the next stage or stored at 4℃ with 0.5 ml PBS/1% calf serum. 
2.2.7.5 Permeabilisation 
20 ml permeabilisation solution contains 19 ml PBS, 1 ml 10% NP40 and 2 g sucrose. This 
permeabilisation solution (0.5 ml per well) was added to each coverslip and incubated for 5 
min at RT. Then the coverslips were washed twice with PBS/1% calf serum. 
2.2.7.6 Primary antibody staining 
Primary antibodies were used at different dilutions for staining, as indicated in Table 2.13 
The appropriate dilutions of primary antibodies were made up in PBS/1% calf serum. Cells 
could be stained with as many as three primary antibodies simultaneously. In this stage, too 
much antibody could increase background. 
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Table 2.13 List of primary antibodies for IF. 
Antibody Dilution 
mouse anti ICP0 (11060) 1/2000 
mouse anti IE1 (E13) 1/1000 
mouse anti IE1 (1B12) 1/1000 
mouse anti IE2 (5A8.2) 1/1000 
mouse anti pp52 (UL44) 1/1000 
mouse anti myc (9E10) 1/500 
mouse anti FLAG (M2) 1/2000 
rabbit anti PML (A301-167A) 1/1000 
rabbit anti myc (Ab9106) 1/1000 
 
Most antibodies could be diluted to an intermediate concentration using PBS/1% calf 
serum in the presence of 1% sodium azide, then stored at 4℃ for several months without 
loss of functionality. 
For each coverslip, 15-20 µl antibody dilution was enough for staining. The coverslip was 
placed upside down on an antibody dilution drop on the lid of a 24-well culture dish and 
incubated at room temperature for 1-2 h. Then the coverslips were washed at least three 
times with PBS/1% calf serum over 20 min. 
2.2.7.7 Secondary antibody staining 
This was similar to the primary antibody staining. Dilutions of secondary antibodies could 
be prepared at an intermediate concentration using the same storage solution as above and 
stored in 4℃.  
Table 2.14 List of secondary antibodies for IF 
Antibody Dilution 
anti-mouse Alexa555 antibody 1/2000 
anti-rabbit Alexa 633 antibody 1/1000 
anti-mouse Alexa 633 antibody 1/2000 
anti-rabbit Alexa 555 antibody 1/1000 
 
 
Secondary antibodies were incubated with the coverslips in the same manner as described 
above, and then washed several times with PBS/1% calf serum as before. As a final step, 
an extra wash with de-ionized water was required to remove salts from the surface of the 
sample to give cleaner images. Finally, the coverslips were dried and mounted on galas 
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slides with a drop a Citifluor AF1 glycerol-based mounting medium, which includes and 
anti-fade reagent. 
2.2.7.8 DAPI staining 
DAPI (4', 6-diamidino-2-phenylindole) is a fluorescent stain that binds to DNA. It was 
diluted to 0.5 µg/ml for staining the nucleus of cells. DAPI was added with secondary 
antibodies for staining. 
2.2.7.9 Confocal Microscopy 
Confocal microscopy analysis was carried out using a Zeiss LSM 510 or a Zeiss LSM 710 
confocal microscope with 488 nm, 543 nm (561 nm for the LSM 710) and 633 nm laser 
lines, capturing images for each channel sequentially. Samples were observed with a ×63 
(NA 1.4), or ×40 NA oil immersion objective lenses. The images were exported as files in 
tif format using the Zeiss software then edited and assembled for presentation using Adobe 
Photoshop and Adobe Illustrator. 
 
 
 
 
 
 
 
 
101 
 
3 Complementation of ICP0 null HSV-1 infection 
by IE1 and its mutants 
3.1 Introduction to the similarity between IE1 and ICP0 
As described in detail in Chapter 1, IE1 and ICP0 are immediate early proteins expressed 
by HCMV and HSV-1, and they are required for viral infection at low MOI for efficient 
entry into the lytic stage (Everett, 2006b). Although they share no similarities within their 
amino sequences, they still initially co-localise with the same host proteins located in 
ND10. ICP0 degrades PML and SUMO-modified Sp100 in infected cells, whereas IE1 
induces desumoylation of PML and Sp100 instead of degrading them, and disperses them 
into the general nucleoplasm. ICP0 also disperses hDaxx and ATRX from ND10, whereas 
in HCMV the tegument protein pp71 inhibits the repressive activity by interfering with 
their complex formation (Lukashchuk et al., 2008). Previous data have shown the 
expression of IE1 also disperses hDaxx and ATRX from ND10, but this is an indirect 
consequence of PML dispersal(Everett et al., 2013a). An interaction between IE1 and 
hDaxx has been reported, and this was found to rescue the LUNA promoter in latent and 
lytic infection from repression mediated by ATRX (Reeves et al., 2010). The above 
information gave rise to the possibility that the functional similarities between IE1 and 
ICP0 might allow their functional interchange between HSV-1 and HCMV. 
In the work conducted by others prior to initiating the work of this thesis, expression of wt 
IE1 in an inducible cell line system was found to substantially increase plaque formation 
by ICP0 null mutant HSV-1 (Everett et al., 2013a). The work described in this chapter 
investigated characteristics of IE1 that were required for this activity. 
 
3.2 Generation of IE1 mutant sequences 
Previous studies in the laboratory showed that the replication defect of ICP0-null mutant 
HSV-1 could be partially overcome by HCMV protein IE1 (Everett et al., 2013a). Here, 
this study was extended to several IE1 mutants.  By analysing IE1 protein sequences from 
different primate CMVs (as indicated in Figure 3.1 A; original alignments provided by Dr 
Andrew Davison), a number of conserved regions and potential SUMO interaction motifs 
(SIMs) were identified. The potential SIMs (characterised by a quartet of residues rich in 
leucine, isoleucine and valine residues (Song et al., 2004) were of interest because one 
potential mechanism of IE1 inducing desumoylation of PML might involve SUMO-SIM 
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interactions. Conserved amino acid residues within these regions were changed to glycine 
or alanine by site directed mutagenesis. The IE1 mutants prepared in this stage were later 
assayed for complementation of ICP0-null HSV-1 infection to analyse the properties of the 
mutants.  
 
 
 
 
 
 
Figure 3.1 A map of the locations of the IE1 mutants analysed in this study. 
(A) IE1 sequences of the regions chosen for mutagenesis, showing the aligned 
sequences of human, chimpanzee, green monkey, and rhesus macaque CMVs (HCMV, 
CCMV, gmCMV, and rhCMV). The conserved residues are indicated, with an asterisk 
indicating similar residues rather than precise conservation in all sequences. The 
lowermost row shows the sequences of the mutants, with the mutated residues highlighted. 
(B). A map of the IE1 coding sequence showing the locations of the exon2 and exon3 
sequences shared with IE2,  the acidic C-terminal region, the chromatin tethering domain 
(CTD) and the positions of IE1 mutants. Figure taken from (Everett et al., 2013a). 
 
YL1 and YL2 are located in the region that is shared between IE1 and IE2. The mutation 
sites of YL3 and YL4 are located within the hydrophobic core of IE1 and the mutations 
also affect the hydrophobic groups within YL3 and YL4. Although these are substitution 
rather than more drastic deletion mutations, these might lead to instability of the IE1 3D 
structure and therefore impair its function. YL5 and YL6 were identified as potential SIMs 
for which the importance required investigation. YL7 deletes 12 amino acids of the C-
terminal domain where contains an acidic domain that plays a regulatory role and a 
chromatin-tethering domain (Reinhardt et al., 2005). Furthermore, the investigation by 
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different groups demonstrated the dispensable role of this region during HCMV infection 
(Reinhardt et al., 2005; Shin et al., 2012). IE1 mutant K450R was reported to be deficient 
in SUMO modification but it had no effect on IE1 bioactivity when analysed in 
transfection assays (Xu et al., 2001), although it does reduce virus growth in the context of 
the viral genome (Nevels et al., 2004a).  
 
3.3 HepaRG cells expressing IE1 wt or IE1 mutants 
The IE1 mutant sequences were inserted into lentivirus plasmid vectors for transduction 
into HepaRG-based cells (for convenience, all cells based on HepaRG are named with the 
prefix HA-). The inducible expression system used is controlled by Tet-On elements that 
are provided by two lentivirus plasmids. Lentiviruses produced by the 
pLKOneo.CMV.EGFPnlsTetR vector produce a fusion protein EGFPnlsTetR that localizes 
in the nucleus, provides EGFP for visualisation and has tetracycline repressor activity 
(Everett et al., 2009). Cells produced by transduction with this vector are named HA-TetR. 
The IE1 sequence was inserted into another lentivirus vector plasmid, pLDT.IE1 (Everett 
et al., 2013a). In this plasmid, the IE1 coding sequence is located downstream of TetO 
operator sequences with a truncated HCMV promoter/enhancer (DCMV) upstream. HA-
TetR cells transduced with this vector are named HA-TetR-IE1 wt. 
104 
 
 
 
Figure 3.2 Plasmid map of pLKOneo.CMV.EGFPnlsTetR and pLDT.IE1. 
(A) Plasmid map of pLKOneo.CMV.EGFPnlsTetR vector. This plasmid encodes 
the EGFPnlsTetR fusion protein under the control of the HCMV IE promoter. The key 
features of the lentivirus vector are noted: pac, HIV packaging sequence; RSVp, RSV 
promoter; RRE, Rev response element; hPGK, human phosphoglycerate kinase promoter; 
Neo r, G418 resistance coding sequence. (B) Plasmid map of pLDT.IE1. The expression of 
IE1 is controlled by TetO operator sequences and promoted by a truncated HCMV 
promoter-enhancer. Puro r indicates puromycin resistance. 
 
This system has been used extensively in our laboratory (Everett et al., 2009) and has been 
used to express IE1 in MRC-5 cells successfully (Knoblach et al., 2011). Three vectors 
were used in this system for transduction. They are pVSV-G, pCMV.DR.8.91 and 
pLKOneo.EGFPnlsTetR or pLDT.IE1. Plasmids functions were described in Table 2.1. 
HEK-293T cells were transfected with the plasmid mixture in order to cultivate lentivirus 
for transduction. HA cells were transduced with the EGFPnlsTetR lentivirus in the first 
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step, then the resulting HA.TetR cells (selected with G418 resistance) were used for 
secondary transduction to insert the IE1 gene into the cellular genome. In uninduced cells, 
the tetracycline repressor fusion protein binds to the TetO operator sequences and inhibits 
transcription of the IE1 coding sequence. Treatment with doxycycline inhibits the binding 
of the EGFPnlsTetR to TetO sequences and thus allows IE1 gene expression.  
To make each mutant, the IE1 sequence was modified by a PCR splicing approach. For 
each mutant, forward and reverse DNA primers were designed to change the IE1 sequence 
in the PCR amplification process, and in the initial PCR these were used with primers 
encoding the N- or C-terminal ends of IE1, as relevant. These latter primers also included 
restriction sites to enable later insertion into the vector. The information on the primers is 
shown in Table 2.2. The two PCR products were then mixed and used as a template for a 
second PCR reaction with the N- and C-terminal primers only, to produce a full length IE1 
coding sequence product with the required mutations. The IE1 mutant sequences were 
digested by restriction enzymes and then ligated with the pLDT vector to replace the IE1 
wt sequence. Ligation products were transformed into Stbl3 chemical competent E.coli 
cells and plated on agar plates with selection antibiotics. Single colonies were picked up 
for miniprep analysis, then purified plasmids were sequenced and analysed to confirm the 
IE1 mutation sequence. 
HA.TetR.IE1 YL1-YL7 and K450R cells were generated by the same methods as used for 
the HA.TetR.IE1 wt cells. The resulting cell lines were analysed by WB (Figure 3.3) and 
IF (Figure 3.5) to investigate IE1 expression after induction with doxycycline. 
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Figure 3.3 WB analyses of HA.TetR.IE1 and IE1 YL1-YL7 and IE1 K450R cell lines.  
Cells were induced by treatment with 100 ng/ml doxycycline for 24 h (+) or left 
untreated (-). The induced and uninduced whole cell lysates were collected and analysed 
by western blotting using anti-IE1 (mAb E13) and anti-tubulin antibodies as indicated. The 
positions of molecular weight standards (in thousands) are indicated to the right of each 
panel. 
 
All IE1 mutant cell lines expressed similar levels of IE1 after 24 h induction by 
doxycycline. The anti-IE1 mAb used in this experiment (mAb E13) recognizes an epitope 
in the first 24 amino acid residues of IE1 (Mazeron et al., 1992). It appears that the 
mutation sites of IE1 YL1 at residues 14 and 16 damage the binding site of this IE1 
antibody. Thus, anti-IE1 E13 mAb detected IE1 very inefficiently in Figure 3.3. SUMO 
modification of IE1 YL2, IE1 YL5 and IE1 YL6 were similar to IE1 wt, whereas IE1 YL3, 
IE1 YL4, IE1 K450R and IE1 YL7 were not SUMO modified. The absence of sumoylation 
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of mutant K450R is expected from the published mapping of the sumoylation site of IE1 
(Nevels et al., 2004a; Xu et al., 2001), whereas mutations YL3 and YL4 in the 
hydrophobic core of the protein may destabilise the whole structure, as noted above. 
Deletion of the conserved C-terminal motif (residues 480-491) in YL7 also disrupts 
sumoylation, perhaps by affecting the conformation of the protein in the vicinity of the 
nearby K450 residue, or interactions with the sumoylation machinery. Reduction of 
sumoylation of IE1 lacking the CTD is consistent with other recent work (Shin et al., 
2012). 
 
3.3.1 Characterisation of the effects of the IE1 mutants on 
sumoylation of PML 
IE1 interacts with ND10 and de-sumoylates PML, activities that are important functions 
for HCMV to counter the intrinsic immune resistance of host cells. Desumoylation of PML 
was analysed in IE1 mutant expressing cell lines. (Figure 3.4) 
 
 
 
Figure 3.4 WB analysis of HA.TetR.IE1 wt and IE1 YL1-YL7 and IE1 K450R cell lines. 
 Cells were treated with 100 ng/ml doxycycline for 24 h. The induced and 
uninduced cell lysates were collected and analysed by western blotting, then probed by 
anti-IE1 mAb, anti-PML rAb and anti-Tubulin mAb as indicated. (IE1 expression images 
are also shown in Figure 3.3). The positions of molecular weight standards (in thousands) 
are indicated to the right of each panel. 
 
Figure 3.4 shows that PML was de-sumoylated by IE1 YL1 in the same manner as IE1 wt, 
confirming the expression and activity of IE1 YL1 despite it not being detected by mAb 
E13. Mutants IE1YL3 and IE1 YL4 cannot de-sumoylate PML in HA cells. These two 
mutant sequences are located in the hydrophobic core of IE1, therefore, changing the 
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amino acids from Y or L to G deletes the hydrophobic groups which may influence the 
hydrophobic interaction between amino acids and destabilize the whole protein 3D 
structure. Mutants IE1 YL2, YL5, YL6, K450R and YL7 all de-sumoylated PML in a 
similar manner as IE1 wt, indicating that the mutated amino acids are dispensable for IE1’s 
effects on PML. 
 
3.3.2 IF analysis of the IE1 mutants 
IE1 initially co-localises with PML in ND10, then desumoylates PML and disperses PML 
and the other ND10 proteins. These functions are important for HCMV to progress into 
lytic infection. HA.TetR.IE1, IE1 YL1-YL7 and IE1 K450R cells were induced to express 
the inserted viral genes to investigate IE1 and the IE1 mutants’ interaction with PML and 
ND10. The confocal microscopy images are shown in Figure 3.5. 
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Figure 3.5 IF assay of the interaction between IE1 and PML.  
Panels A, B, C, D, E, F, G, H, I, J are the IF images of HA.TetR cells expressing 
IE1,  IE1 YL1, IE1 YL2, IE1 YL3, IE1 YL4, IE1 YL5, IE1 6YL, IE1 YL7, IE1 K450R 
respectively. EGFP images indicate EGFPnlsTetR expression in the HA cell lines. Induced 
cells were incubated with medium containing 100 ng/ml doxycycline for 24 h. Induced and 
uninduced cells were fixed and permeabilized, then stained with anti-IE1 mAb and anti-
PML rAb primary antibodies, followed by anti-mouse Alexa 555 and anti-rabbit Alexa 633 
conjugated secondary antibodies. 
 
Figure 3.5 (A) shows EGFPnlsTetR expression in HA.TetR cells and doxycycline 
treatment of these cells had no effect on PML localization. In Figure 3.5 (B), HA.TetR.IE1 
cells expressed IE1 after induction. IE1 dispersed PML in the nucleus and de-SUMO 
modified PML, which was shown in Figure 3.4. Figure 3.5 panels (C), (D), (G) and (H) 
show expression of IE1 YL1, IE1 YL2, IE1 YL5 and IE1 YL6 mutants in HA-TetR cells. 
These IE1 mutants have different mutation sites in the IE1 sequence that are conserved 
among different primate CMVs and they have some similarity to SIMs. WB analysis 
showed that these mutations had no effect on the ability of IE1 to desumoylate PML 
(Figure 3.4). In the IF analysis, these IE1 mutants dispersed PML in nucleus in the same 
manner as IE1 wt. In Figure 3.5 (J), IE1 K450R (which cannot be SUMO modified but can 
de-sumoylate PML (Figure 3.4)) was also able to disperse PML, which is consistent with 
reported data (Spengler et al., 2002; Xu et al., 2001). Figure 3.5 (I) shows IE1 YL7 
expression in HA-TetR cells. IE1 YL7 has a deletion of residues 480-491, and these 12 
amino acids at the C- terminal end of IE1 were shown to be important for SUMO 
modification, but dispensable for PML desumoylation (Figure 3.4) and dispersal of PML in 
the nucleus. Mutants IE1 YL3 and IE1 YL4, which had no effect on PML in the WB assay 
(Figure 3.4), were unable to disperse PML from ND10 (Figure 3.5 parts E and F). 
The viral protein expression system that has been used in this study allows a minor amount 
of expression prior to induction (less than 1% cells observed are IE1 positive). This 
leakiness provides a chance to observe the activity of IE1 and its mutants when expressed 
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Figure 3.6 Localisation of IE1 wt and the YL mutants when expressed at low levels. 
IF images of induced and uninduced HA.TetR.IE1 and IE1 YL3, YL4 cells. Cells 
were treated with medium containing 100 ng/ml doxycycline for 24 h, or left uninduced. 
Induced and uninduced cells were fixed and permeabilized, then stained for IE1 (lower row 
of each pair of rows) and PML as described for Figure 3.5. 
 
Figure 3.6 shows that IE1 wt co-localizes with PML expressed at low levels within leaky 
uninduced cells and disperses PML when the cells were induced to express high levels of 
IE1. On the other hand, mutants IE1 YL3 and IE1 YL4 didn't co-localize with PML when 
expressed at low levels or disperse it after induction. These results indicate the importance 
of the YL3 and YL4 sequences for the ability of IE1 to co-localise with PML. 
3.4 Complementation of ICP0 null HSV-1 by IE1 and its 
mutants 
Previous work in the laboratory conducted by MRes student Adam Bell had shown that wt 
IE1 can partially complement ICP0-null mutant HSV-1 infection. Therefore the 
HA.TetR.IE1 mutant cell lines constructed in this study were investigated for their ability 
to complement ICP0 null HSV-1. Induced cells were infected by ICP0-null mutant HSV-1 
(dl1403CMVlacZ; indicated as ∆ICP0 in this thesis) and plaque assays were performed by 
113 
 
staining for the β-galactosidase marker gene after 24 h to evaluate the plaque formation 
efficiency. HA.TetR and HA.TetR.IE1 cells were used as negative and positive controls in 
this study. The same experiment was performed three times to work out an average figure 
and standard deviation. Figure 3.7 shows the results of the above experiment. 
 
 
 
Figure 3.7 Complementation assay of ∆ICP0 HSV-1 infection on HA.TetR.IE1 wt and IE1 
mutant expression cell lines.  
Cells were induced by doxycycline treatment for 24 h before infection. Induced 
cells were infected by ∆ICP0 HSV-1 at a series of MOIs from 0.004 to 1. At 4 h post 
infection, the cell medium was changed and medium containing 100 ng/ml doxycycline 
and 1% human serum was added. After 24 h of infection, infected cells were fixed and blue 
plaque assays were performed to determine the plaque formation efficiency data. The 
results are expressed as a percentage in absolute titre (PFU per ml) in each cell type over 
that in HA.TetR.IE1 cells. 
 
Fold increases in plaque formation in the IE1 wt expression cells were calculated and then 
expressed as a percentage of that of the wt in the data analysis in Figure 3.7. In these 
experiments, IE1 wt stimulated plaque formation by ∆ICP0 HSV-1 by an average of 120-
fold, and therefore mutants with as little as 20% of the activity of the wt protein still enable 
a considerable increase in plaque formation. IE1 mutant K450R produced similar 
complementation efficiency as IE1 wt, which was consistent with previous data reported 
(Xu et al., 2001). IE1 mutants YL1, YL5, YL6 and YL7 have retained 40-80% of the 
activity of the wt protein in complementing ∆ICP0 HSV-1 infection. YL7 can’t be SUMO 
modified, but this didn’t impair its complementation efficiency. This is consistent with a 
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previous report from another research group who examined a similar deletion in other 
assays (Shin et al., 2012). IE1 YL2 complemented the ∆ICP0 HSV-1 infection at about 
20% efficiency, while mutants YL3 and YL4 were completely negative in this assay. The 
WB analysis in Figure 3.4 showed that IE1 YL2 can be SUMO modified, and it also 
dispersed PML in a similar manner as IE1 wt in (Figure 3.5D). It is possible that the 
mutation site in YL2 damages the 3D structure of IE1 more than other mutants except YL3 
and YL4, but it still retains significant activity. Mutants YL3 and YL4 have completely 
lost the ability to complement ∆ICP0 HSV-1 infection, also to desumoylate and disperse 
PML in WB and IF assays (Figures 3.4 and 3.5). Therefore, along with a previously 
characterised point mutant in the central hydrophobic region (Muller & Dejean, 1999), 
changing the hydrophobic residues of the YL3 and YL4 regions into neutral residues such 
as glycine may severely damage the IE1 3D structure and lead to the loss of IE1 activity in 
several assays.  
3.5 Yeast-2-Hybrid analysis of IE1 and PML interaction 
PML is a major component of ND10. It is sumoylated and co-localizes with ND10 in the 
nucleus. IE1 is responsible for de-sumoylation of PML and dispersal of ND10 during 
HCMV infection. IE1 and PML were confirmed to interact directly by Y2H in previous 
reports (Ahn et al., 1998).  
Several important amino acids were identified to be essential for IE1 function in section 
3.1.4. Therefore, the interactions between these IE1 mutants and PML were investigated by 
Y2H analysis in this section. The study was also extended to include two PML isoforms 
(PML.I and PML.VI) and several PML.I mutants which have lesions in different structural 
elements of PML. The aim of this experiment was to extend previous work (Ahn et al., 
1998; Kang et al., 2006; Lee et al., 2007; Tavalai et al., 2008b) on the characteristics of 
PML that are required for the IE1 interaction. The PMLI mutants used in these Y2H assays 
were previously studied for their restrictive effects on ICP0-null mutant HSV-1 plaque 
formation (Cuchet et al., 2011) and the detail of these PML.I mutants is shown in Figure 
3.8. 
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Figure 3.8 Sites of the mutations in PML used in this study. 
 The figure shows a map of the conserved exons 1 to 6 of PML that are present in all 
isoforms (detail about PML isoforms is shown in Figure 1.10), and the RING, B-box 1 
(BB1), B-box-2 (BB2) and coiled-coli (CC) elements of the tri-partite motif. The actual 
residues mutated in each mutant (designated ΔRING, ΔBB1, ΔBB2 and ΔCC) are shown. 
These mutants were provided by Dr Delphine Cuchet-Lourenco and the figure is taken 
from (Cuchet et al., 2011). 
 
Figure 3.8 shows the detail of PML.I mutants used to study the IE1 - PML.I interaction. 
∆RING, ∆BB1 and ∆BB2 are located in conserved cysteine residues in the three zinc 
binding elements within the tri-partite motif (TRIM) region. The entire TRIM region of 
PML is required for antiviral defence against HSV-1 infection (Cuchet et al., 2011). The 
mutation changes the cysteine to alanine residues that delete the –SH groups that are 
involved in zinc coordination. The ∆CC mutation deletes the coiled-coil region, which is 
responsible for homomeric and heteromeric interactions among TRIM family members 
(Ozato et al., 2008).  
Three IE1 mutants were used in this study of IE1-PML interactions, namely IE1 YL3, IE1 
YL4 and IE1 K450R. It was shown above that IE1 YL3 and IE1 YL4 neither co-localize 
with PML nor disperse PML in nucleus. IE1 K450R dispersed PML in the nucleus but is 
not SUMO modified. SUMO1 was used in this Y2H experiment as a positive control for 
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interaction with PML.I, whereas the empty vector was used as a negative control. The 
results of the Y2H analysis are shown in Figure 3.9. 
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Figure 3.9 Y2H assay of the PML - IE1 interaction.  
Mated yeast strains were grown on –L-W-H agar plates (A), –L-W-H plates with 1 
mM 3AT (B) and –L-W-H plates with 5 mM 3AT (C). The PML.I and PML.VI matings 
were done partially in both orientations, with the proteins fused to either the GAL4 
activation domain (AD) or DNA binding domain (BD). 
 
In Figure 3.9 (A), AD fusion protein and BD fusion protein interact with each other and 
express reporter genes which can be detected by X-gal staining. But the background HIS3 
gene expression could infect the sensitivity of the assay. In B and C, by adding 3AT in 
increasing concentration, which is a competitive inhibitor of the HIS3 gene product (Joung 
et al., 2000) , the background expression of HIS3 can be reduced, thereby reducing the 
possibility of false positive results.  
Despite several repeated experiments and much exploratory work not shown here, these 
results illustrate some unexpected difficulties with the Y2H system. For example, previous 
work found that IE1 interacted with PML.VI, and this worked best when IE1 was used on 
the AD side of the hybrid interaction (Ahn et al., 1998). In the current study, an interaction 
between IE1 and PML.VI was not observed in either orientation (Figure 3.9 and data not 
shown). Indeed, the expected interaction between PML.VI and PML.I was weak in this 
study. Another issue is that the positive control interaction between PML.I and SUMO1 
was detected only when SUMO1 was on the AD side (Figure 3.9). These considerations 
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weaken the interpretation of the data, but nonetheless the strong interactions between 
PML.I and PML.I, and PML.I and IE1 in the appropriate orientations allow some 
conclusions to be made. 
IE1 and IE1 K450R interacted strongly with PML.I under all conditions in Figure 3.9 parts 
A, B and C. The IE1 and SUMO1 interaction in Y2H was negative, which is consistent 
with another publication reported (Xu et al., 2001). IE1YL3 and IE1 YL4 showed no 
interaction with PML.I or any PML.I mutants, while neither wt PML.I nor IE1 interacted 
with any of the PML.I mutants. These data indicate that the integrity of all elements of the 
TRIM motif is required for the PML.I-PML.I interaction, not only coiled-coil motif, and 
this is also true for the IE1-PML.I interaction. Therefore mutations YL3 and YL4 affect the 
structural interface between PML.I and IE1, and on the PML side this interface includes 
the entire TRIM region. 
 
 
3.5.1 Does IE1 affect the PML - PML interaction? 
ND10 structures are a complex of many proteins, of which PML is a major component. 
PML has 6 major isoforms in the nucleus, of which PML.I is the most abundant, that all 
co-localize with ND10 (Condemine et al., 2006; Jensen et al., 2001). The infection of 
HCMV disperses the PML from ND10 and IE1 is responsible for this effect. The results of 
Figure 3.8 confirm the interaction between IE1 and PML.I in the Y2H assay. IE1 also 
induces the desumoylation of PML, but the mechanism of this effect is so far not 
understood. For example, there is no evidence that IE1 itself possesses a SUMO protease-
like activity, or interacts with SENPs (Kang et al., 2006). Sumoylation of PML requires all 
elements of the TRIM but can occur in heterodimers between wt and certain TRIM 
element mutants (Cuchet et al., 2011). Since the IE1 interaction with PML requires the 
same structural elements as the PML-PML interaction (Figure 3.8), it is possible that the 
IE1-PML interaction disrupts PML-PML interactions that are required for PML 
sumoylation. Thus, the following experiments were designed to investigate whether the 
PML-PML interaction could be interrupted by IE1 expression.  
The initial approach taken was to express different isoforms of PML in the absence of 
endogenous PML (which would complicate the results), then to use the inducible IE1 
expression system to provide IE1. This would allow analysis of the interaction between 
IE1 and PML, and the PML-PML interaction, by immunoprecipitation from cell extracts. 
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This required the construction of lentiviruses that could express both an anti-PML shRNA 
and EYFP-tagged PML.I, another expressing myc tagged PML.VI, and a third expressing 
IE1 inducibly from a single vector that includes both IE1 and TetR elements. Although 
cells expressing both PML.I and PML.VI with depleted endogenous PML were 
established, and co-immunoprecipitation of the two PML isoforms was demonstrated, it 
was found that the amount of IE1 expressed was not sufficient to disrupt the ND10 
structures formed by the over-expressed PML.I and PML.VI (data not shown). Therefore a 
simpler approach was adopted which involved expression of IE1 during HCMV infection. 
Therefore in this part, PML was knocked down firstly with lentivirus made from 
pLKO.shPML1 (Everett et al., 2008), then these cells were transduced sequentially with 
lentiviruses made from pLNGY.PML.I (Cuchet et al., 2011) and pLBG.myc.PML.VI in 
the same cell line. HCMV only infects and replicates efficiently in human fibroblast cells. 
Thus, the above procedures were applied on immortalized human fibroblast cells (HFT). 
The resulting cell line was infected by HCMV to study the effect of HCMV infection and 
IE1 expression on the PML-PML interaction. Those techniques have been used extensively 
to knock down ND10 components and express different isoforms of PML (Cuchet et al., 
2011; Glass & Everett, 2013), and should in principle allow investigation of the effects of 
IE1 on the physical interaction between different PML isoforms. 
The cell lines generated for this assay were analysed by WB and IF. Figure 3.10 shows the 
WB analysis results, and the IF analysis is shown in Figure 3.11 
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Figure 3.10 WB analysis of PML expression in HFT, HFT.shPML and 
HFT.shPML.EYFP-PMLI/myc-PMLVI cells.  
PML was probed by anti-PML rAb, EYFP-PMLI was probed by mouse anti-EGFP 
mAb and  myc-PML VI was probed by mouse anti-myc mAb. Tubulin was used as loading 
control. The positions of molecular weight standards (in thousands) are indicated to the 
right of each panel. 
 
In Figure 3.10 an HFT cell extract was used in the WB analysis for an endogenous PML 
expression control. PML expression in HFT.shPML cells has been efficiently repressed. 
PML.I and PML.VI have a 322 amino acid residue difference in size, which allows easy 
identification by WB. HFT.shPML.EYFP-PMLI/myc-PMLVI cells only express these two 
isoforms of PML which form two strong bands at the tagged PML.I and PML.VI positions, 
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as indicated. Probing of the blots for EYFP and the myc tag further confirmed the 
expression of EYFP-PML.I and myc-PML.VI in HFT.shPML.EYFP-PML.I/myc-PML.VI 
cells. The results also confirmed the SUMO modification of EYFP-PML.I and myc-
PML.VI by WB blot analysis. 
To investigate the properties of expressed EYFP-PML.I and myc-PML.VI, 
HFT.shPML.EYFP-PML.I.myc-PML.VI cells were analysed by IF (Figure 3.11)  
 
 
Figure 3.11 IF analysis of HFT.shPML.EYFP-PML.I/myc-PML.VI cells.  
(A) The co-localization of EYFP-PML.I and myc-PML.VI in a single cell. (B) IF 
images of a wide field view. Cells were fixed and permeabilized then stained for the myc 
tag using anti-myc rAb staining after 24 h incubation on coverslips. EYFP-PML.I was 
detected by auto fluorescence. 
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More than 90% of the cells expressed both EYFP-PML.I and myc-PML.VI. As with 
endogenous PML in normal cells, the EYFP-PML.I and myc-PML.VI expressed in 
HFT.shPML both co-localized in ND10-like structures and were observed as dots in the 
nucleus. The knock down of PML in HFT cells didn’t appear to cause damage to HFT cells 
and neither did the expression of EYFP-PML.I and myc-PML.VI, as the cells could be 
propagated normally. That EYFP-PML.I co-localized with myc-PML.VI is consistent with 
a previous report that different PML isoforms can co-localize with ND10 (Cuchet et al., 
2011).  
 
3.5.2 HCMV infection disperses co-localized PML.I and PML.VI 
Several HCMV proteins interact with ND10. Tegument protein pp71 interacts with hDaxx 
(Hofmann et al., 2002) and disrupts the ATRX-hDaxx complex (Everett et al., 2013a), 
while IE1 desumoylates and disperses PML and Sp100 in nucleus (Ahn & Hayward, 1997; 
Korioth et al., 1996). IE2 also co-localizes with ND10 but it neither desumoylates nor 
disperses any ND10 components (Ahn & Hayward, 1997). The development of 
HFT.shPML.EYFP-PML.I/myc-PML.VI cell line has built up a model to study the 
interaction between viral proteins and PML isoforms I and VI in the absence of other PML 
isoforms.  
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Figure 3.12 IF analysis of HCMV infection of HFT.shPML.EYFP-PML.I/myc-PML.VI 
cells.  
1x105 cells were seeded on coverslips in a 24-well plate 24 h before infection. On 
the next day, the cells were infected by HCMV AD169 at MOI 1 (titred on HFT cells). IF 
images were taken at different time point as indicated. Infected cells were fixed and 
permeabilized, then stained with anti-myc rAb and anti-IE1 mAb antibodies. EYFP-PML.I 
was detected by auto fluorescence. 
 
At 24 h post infection, the IE1 expression in some cells reached a high level, but most of 
the infected cells were expressing the IE1 at a low level which was not sufficient to 
disperse EYFP-PML.I and myc-PML.VI. After 2 days infection, the infected cells 
expressed high levels of IE1 as indicated in Figure 3.12. But at this stage, the IE1 
expressed in some cells was still not enough to disperse the PML proteins. In the EYFP-
PML.I and myc-PML.VI images, both proteins were still co-localizing with each other 
within about 50% of the infected cells. At 4 days post infection, high level IE1 expression 
was observed in every single cell, and meanwhile there were no PML dots observed. By 
observation of single infected cells at the different time points, the interaction process 
between IE1 and PML was recorded. Figure 3.13 shows IF images of single infected 
HFT.shPML.EYFP-PML.I.myc-PML.VI cells. 
124 
 
 
 
Figure 3.13 IF images of single HCMV infected cell.  
(A) An infected cell expressing IE1 at an insufficient amount for PML dispersion 
(1 day post infection). (B) An infected cells expressing IE1 at an amount sufficient for 
PML dispersion (1 day post infection). Infected cells were fixed and permeabilized then 
stained for anti-myc rAb and anti-IE1 mAb, with EYFP-PML.I detected by auto 
fluorescence. 
 
Previous data showed that IE1 expression in HA cells can desumoylate and disperse PML 
in the nucleus. When expressed at low levels the IE1 co-localized with PML. In this assay, 
it was confirmed that the IE1 co-localized with PML.I and PML.VI in the early stages of 
HCMV infection. Once the IE1 expressed by HCMV reached a high level, it dispersed the 
PML.I and PML.VI simultaneously, which implies that IE1 co-localized with ND10 and 
then interferes with the co-localization of specific PML isoforms in the absence of 
endogenous PML.  
This experimental system therefore should in principle allow the study of the physical 
interaction between PML.I and PML.VI and the effects of IE1 on this interaction using co-
immunoprecipitation analysis of infected cell extracts. Unfortunately there was insufficient 
time during the work for this thesis to conduct these interesting experiments.  
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3.6 Conclusions and discussion 
ND10 contribute to intrinsic immunity to resist herpes virus infection. The research work 
among different herpes virus labs discovered many viral proteins that target ND10 
members to overcome the repression of viral genes expression (for example (Everett et al., 
2013b; Tavalai & Stamminger, 2008; 2009); see Chapter 1 for more complete references). 
IE1 is indispensable for  lytic HCMV infection at low MOI (Greaves & Mocarski, 1998), 
and it has been shown to be an important factor for HCMV infection and gene expression 
in many scientific reports (Davis et al., 1987; Hermiston et al., 1987; Scherer & 
Stamminger, 2014). IE1 de-SUMO modifies PML and Sp100 during HCMV infection and 
disperse them in the nucleus (Kang et al., 2006; Kim et al., 2011b; Lee et al., 2004; Muller 
& Dejean, 1999; Tavalai et al., 2011). Another research paper also indicated that IE1 
interacts with hDaxx to stimulate HCMV gene expression (Reeves et al., 2010). For the 
reasons stated above, understanding IE1 function and properties is essential for the control 
of HCMV infection. In the experiments described in this Chapter, the functional and 
physical interactions between IE1 and PML have been studied from different aspects. To 
extend the study, PML - PML interactions were also studied in different aspects. 
The expression of IE1 was isolated from HCMV infection in this study. In this scenario, 
the interaction between IE1 and PML was studied independently of infection. Furthermore, 
the properties of IE1 were also explored by constructing several IE1 mutants that mutated 
potential SIM sites or sequences that are conserved among different primate CMVs. Some 
of the IE1 mutants prepared in this chapter have similarities to mutants that were reported 
before, but the aim here was to study their effects on IE1 complementation of ICP0 null 
mutant HSV-1 infection. The IE1 mutant YL1 which is located in the exon 2, a common 
region shared by IE1 and IE2, is mutated at the 14th and 16th amino acids to glycine. This is 
a less invasive mutation than the deletion of sequences within this region studied 
previously. A previous paper reported that the first 24 amino acids in the IE1 N-terminal 
region were responsible for nuclear localization (Lee et al., 2007). This was not observed 
in IE1 YL1 expression cells. IE1 YL1 can be SUMO modified and can de-SUMO modify 
PML in the same manner as IE1 wt, which indicates that these conserved amino acids 
located in the IE1 N-terminal region are dispensable for IE1 localization and function. The 
IE1 YL2 mutation is located in exon 3 which is also a common region shared by IE1 and 
IE2. It changes the 52nd, 54th and 55th amino acids to alanine within a highly conserved 
sequence motif. This region was previously investigated by mutations that deleted the first 
69 amino acids of the N-terminal region and it was reported that the ∆69 IE1 cannot 
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disperse PML in the nucleus (Lee et al., 2007). A similar HCMV mutant virus was also 
prepared in another HCMV laboratory. Deletion of IE region exon 3 sequence residues 33-
77 severely impaired the virus infection even at high MOI, but this mutation affects both 
IE1 and IE2 in the context of the viral genome (White & Spector, 2005). In this studies 
described above, IE1 YL2 de-SUMO modified PML and dispersed it in the nucleus. The 
major difference between IE1 YL2 with IE1 wt was lower complementation activity on 
ICP0 null HSV-1 infection, where IE1 YL2 retained 25% of the activity of IE1 wt. 
Therefore, the mutants within exon 2/3 showed that the conserved motifs were not 
essential for IE1 activity in the above assays. Further studies of those mutants’ properties 
will be introduced in next chapter. IE1 YL3 mutated the 130th, 132nd and 133rd amino acids 
to glycine. This mutation impaired the functional interactions between IE1 and PML in 
WB, IF and Y2H assays. It also abolished the ability of IE1 to complement ICP0 null 
HSV-1. These results indicate the importance of this region for IE1 bio-activity. Previous 
work reported that deletion of IE1 amino acid residues 132-274 (∆132−270 IE1) impaired 
the interaction between IE1 and PML in Y2H assays. The WB analysis also showed that 
this mutant cannot de-SUMO modify PML (Lee et al., 2004). IE1 YL3 has two mutation 
sites located in the deleted region of the above IE1 mutant. Therefore, these results indicate 
that two amino acids, the 132nd and 133rd, might be essential for IE1 bio-activity. IE1 YL4 
has the same properties as IE1 YL3 in the above investigation. It also lost the ability to 
interact with PML and complement ICP0 null HSV-1 infection. Lee et al. also produced a 
deletion mutant that encompasses the IE1 YL4 in a previous publication. (Lee et al., 2004) 
They deleted 30 amino acids from residues 290 to 320 (∆290−320 IE1) in the IE1 
sequence, whereas IE1 YL4 mutated the 316th, 317th and 318th amino acids to glycine. 
Deletion mutant ∆290−320 IE1 performed in a similar manner to ∆132−270 IE1 in PML 
interaction and PML de-sumoylation. Thus, YL4 defines three amino acids within this IE1 
sequence that are essential for IE1 function. One interesting difference between 
∆290−320 IE1 and IE1 YL4 is in IE1 SUMO modification. Lee et al. reported that 
∆290−320 IE1 can be SUMO modified whereas IE1 YL4 performed the opposite way.  
This difference may reflect the different cell types, expression methods and expression 
levels in the two studies. Mutation on IE1 L174 was reported incapable on co-localization 
with PML and SUMO-1, and further more PML and Sp100 de-sumoylation (Muller & 
Dejean, 1999; Xu et al., 2001). YL3 is close to L174 in IE1 sequence, and this mutation 
also abolished the IE1 function on PML co-localization and de-sumoylation. The above 
information indicated the importance of this hydrophobic region on IE1 function. 
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IE1 YL5 and YL6 performed in the same manner as IE1 wt in all the assays above. These 
studies confirmed that these two mutation sites are neither important for sumoylation nor 
indispensible for PML interaction. IE1 K450R has been studied in many aspects by 
different research groups (Lee et al., 2004; Spengler et al., 2002; Xu et al., 2001). This 
mutant showed no difference from IE1 wt on PML interaction but IE1 sumoylation was 
abolished, as expected from previous results, confirming the conclusion that the SUMO 
modification of IE1 is dispensable for IE1 bio-activity. Furthermore, IE1 K450R was able 
to complement the ICP0 null HSV-1 infection to the same extent as IE1 wt. Despite having 
no apparent effects in the assays performed in this chapter, IE1 K450R was reported to be 
important for HCMV replication (Nevels et al., 2004a). Thus, further investigation of IE1 
K450R in HCMV infection will be performed in next chapter. IE1 YL7 deleted the last 12 
amino acids at the C–terminal end of the protein, another highly conserved region that has 
been defined as the chromatin tethering domain (Reinhardt et al., 2005; Wilkinson et al., 
1998). This deletion region was found to be essential for sumoylation in the current study 
(Figure 3.3), which is consistent with a previous study that found that sumoylation of IE1 
was impaired by deleting the 16 amino acids at the C-terminal end (Kim et al., 2011b). The 
un modified IE1 YL7 performed in the same way as IE1 wt in the ∆ICP0 HSV-1 
complementation assay, indicating the deletion of the C-terminal end did not have a  
negative effect on IE1 bio-activity. Table 3.1 summarizes the properties of the IE1 mutants 
in the above investigation. 
Table 3.1 Summary of IE1 mutants properties 
 
To minimize the damage that the mutation cause to the IE1 structure, site mutation was 
applied in this study instead of sequence deletion. By using specific designed primers 
(detail in section 2.1.7), single amino acids in IE1 sequence were mutated to A or G 
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through PCR amplification. This provided direct testing of the role of conserved motifs and 
less chance of drastic structural defects and hence complete protein destabilisation. 
Y2H assay was applied to study the interaction between IE1 and PML and the interaction 
between PML and PML. Table 3.2 presents the summary of the Y2H analysis. 
Table 3.2 Summary of Yeast 2 Hybrid assay. 
 
The data confirmed a direct interaction between IE1 and PML. Meanwhile, the amino acid 
sequences located at the IE1 YL3 and IE1 YL4 mutations was shown to be essential for the 
IE1 and PML interaction. Surprisingly, PML.I and PML.VI showed no interaction in this 
Y2H assay, but given the established abilities of different PML isoforms to interact 
through the coiled-coil domain this result is likely to illustrate a weakness in this particular 
assay method rather than a true lack of interaction. Meanwhile, PML.I interacted with itself 
in a strong manner. PML.I ∆CC shown no interaction with PML.I in the Y2H assay, which 
confirm that the coiled-coil motif is essential for self-association of TRIM proteins (Ozato 
et al., 2008). PML.I ∆BB1, PML.I ∆ΒΒ2 and PML.I ∆RING also showed no interaction 
with PML.I,  indicating that the entire N-terminal RBCC motif is essential for 
PML.I/PML.I interaction. IE1 wt didn’t interact with SUMO1 in the Y2H assay. This is 
consistent with previous report that IE1 neither interacted with SUMO1 nor Ubc9 in the 
Y2H assay (Xu et al., 2001).  
While many of the results of the Y2H analysis replicate or are consistent with previously 
published data, the results do extend the known information on the motifs of PML that are 
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required for its interaction with IE1. The data show that these motifs are also required for 
PML-PML interactions, suggesting the same interface is required for both. This led to the 
hypothesis that IE1 might interfere with PML sumoylation through disruption of PML-
PML interactions. This is consistent with several published observations. Tools were 
generated to test this hypothesis more directly, but insufficient time was available to 
complete this part of the study. 
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4 Analysis of complementation of IE1 null HCMV 
and pp71 null HCMV infection by ICP0 
4.1 Introduction 
Previous studies demonstrated that ICP0 is largely interchangeable with the combination of 
IE1 and pp71 in complementation assays of ICP0 null HSV-1 (Everett et al., 2013a). These 
results confirmed the activity of IE1 and pp71 on complementing ICP0 but gave no 
information about whether ICP0 could replace IE1 or pp71. ICP0 not only de-sumoylates 
PML and disperses it like IE1, but it also degrades PML in nucleus. It also disperses hDaxx 
and ATRX in nucleus, an activity shared with pp71, but unlike pp71 it does not disrupt the 
hDaxx-ATRX complex. Therefore ICP0 combines many ND10 interactions and activities 
of IE1 and pp71, and this makes it a potential candidate to complement IE1-null HCMV 
and pp71-null HCMV. In this chapter, ICP0 was investigated for its ability to complement 
HCMV mutants that lack IE1 or pp71.  
Three HCMV strains were used in this study, namely TBE40 (TB), Towne (TN) and 
AD169. AD169 and TN have been extensively used in HCMV labs over decades and are 
highly laboratory adapted. Previous reports have shown that these two intensely passaged 
strains lack many genes that are found in low passaged clinical strains (Cha et al., 1996), 
although they do encode pp71 and IE1. To further support this study, therefore, strain 
TBE40 was included as it has been described as a relatively low passage strain with greater 
similarity to clinical isolates (Zalckvar et al., 2013).    
HCMV infects and replicates in human fibroblasts in vitro, but not in HepaRG based cell 
lines. Thus, an immortalized human fibroblast (HFT) cell line was applied in this study. 
Details about HFT cells were introduced in section 2.1.1. 
4.2 Development of IE1, pp71 and ICP0 expression HFT 
cell lines 
4.2.1 ICP0 expression cell line 
A single lentivirus vector expression system was used for this study. The TetR repressor 
protein coding sequence was inserted into pLDT vectors after hPGK promoter, followed 
by an internal ribosome entry site (IRES) and the puromycin resistance coding sequence. 
This new system combined the two plasmids used in the HepaRG cell based system for 
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expressing viral proteins in an inducible manner and simplified the cell line generating 
process to a single transfection (with no need for TetR expression vector transfection). The 
basic vector for this system was constructed in the laboratory of Dr Chris Boutell, and was 
derived from the pLDT vectors described in Chapter 3. A minor negative effect of this new 
expression system was a weakened expression of puromycin resistance and in some cases a 
reduced expression of the inducible gene.  
Plasmid pLDT.EYFP.TetR.IRES.P was constructed as a single inducible vector to express 
EYFP (Chris Boutell, personal communication). To prepare a derivative that could express 
ICP0 (pLDT.ICP0.TetR.IRES.P) (Figure 4.1), the EYFP coding sequence in 
pLDT.EYFP.TetR.IRES.P was replaced by the ICP0 cDNA sequence which is present in 
the pLDT.ICP0 vector. Plasmids pLDT.EYFP.TetR.IRES.P and pLDT.ICP0 were digested 
by the same restriction enzymes which have sites located at the 3’ and 5’ ends of the EYFP 
and ICP0 coding sequences. The fragments were separated by DNA gel electrophoresis 
and purified using a commercial DNA extraction kit. The purified DNA segments were 
ligated overnight and transformed into Stbl3 chemical competent E.coli strain the next day. 
Transformed bacteria were plated on to agar plates with 100 µg/ml ampicillin for selection. 
Single colonies were picked to inoculate small scale liquid cultures, then miniprep 
plasmids were extracted using the boiling method (section 2.2.2.1) and analysed by 
restriction enzyme digestion. Plasmids with the correct digestion segments were purified 
using a commercial DNA purification kit and sent for DNA sequencing to further confirm 
the vector structure and viral gene sequence. A large scale plasmid stock was prepared by 
transformation of the purified miniprep DNA into DH5α E.coli strain.  
132 
 
pLDT.ICP0.TetR.IRES.P
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HIV 3' si LTR
HIV 5' LTR
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TetR
IRES
RSV p
cICP0
 
 
Figure 4.1 Plasmid map of pLDT.ICP0.TetR.IRES.P. 
This vector encodes TetR protein under the promotion from the hPGK promoter. 
The key features of the lentivirus vector are noted: pac, HIV packaging sequence; RSVp, 
RSV promoter; RRE, Rev response element; hPGK, human phosphoglycerate kinase 
promoter; IRES, internal ribosome binding site; Puro r, puromycin resistance coding 
sequence. 
 
 
Plasmid pLDT.ICP0.TetR.IRES.P was used to transfect HEK-293T cells together with 
plasmids pCMV.DR.8.91 and pVSV-G to produce lentivirus vector particles. HFT cells 
were transduced with the resulting lentivirus and selected with puromycin for 2 weeks. The 
resulting HFT.ICP0 cell line was analysed by IF (Figure 4.2 A) and WB (Figure 4.2 B).  
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Figure 4.2 IF and WB analysis of HFT.ICP0 cells. 
(A) HFT.ICP0 IF images of ICP0 expression. HFT and HFT.ICP0 cells were 
treated with 100 ng/ml doxycycline or left untreated, then stained by anti-ICP0 mAb and 
anti-PML rAb 24 h later. (B) WB analysis of ICP0 expression and degradation of PML. 
Cells were treated as in A then whole cell extracts were prepared for WB analysis. PML 
was probed for using rabbit anti-PML antibody and ICP0 was probed using mouse anti-
ICP0 antibody. Tubulin was used as the loading control. The positions of molecular weight 
standards (in thousands) are indicated to the right of each panel. 
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The treatment with doxycycline had no effect on PML or ICP0 expression in the parental 
HFT cells. The induced and uninduced HFT.ICP0 cells have significant differences in the 
PML and ICP0 signals in both assays. PML localized at ND10 to form bright dots in 
uninduced HFT.ICP0 cells, but after ICP0 expression the PML signal was weak and 
dispersed in more than 90% of HFT.ICP0 cells at 24 h after induction (Figure 4.2 A). ICP0 
also degraded the PML signal in the WB analysis (Figure 4.2 B).  
The function of ICP0 in HFT-ICP0 cells was also analysed by a ∆ICP0 HSV-1 
complementation assay. HFT.EYFP cells (constructed using the single inducible EYFP 
expression vector described above) were used in parallel as a control to analyse the effect 
of inducible system control elements on ∆ICP0 HSV-1 infection. Another negative control 
for the complementation assay was the parental HFT cells. Cells were seeded in 24-well 
plates at 1x105cells/well. Seeded cells were induced in the next day for 24 h by treatment 
with 100 ng/ml doxycycline, then the induced cells were infected with ∆ICP0 HSV-1 at 
different MOIs from 0.004 to 1. At 4 h post infection, the cell culture medium was changed 
routinely to medium with 100 ng/ml doxycycline and 1% human serum. After 24 h of 
infection, the cells were fixed and blue plaque assays were performed for collecting plaque 
formation efficiency data (Figure 4.3).  
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Figure 4.3 Complementation assay of ∆ICP0 HSV-1 on HFT.ICP0 cells.  
Induced cells were treated with DMEM containing 100 ng/ml doxycycline for 24 h 
prior to infection. At 4 h post infection, cell medium was changed to DMEM with 100 
ng/ml doxycycline and 1% human serum. Blue plaque assays were performed at 24 h after 
infection. The results are expressed as fold-increase in absolute titre (PFU per ml) in each 
cell type over that in HFT cells. This experiment was performed three times independently 
to work out an average figure and standard deviation. 
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ICP0 expression in HFT-ICP0 cells complemented the ∆ICP0 HSV-1 infection about 
3000-fold compared to parental HFT cells (Figure 4.3). This was similar to previous work 
reported (Everett et al., 2013a), except that the effect in these HFT derived cells is even 
greater than in the HepaRG cell based system. HFT.EYFP cells could not complement 
∆ICP0 HSV-1 infection, which is consistent with expectation. 
In this part of the study, the single inducible system has been proved to be a reliable 
system. The preparation of the HFT.ICP0 cell line has been simplified to one transduction 
and the ICP0 expressed in HFT cells has the same functions as that expressed in HA-TetR-
cICP0 cells. 
4.2.2 IE1 expression cell line 
HFT.IE1 cells were constructed using the same lentivirus system as HFT.ICP0 cells. The 
ICP0 coding sequence in plasmid pLDT.ICP0.TetR.IRES.P was replaced by the IE1 
coding sequence to make plasmid vector pLDT.IE1.TetR.IRES.P (Figure 4.4). 
 
 
Figure 4.4 Plasmid map of pLDT.IE1.TetR.IRES.P vector. 
 The features of the plasmid are as described in the legend to Figure 4.1. 
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Plasmid pLDT.IE1.TetR.IRES.P was constructed in the same way as plasmid 
pLDT.ICP0.TetR.IRES.P. In brief, the ligation product was transformed into Stbl3 
chemical competent E.coli. The resulting transformation mixture was plated on selective 
agar plates for overnight incubation. Single colonies were selected in the next day for 
miniprep plasmid extraction. Purified plasmids were sent for sequencing to confirm the 
viral gene sequence and plasmid structure. A maxiprep stock was prepared after DNA 
sequencing and this was then transfected into HEK-293T cells (with the helper plasmids) 
for lentivirus cultivation. HFT cells were tranduced by the resulting lentivirus for 24 h, 
then the transduced HFT cells were selected using puromycin for 2 weeks. The resulting 
HFT.IE1 cells were analysed by IF and WB (Figure 4.5). 
 
 
A 
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Figure 4.5 IF and WB analysis of HFT.IE1 cells.  
(A) IF images of IE1 expression in HFT.IE1 cells. Induced cells were treated with 
DMEM containing 100 ng/ml doxycycline for 24 h. Uninduced and induced cells were 
fixed and permeabilized then stained with anti-IE1 mAb and anti-PML rAb as indicated. 
Secondary antibodies were AlexaFluor-conjugated anti-rabbit 633 and anti-mouse 555. (B) 
IF images of the IE1 signal in a proportion of uninduced HFT.IE1 cells. (C) WB analysis 
of IE1 expression. Induced and uninduced cells were treated with the same medium as for 
the IF assay. Cell lysates were collected and analysed by western blotting, probing with 
anti-IE1 mAb and anti-PML rAb as indicated. The positions of molecular weight standards 
(in thousands) are indicated to the right of each panel. 
 
A proportion of uninduced HFT.IE1 cells expressed low levels of IE1 that could be 
detected by IE1 staining in IF (Figure 4.5 A), but this leaky expression of IE1 wasn’t 
sufficient to disperse PML and it was not detected by WB (Figure 4.5 B, C). More than 
95% of HFT.IE1 cells expressed IE1 after 24 h of induction, and this induced IE1 was 
sufficient to de-sumoylate PML (Figure 4.5 C) and disperse the PML in nucleus (Figure 
4.5 A). Unlike the IE1 that was expressed at low level prior to induction (which co-
localised with PML in ND10; Figure 4.5 B), induced high level expressed IE1 was 
dispersed throughout the nucleus (Figure 4.5 A). This functional analysis of IE1 expressed 
in HFT cells was consistent with that in HA.TetR.IE1 cells (Figure 3.3). PML expression 
in uninduced HFT.IE1 cells was the same as HFT controls, which is consistent with the IF 
analysis. The above data show that the IE1 expressed by lentivirus made from plasmid 
vector pLDT.IE1.TetR.IRES.P performed the same bioactivities as that expressed in 
HA.TetR.IE1 cells. 
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4.2.3 pp71 expression cell lines 
A myc-tagged pp71 coding sequence was also inserted into the same vector used for 
inducible ICP0 and IE1 expression. However, it was found that the expression of myc-
pp71 in the transduced cells was not high enough to give a detectable signal in WB 
analysis. Thus, the expression of myc-pp71 was achieved using the double vector system 
as introduced in section 3.1.2. A pp71 mutant (pp71 DID2/3) lentivirus vector (Everett et 
al., 2013a) was also used as a control for expression of an inactive form of pp71 in this part 
of the experiments.  
HFT cells were transduced by the lentivirus cultivated from HEF-293T cells transfected 
with plasmid pLKOneo.CMV.EGFPnlsTetR. The resulting cell line was selected using 
neomycin for 2 weeks. The second transduction used lentivirus cultivated from transfection 
with pLDT.myc.pp71 or pLDT.myc-pp71 DID2/3, and the transduced HFT.TetR cells 
were selected using blasticidin for 2 weeks. The study was also extended to express pp71 
and IE1 simultaneously. Thus, HFT.TetR.myc-pp71 cells were transduced for the third 
time by pLDT.IE1.TetR.IRES.P and the resulting cells were selected using puromycin for 
2 weeks. HFT.TetR, HFT.TetR.myc-pp71 DID2/3, HFT.TetR.myc-pp71 and 
HFT.TetR.myc-pp71.IE1 cells were induced and probed using anti-myc and anti-IE1 
monoclonal antibodies (Figure 4.6). 
 
Figure 4.6 WB analysis of HFT.TetR, HFT.TetR.myc-pp71 DID2/3, HFT.TetR.myc-pp71 
and HFT.TetR.myc-pp71.IE1 cell lines.  
Cells were induced using DMEM with 100 ng/ml doxycycline for 24 h. Uninduced 
and induced cell lysates were collected and probed using anti-myc mAb, anti-IE1 mAb and 
anti-tubulin mAb as indicated. The positions of molecular weight standards (in thousands) 
are indicated to the right of each panel. 
 
139 
 
The pp71 protein was tagged with myc to simplify the detection by antibodies in this study. 
This approach has been applied in cellular expression systems in the laboratory and was 
also found suitable for functional pp71 expression (Everett et al., 2013a). Expression of 
pp71 and IE1 together has been shown to largely complement the ∆ICP0 HSV-1 infection 
in HepaRG-based cell lines (Everett et al., 2013a). To confirm this activity in the HFT cell 
system, HFT.TetR.myc-pp71.IE1 cell line was also generated. The mutant pp71 DID2/3 
protein was expressed in a lower amount compared with wt myc-tagged pp71, which was 
consistent with previous studies (Everett et al., 2013a). Expression of pp71 in 
HFT.TetR.myc-pp71.IE1 cells was much higher than HFT.TetR.myc-pp71 cells (Figure 
4.6), which might be due to a higher efficiency of transduction with the double vector 
system (perhaps because of reduced puromycin resistance expression from the single 
inducible vector, as noted above). Functional analysis of myc-pp71 and IE1 expressed in 
the above cell lines is described in the following sections. 
4.3 IE1 and pp71 complement ICP0 null HSV-1 infection 
in HFT cells 
That ICP0 can be replaced almost entirely by IE1 and pp71 acting together has been 
reported in previous work in HepaRG-based cells (Everett et al., 2013a). The viral gene 
expression cell lines constructed here provide a chance to confirm this in HFT cells. 
4.3.1 IE1 improves ICP0 null HSV-1 infection in HFT cells 
HFT and HFT.EYFP cells were used as negative controls for HFT.IE1 cells in ∆ICP0 
HSV-1 complementation assays. The ∆ICP0 HSV-1 infection protocols were similar to 
those used in the complementation assays described in section 4.2.1. Complementation 
efficiency in HFT.EYFP and HFT.IE1 cells was expressed as fold-increase in plaque 
formation over that in HFT cells (Figure 4.7). 
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Figure 4.7 ∆ICP0 HSV-1 complementation assays on HFT, HFT.EYFP and HFT.IE1 cell 
lines.  
Induced cells were treated with DMEM containing 100 ng/ml doxycycline for 24 h 
prior to infection. At 4 h post infection, cell medium was replaced with DMEM with 100 
ng/ml doxycycline and 1% human serum. Blue plaque assays were performed 24 h after 
infection. The results are expressed as fold-increases in absolute titre (PFU per ml) in each 
cell type over that in HFT cells. The same experiment was performed three times to work 
out an average figure and standard deviation. 
 
Induced HFT.IE1 cells increased ∆ICP0 HSV-1 plaque formation about 7-fold compared 
to HFT cells, which is lower than the same complementation assay performed in 
HA.TetR.IE1 cells (Everett et al., 2013a). This might be related to differences between 
HFT and HepaRG-based cells or perhaps the expression level of IE1. To investigate in 
more detail about the consequences of IE1 expression in HFT cells, the same 
complementation assay was performed on pp71 and IE1 expression cell lines (see Section 
4.3.3 below). 
4.3.2 pp71 increases ICP0 null HSV-1 infection in HFT cells 
It was found that pp71 can also complement ∆ICP0 HSV-1 infection in HepaRG-based 
cells in a previous study (Everett et al., 2013a) increasing the mutant virus plaque 
formation about 10-fold compared with control cells. Here, similar experiments were also 
performed on HFT.TetR.myc-pp71 cells, using. ∆ICP0 HSV-1 infection protocols that 
were the same as the complementation assay described in section 4.2.1. Complementation 
efficiency of HFT.EYFP and HFT.TetR.myc-pp71 was expressed as fold-increase over 
that in HFT cells (Figure 4.8). 
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Figure 4.8 ∆ICP0 HSV-1 complementation assays on HFT, HFT.EYFP and 
HFT.TetR.myc-pp71 cells.  
Induced cells were treated with DMEM with 100 ng/ml doxycycline for 24 h prior 
to infection. At 4 h post infection, cell medium was replaced with DMEM with 100 ng/ml 
doxycycline and 1% human serum. Blue plaque assay were performed 24 h after infection. 
The results are expressed as fold-increases in absolute titre (PFU per ml) in each cell type 
over that in HFT cells. The same experiment was performed three times to work out an 
average figure and standard deviation. 
 
4.3.3 IE1 and pp71 acting together can largely complement ICP0 
null HSV-1 infection in HFT cells 
It was demonstrated in a previous report that single expression of IE1 or pp71 increased 
∆ICP0 HSV-1 infection about 100- and 10-fold in HepaRG-derived cells respectively. The 
expression of IE1 and pp71 together achieved a greater increase, which was 400-fold 
(about half that of ICP0 in this cell type), on complementing ∆ICP0 HSV-1 infection 
(Everett et al., 2013a). To analyse the HFT.TetR.myc-pp71.IE1 cell line, the same 
experiment was performed. HFT, HFT.EYFP, HFT.TetR.myc-pp71.IE1 and HFT.ICP0 
cells were seeded on 24-well plates and 24 h after treatment with 100 ng/ml doxycycline 
the cells were infected by ∆ICP0 HSV-1 at different MOIs. On the next day, blue plaque 
assays were performed to collect the plaque formation efficiency data (Figure 4.9). 
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Figure 4.9 ∆ICP0 HSV-1 complementation assays on HFT, HFT.EYFP, HFT.TetR.myc-
pp71.IE1 and HFT.ICP0 cell lines.  
The above cell lines were seeded on 24-well plates at 1x105 cells/well. In the next 
day, cells were induced with DMEM containing 100 ng/ml doxycycline for 24 h prior to 
infection. Induced cells were infected by ∆ICP0 HSV-1 at different MOIs from 0.004 to 1. 
At 4 h post infection, the cell medium was replaced with medium containing 100 ng/ml 
doxycycline and 1% human serum. Blue plaque assays were performed 24 h after 
infection. The results are expressed as fold-increases in absolute titre (PFU per ml) in each 
cell type over that in HFT cells. The same experiment was performed three times to work 
out an average figure and standard deviation. 
 
HFT.ICP0 cell lines achieved a 3000-fold increase in plaque formation of the mutant virus 
over that in HFT cells, which was a further increase compared with the same experiment 
performed on HA.TetR.cICP0 cells. Meanwhile, the ∆ICP0 HSV-1 infection 
complementation by HFT.TetR.myc-pp71.IE1 cells was also improved substantially from 
that achieved in cells expressing either IE1 or pp71 alone (compare Figures 4.7, 4.8 and 
4.9). In general, the simultaneous expression of IE1 and pp71 achieved about 50% of the 
activity of ICP0 in this study, which is consistent with the previous report in HepaRG-
based cells. Previous work using single knock down or triple knock down cell lines 
demonstrated that PML, Sp100 and hDaxx cooperatively repress HSV-1 infection (Glass & 
Everett, 2013). However, the triple knock down cell lines based on HFs and HepaRG cells 
increased ∆ICP0 HSV-1 plaque formation by about 20- and 50-fold respectively,  much 
less than that achieved by ICP0 itself. Taken with the 3000-fold increase in ICP0-
expressing HFT cells in this study, the knock down of PML, Sp100 and hDaxx is not as 
efficient as either ICP0, or IE1 and pp71 acting together. This implies that ICP0 has 
additional functions besides the interaction with ND10 components, or possibly that 
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residual protein expression in the shRNA expressing cells is sufficient to mediate 
significant repression. Meanwhile, the cooperation of IE1 and pp71 increase the infection 
of ∆ICP0 HSV-1 about 1500-fold which is still much more efficient than knock down in 
HFT-derived cells of three ND10 components that are affected by ICP0. This illustrates the 
notion that IE1 and pp71 not only share common targets within ND10 with ICP0, but also 
perhaps other mechanisms to stimulate HSV-1 gene expression.  
4.4 IE1 and ICP0 enhance wt HCMV infection 
Plaque formation by wt HCMV was increased about 20-fold in HF cells that had been 
depleted of PML, Sp100 and hDaxx by shRNA (Glass & Everett, 2013), and wt HCMV 
infection is also increased in cells singly depleted of PML, hDaxx or Sp100, or a 
combination of PML and hDaxx (Tavalai et al., 2006; Tavalai et al., 2008b). Because PML 
was degraded by ICP0 expression in HFT.ICP0 cells (Figure 4.2), and by extension from 
the known effects of ICP0 on Sp100 and hDaxx, plaque formation and viral gene 
expression of wt HCMV on HFT.ICP0 and HFT.IE1 cells were investigated. 
4.4.1 Cultivation of wt HCMV 
HCMV strains Towne (TNwt) and AD169 are widely studied laboratory HCMV strains 
which have been highly passaged and adapted to infect and replicate in cultured human 
diploid fibroblasts. An earlier study using cells analogous to HFT.IE1 cells (made using 
the double transduction method) found increased wt HCMV infection on induced cells, 
with a reduced cultivation time and higher titres (Knoblach et al., 2011). In this study, 
stocks of TNwt and AD169 that had been cultivated in human fibroblasts were obtained 
and then cultivated on induced HFT.IE1 cells. After the initial infection for 2 days, the 
medium was changed so that the eventual virus stocks were in doxycycline-free medium. 
Virus stocks were then titrated on HFT.IE1 cells. 
4.4.2 Prior expression of IE1 and ICP0 facilitates wt HCMV 
infection 
To investigate whether prior expression of ICP0 and IE1 could enhance wt HCMV 
infection, three wt HCMV strains were used to infect HFT.IE1 and HFT.ICP0 cells. These 
were TNwt, AD169 and strain TBE40 (TBwt). TNwt and AD169 were cultivated in 
HFT.IE1 cells whereas TBwt was a relatively low passage strain that was provided by Dr 
Michael Nevels and was used without further passage in the laboratory here. Meanwhile, 
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another HCMV strain, TBrvlIE1, an IE1 repaired version of the TBE40 IE1 deletion 
mutant TBdlIE1 (see below), was also used in this study.  
Doxycycline treated or untreated HFT, HFT.IE1 and HFT.ICP0 cell lines were infected by 
TNwt at sequential dilutions determined empirically to give countable numbers of plaques 
on each cell line. At 4 h post infection, cell medium was changed to DMEM with 100 
ng/ml doxycycline (for induced cells only) and 1% human serum. Infected cells were 
incubated at 37℃ for a further 7 days. The infected cells were fixed and permeabilized for 
histochemical staining of HCMV plaques to collect the plaque formation efficiency data. 
The same experiment was performed three times to work out an average figure and 
standard deviation. 
 
 
Figure 4.10 TNwt infection on HFT, HFT.IE1 and HFT.ICP0 cell lines.  
Induced cells were incubated in DMEM with 100 ng/ml doxycycline for 24 h prior 
to infection. Uninduced and induced cells were infected by TNwt at different MOIs. At 4 h 
post infection the cell medium was replaced to routinely maintain cell culture with 100 
ng/ml doxycycline (for induced cells) and 1% human serum. HCMV plaque assays were 
performed by histochemical staining at 7 days after infection. Anti-UL44 mAb was used to 
detect HCMV plaques. The secondary antibody was sheep horse radish peroxidase 
conjugated anti-mouse IgG antibody A4416. The results are expressed as PFU per ml in 
each cell type. 
 
Both IE1 and ICP0 enhanced the TNwt plaque formation by about 20-fold compared with 
HFT and uninduced cells, which is similar to the increase in wt HCMV plaque formation 
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in triple knock down cell lines (PML, hDaxx and Sp100) described in previous work 
(Glass & Everett, 2013). The expression of IE1 by TNwt was sufficient for estimating the 
efficiency of viral infection observed in HFT cells, whereas prior expression of the extra 
IE1 expressed in the HFT.IE1 cells created a scenario similar to a higher MOI infection. 
These data are consistent with the hypothesis that even wt HCMV infection is restricted by 
cellular factors that reduce the probability of plaque formation, and that prior expression of 
IE1 or ICP0 increases the probability that a cell receiving a virus particle will become 
lytically infected. AD169 was also used in the same study and performed in a similar 
manner as with TNwt, giving essentially similar results. (Figure 4.11)  
 
 
Figure 4.11 AD169 infections on HFT, HFT.IE1 and HFT.ICP0 cell lines.  
Cells were induced by treatment with DMEM containing 100 ng/ml doxycycline 
for 24 h prior to infection. Then, the cells were infected by AD169 at sequential dilutions 
determined empirically to give countable numbers of plaques on each cell line. At 4 h post 
infection, the cell medium was replaced with DMEM containing 100 ng/ml doxycycline 
and 1% human serum. HCMV plaque assays were performed at 7 days after infection. 
Anti-UL44 mAb was used to detect HCMV plaques. The results are expressed as fold-
increase in absolute titre (PFU per ml) in each cell type over that in HFT cells. The same 
experiment was performed three times to work out an average figure and standard 
deviation. 
 
TNwt and AD169 are extensively passaged HCMV strains that lack several genes 
possessed by clinical isolated strains. To investigate whether this phenomenon occurred 
only with laboratory adapted strains, the same infection experiment was performed using 
stocks of TBwt titrated on HFT.IE1 cells. Doxycycline induced cells were infected with 
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TBwt at different MOIs. The results are expressed as plaque formation efficiency relative 
to that in HFT cells (Figure 4.12). 
 
 
Figure 4.12 TBwt plaque assays on HFT, HFT.IE1 and HFT.ICP0 cell lines.  
Cells were seeded on 24-well plates at 1x105/well. In the next step, cells were 
treated with DMEM with 100 ng/ml of doxycycline for 24 h and infected by TBwt at 
sequential dilutions determined empirically to give countable numbers of plaques on each 
cell line. At 4 h post infection, the cell culture was changed to routine culture medium with 
100 ng/ml doxycycline and 1% human serum. HCMV plaque assays were performed 7 
days after infection by anti-UL44 mAb staining. The results are expressed as fold-increase 
in absolute titre (PFU per ml) in each cell type over that in HFT cells. The same 
experiment was performed three times to work out an average figure and standard 
deviation. 
 
HCMV strain TBwt infection was increased by IE1 and ICP0 in a similar manner as TNwt 
and AD169, with IE1 being around 2-fold more effective than ICP0. The data above 
confirmed that even though the IE1 expressed by HCMV is efficient enough to initiate the 
lytic infection in host cells, the prior expression of these ND10 disrupting proteins 
increases the probability of lytic viral infection. Considering the similarities between IE1 
and ICP0, it is perhaps not surprising that ICP0 could facilitate the infection of HCMV.  
TBrvIE1 is a revertant of TBdlIE1 HCMV strain (Zalckvar et al., 2013) that performed in 
a similar manner as TBwt during titration on HFT.IE1 and HFT.ICP0 cells (Figure 4.13).  
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Figure 4.13 TBrvIE1 infections of HFT, HFT.IE1 and HFT.ICP0 cell lines.  
Experimental details are as described in the legends to figures 4.10 – 4.12. 
 
The plaque assays presented above illustrate that the titre of any stock of even wt HCMV 
varies with the cell type or line in which it was determined. Conventionally, most studies 
have used titres determined in normal human diploid fibroblasts as the basis for calculating 
the amount of virus stock to be used for a given multiplicity of infection. The work 
presented in this chapter, however, analyses a number of IE1 mutant HCMV strains whose 
titres must of necessity be determined on IE1 complementing cells. In order to maintain 
consistency between the amounts of wt and mutant viruses when used in parallel, it was 
therefore important to use the wt viruses according to their titres on IE1 complementing 
cells. The results of Figures 4.10 – 4.13 indicate that these MOIs will be 10- to 30-fold 
lower than if the MOIs were calculated on the basis of titres in ordinary HFT cells. In 
consequence, in the experiments presented below, all experiments were performed at what 
would be defined as low MOI on the basis of titres in HFT cells.  
4.4.3 IE1 and ICP0 enhance immediate-early and late gene 
expression of wt HCMV 
The data above demonstrated the plaque formation efficiency of wt HCMV can be 
increased by prior expression of IE1 and ICP0. In this section, WB and IF were applied to 
observe the enhancement of HCMV infection in HFT.IE1 and HFT.ICP0 cells. Different 
gene expression products were detected by WB to investigate HCMV replication (Figure 
4.14). HFT.ICP0 cells were seeded in a 24-well plate, induced on the next day, then the 
induced cells were infected by TNwt at MOI 1 after 24 h of induction. At 4 h post 
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infection, the cell medium was replaced with DMEM containing 100 ng/ml doxycycline 
and 1% human serum. A control experiment using uninduced cells was performed in 
parallel. Cell lysates were collected at 24 h, 48 h, 72 h and 96 h post infection and probed 
by antibodies as indicated. A mock infected cell lysate was collected at 48 h post 
induction. 
 
Figure 4.14 WB analysis of gene expression during wt HCMV infection in HFT.ICP0 
cells.  
HFT.ICP0 induced cells and uninduced cells were infected by TNwt at MOI 1. 
Samples were collected at 24 h, 48 h, 72 h and 96 h after infection then probed with anti-
IE1 mAb E13, anti-pp28 mAb, anti-UL44 mAb, anti-GFP rAb, anti-ICP0 mAb 11060 and 
anti-tubulin mAb, as indicated. Tubulin was a loading control. The positions of molecular 
weight standards (in thousands) are indicated to the right of each panel. 
 
HCMV genes expressed at different stages of HCMV infection were probed with relevant 
antibodies: IE1 is expressed at the immediate early stage of HCMV infection, UL44 is 
expressed in the early phase prior to DNA replication and pp28 is expressed in the late 
stage after DNA replication has commenced. EGFP is a SV40-driven EGFP marker gene 
inserted into a non-essential region of the US segment of TNwt viral genome that was 
shown to express in early or late stage of viral infection (Marchini et al., 2001). ICP0 was 
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steadily expressed in HFT cells with a slight increase within 96 h of HCMV infection. 
Prior and continuing ICP0 expression stimulated HCMV immediate-early, early and late 
gene expression as indicated in WB analysis, with the effect on IE1 being relatively slight, 
but expression of both UL44 and pp28 started earlier and accumulated to higher levels in 
the induced HFT.ICP0 cells. These data are consistent with the plaque formation data 
presented above.  
IF analysis provides detail of gene expression in single HCMV infected cells and also 
plaque forming efficiency. HFT cells were seeded on coverslips at 1x105 cells/well in 24-
well plates. After 24 h induction by doxycycline, cells were infected by TNwt at different 
MOIs as indicated in Figure 4.15. After 4 days of infection, the infected cells were fixed 
and permeabilized for IF analysis using anti-IE2 mAb staining and EGFP autofluorescence 
detection as a surrogate for Late gene expression. 
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Figure 4.15 IF analysis of TNwt infection on HFT, HFT.IE1 and HFT.ICP0 cell lines.  
Cells were treated with DMEM containing 100 ng/ml doxycycline for 24 h prior to 
infection. HFT, HFT.IE1 and HFT.ICP0 induced cells were infected by TNwt at different 
MOI as indicated. Cell medium was replaced to DMEM with 100 ng/ml doxycycline and 
1% human serum at 4 h post infection. Coverslips were collected after 4 days infection. 
Then the cells were fixed and permeabilized for anti-IE2 mAb staining. 
 
TNwt infection at MOI 3 was similar among three cell lines with slightly stronger EGFP 
expression in HFT.IE1 cells. In this scenario, more than one virus particle invaded a single 
cell and hijacked the host cell machinery to express viral genes. This led to a certain 
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amount of cell death or cytopathic effect during the 4 day incubation. Differences between 
HFT and the IE1 and ICP0 expressing cell lines begin to appear when the MOI was 
lowered to 1. For HFT.IE1 cells, every viable HCMV viral particle could infect a single 
cell under the facilitation provided by the IE1 expressed in the host cell, and there was a 
similar situation in HFT.ICP0 cells during HCMV infection at MOI 1. The infection in 
HFT cells was different than in the other two cell lines, as the effective MOI was 
effectively lower than 1 in this cell line and this was indicated by IE2 staining and 
particularly EGFP expression. The increase in HCMV infection by IE1 and ICP0 
compared to the situation in HFT cells was more significant at MOI 0.3 and MOI 0.01. At 
MOI 0.03, there was only one positive cell observed on the HFT cell coverslip, whereas 
around 20 plaques were observed in the fields of view of HFT.ICP0 and HFT.IE1 cells. At 
this MOI the proportion of initially uninfected cells allows the development of plaques.  
This increase in plaque number represents the IE1 and ICP0 enhancement of HCMV 
infection, while the increase in viral gene expression, is indicated by detection of IE2 and 
EGFP. The IF images of TNwt infection at MOI 0.03 indicate that the expression of IE2 
and EGFP were more efficient in HFT.IE1 than HFT.ICP0 cells.  
Plaque formation efficiency assays in section 4.4.2 demonstrated that IE1 and ICP0 
expression also increased TBwt infection. To investigate more detail about TBwt infection 
on HFT.IE1 and HFT.ICP0 cells, IF analysis was performed. TBwt virus stock was titrated 
on HFT.IE1 cells prior to IF analysis. HFT, HFT.IE1 and HFT.ICP0 cells were infected by 
TNwt at MOI 1, then at 4 days post infection, the cells were fixed and permeabilized for 
anti-IE2 mAb and anti-UL44 mAb staining (Figure 4.16). 
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Figure 4.16 Confocal immunofluorescence images of TBwt infection on HFT, HFT.IE1 
and HFT.ICP0 cell line.  
Cells were induced with DMEM contains 100 ng/ml of doxycycline for 24 h prior 
to infection. HFT, HFT.IE1 and HFT.ICP0 induced cells were infected by TBwt at MOI 1, 
then at 4 h post infection, the cell medium was replaced with DMEM with 100 ng/ml 
doxycycline and 1% human serum. Coverslips were collected after 4 days infection, then 
the cells were fixed and permeabilized for anti-IE2 mAb and anti-UL44 mAb staining as 
indicated.  
 
The IE2 and UL44 expression were increased in HFT.IE1 and HFT.ICP0 cells compared 
with HFT cells, consistent with the TNwt infection. The viral gene expression was 
different between TNwt and TBwt. The IE2 expression of TBwt was less efficient than 
TNwt in the same cell line infection. This might be due to the TNwt strain’s adaptation to 
human fibroblast cells, but these experiments were done when time for experimental work 
was very limited. It would be necessary to confirm any differences between TBwt and 
TNwt infections using independently grown and titrated stocks before any firm 
conclusions could be reached. 
 
4.5 IE1 but not ICP0 complements IE1-null mutant HCMV 
infection 
The infection of ∆IE1 HCMV is highly impaired at low MOI but similar to wt HCMV at 
high MOI (Greaves & Mocarski, 1998). It is likely that the accumulation of IE and E gene 
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products is necessary for efficient HCMV lytic infection. The previous section 
demonstrated that ICP0 increases HCMV plaque formation efficiency and viral gene 
expression. Furthermore, IE1 was demonstrated to complement ∆ICP0 HSV-1 infection 
and achieved 50% of the complementation efficiency of ICP0 when expressed 
simultaneously with pp71. The similarities between IE1 and ICP0 led to studies on the 
potential complementation activity of ICP0 on ∆IE1 HCMV strains. In this section, 
whether ICP0 could replace IE1 was investigated using strain Towne and TBE40 IE 
deletion mutants, TNdlIE1 and TBdlIE1, in complementation assays. The results are 
described below. 
4.5.1 IE1 complements IE1 null HCMV infection 
Many laboratories working on HCMV grow ∆IE1 HCMV mutants using IE1 expression 
cell lines (Gawn & Greaves, 2002; Greaves & Mocarski, 1998; Mocarski et al., 1996). The 
IE1 mutant TNdlIE1 (Knoblach et al., 2011) used in this section was also grown and 
titrated on HFT.IE1 cells. To keep the ‘clinical’ HCMV strain TBE40 and its IE1 deletion 
mutant derivative TBdlIE1 (Zalckvar et al., 2013) within a low passage number, TBdlIE1 
was not further cultivated on HFT.IE1 cells and was used direct from the stock provided by 
Dr Michael Nevels. For preparation of stocks of TNdlIE1, induced HFT.IE1 cells were 
infected at MOI 1 in 90 mm plates, then at 12 h post infection, the cell medium was 
replaced to DMEM without doxycycline. After 10 days of infection, the infected HFT.IE1 
cell medium was collected, centrifuged to clarify, and titrated on induced HFT.IE1 and 
HFT cells. The collected TNdlIE1 stock was kept at -70 ℃ to maintain infectivity.   
To ensure that equivalent amounts of potentially infectious TNwt and TNdlIE1 were used, 
both viruses were titrated on HFT.IE1 cells. The virus titre was expressed as PFU per ml 
for each HCMV strain. Both HCMV strains were used to infect 1x105 HFT cells at MOI 1, 
then the infected cell medium was changed to DMEM with 1% human serum at 4 h post 
infection. The infected cell lysates were collected at different time points as indicated in 
Figure 4.17. The WB membrane was probed for HCMV proteins expressed at different 
infection stages. 
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Figure 4.17 WB analysis of TNdlIE1 and TNwt infection of HFT cells.  
HFT cells were seeded on 24-well plates at 1 x 105 cells/well. On the next day, the 
cells were infected by TNwt and TNdlIE1 at MOI 1 (titrated on induced HFT.IE1 cells). 
Cell lysates were collected at 24 h, 48 h, 72 h and 96 h post infection and probed with anti-
IE1 mAb, anti-pp28 mAb, anti-UL44 mAb, anti-GFP rAb and anti-Tubulin mAb as 
indicated. The positions of molecular weight standards (in thousands) are indicated to the 
right of each panel. 
 
At MOI 1, TNwt infected and replicated efficiently in HFT cells, whereas viral gene 
expression by TNdlIE1 was highly impaired. This is consistent with the previous report 
(Greaves & Mocarski, 1998) given that, as explained above, this was effectively a low 
MOI infection of HFT cells.  
Figure 4.18 demonstrates the complementation of TNdlIE1 by IE1 expressed in HFT.IE1 
cells. The expression of IE1 in HFT cells efficiently complemented the TNdlIE1 infection. 
The previously observed IE1 expression in HFT.IE1 cells prior to induction (Figure 4.5) 
was not sufficient to stimulate TNdlIE1 into lytic infection. 
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Figure 4.18 WB analysis of TNdlIE1 infection of HFT-IE1 cells. 
Induced and uninduced HFT.IE1 cells were infected by TNdlIE1 at MOI 1. Cell 
lysates were collected at 24 h, 48 h, 72 h and 96 h post infection and probed with anti-IE1 
mAb, anti-pp28 mAb, anti-UL44 mAb, anti-GFP rAb and anti-Tubulin mAb as indicated. 
The positions of molecular weight standards (in thousands) are indicated to the right of 
each panel. 
 
 
4.5.2 ICP0 does not complement IE1 null HCMV lytic infection but 
does enhance IE2 expression 
ICP0 expressed in HFT cells was shown to efficiently complement ∆ICP0 HSV-1 infection 
and induce PML degradation in section 4.2.1. Therefore, whether ICP0 complements for 
the absence of IE1 during HCMV infection could be investigated by TNdlIE1 infection of 
induced HFT.ICP0 cells. The potential complementation by ICP0 of IE1 null mutant 
HCMV infection was investigated by WB, IF and plaque assays using both the laboratory 
strain TNdlIE1 and relatively low passage strain TBdlIE1. The results are shown below. 
WB analysis of TNdlIE1 complementation assay on HFT.ICP0 cells was performed in a 
similar manner to that of TNdlIE1 infection of HFT.IE1 cells. Briefly, HFT.ICP0 cells 
were seeded in the first day in 24-well plates. After 24 h induction, induced and uninduced 
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cells were infected by TNdlIE1 at MOI 1 (titrated on induced HFT.IE1 cells), then infected 
cell lysates were collected at 24 h, 48 h, 72 h and 96 h post infection. Samples were 
resolved on 7.5% and 10% polyacrylamide gels and viral genes products were detected 
using different antibodies as indicated (Figure 4.19). The infected cell samples were 
analysed by WB and probed for HCMV immediate early, early and late protein expression. 
 
 
Figure 4.19 WB analysis of TNdlIE1 infection on induced and uninduced HFT.ICP0 cells.  
HFT.ICP0 cells were seeded on 24-well plates at 1x105cells/well. Induced cells 
were treated with doxycycline for 24 h before infection. Uninduced and induced cells were 
infected by TNdlIE1 at MOI 1, then at 4 h post infection, the medium was replaced to 
routine medium with 100 ng/ml doxycycline and 1% human serum for induced cells and 
routine medium with 1% human serum for uninduced cells. Samples were collected at 24 
h, 48 h, 72 h and 96 h post infection then probed with anti-ICP0 mAb, anti-IE1 mAb, anti-
pp28 mAb, anti-UL44 mAb, anti-GFP rAb and anti-Tubulin mAb as indicated. The 
positions of molecular weight standards (in thousands) are indicated to the right of each 
panel. 
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Even though ICP0 degrades PML and Sp100 more efficiently than IE1, it cannot replace 
IE1 in stimulating Early and Late IE1 mutant HCMV gene expression, although some 
increase in IE2 expression was observed. This indicated that besides its effects on PML 
and Sp100, IE1 has HCMV specific activities that cannot be provided by ICP0 and which 
are required to initiate efficient lytic infection.  
A similar experiment was performed to investigate plaque formation by TNdlIE1 on HFT-
ICP0 cells, also with negative results, with no plaques formed by the mutant virus in 
induced HFT-ICP0 cells at any dilution used. Compared to the number of plaques obtained 
with the same dilutions in induced HFT-IE1 cells, the plaque forming defect of TNdlIE1 in 
HFT-ICP0 cells was estimated to be at least 5000 times. 
In order to investigate in more detail TNdlIE1 infection of HFT.ICP0 cells, IF analysis was 
performed. HFT, HFT.IE1 and HFT.ICP0 cells were seeded on coverslips and infected by 
TNdlIE1 at MOI 1, then at 5 days post infection the cells were fixed and permeabilized for 
anti-IE2 mAb staining. The secondary antibody for IE2 was AlexaFluor 555-conjugated 
anti-mouse IgG. EGFP expression from the reporter gene inserted into a non-essential 
region of the Us segment of TNdlIE1 is indicative of viral replication and Late gene 
expression (Figure 4.20). 
 
 
Figure 4.20 IF images of TNdlIE1 infection on HFT, HFT.IE1 and HFT.ICP0 cell lines.  
Cells were induced by treatment with DMEM containing 100 ng/ml of doxycycline 
for 24 h prior to infection. Induced cells were infected by TNdlIE1 at MOI 1, then the 
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medium was replaced with routine cell culture medium with 100 ng/ml doxycycline and 
1% human serum after 4 h of infection. At 5 days post infection, the cells were fixed and 
permeabilized for anti-IE2 mAb staining. EGFP expression indicates virus Late gene 
expression. 
 
Consistent with the previous observation in the WB assay, ICP0 did not complement 
TNdlIE1 infection even though the IE2 expression was increased by ICP0 expression. In 
this scenario, ICP0 de-represses the MIEP thus stimulating IE2 expression. TNdlIE1 
infected HFT cells expressed IE2 in a relatively low proportion of cells compared with 
infected HFT.IE1 cells. This indicates that even in the absence of IE1 a proportion of 
infected HFT cells are able to express IE2, but this is insufficient to allow efficient Early 
gene expression, even when the proportion of IE2 positive cells is increased by ICP0. That 
the viral gene expression stimulated by ICP0 was restricted to that of IE2 in HFT.ICP0 
cells potentially indicates that IE1 is required for IE2 to stimulate downstream viral gene 
expression efficiently. The presence of IE1 in HFT.IE1 cells allows efficient 
complementation of TNdlIE1, and therefore at this time point all the cells become highly 
infected.  
HCMV lab strains don’t express a number of genes that are expressed by clinical low 
passage strains. To investigate whether a relatively low passage HCMV strain performed 
in a similar manner to TNdlIE1 in HFT.ICP0 cells, TBdlIE1 was studied in the same 
complementation assay. TBdlIE1 was titrated on HFT.IE1 cells and used to infect induced 
HFT, HFT.IE1 and HFT.ICP0 cells in a series of MOI from 0.01 to 3. Figure 4.21 shows 
the plaque assay results at MOI 1.  
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Figure 4.21 HCMV plaque assay of TBdlIE1 infection on HFT, HFT.IE1 and HFT.ICP0 
cells.  
Cells were treated with DMEM containing 100 ng/ml of doxycycline for 24 h prior 
to infection. Induced cells were infected with TBdlIE1 at MOI 1, and then at 7 days post 
infection, the cells were fixed and permeabilized for HCMV plaque assay by staining for 
UL44.  
 
Due to the attenuated gene expression of TBdlIE1 that was observed in previous report 
(Zalckvar et al., 2013), a notable smaller plaque size of TBdlIE1 was observed after 7 days 
infection, but the plaque formation efficiency of TBdlIE1 was similar to that of TNdlIE1 in 
HFT-IE1 cells. As with TNdlIE1, ICP0 could not complement the infection of TBdlIE1.  
 
4.6 Reactivation of IE1 null HCMV infection in HFT cells 
HCMV viral genomes localize adjacent to ND10 in the early stages of infection (Ishov et 
al., 1997), and IE1 was found to disrupt with ND10 to stimulate viral gene expression and 
lytic infection (Ahn et al., 1998; Korioth et al., 1996; Wilkinson et al., 1998). Even though 
IE1 is dispensable in high MOI infections, it is still an important element for HCMV 
infection in vivo as IE1-null mutant HCMV is impaired for viral infection and gene 
expression in low MOI infections. This scenario could be modified as model for quiescent 
infection in cultured cells, analogous to that developed for studying HSV-1 quiescence 
(Ferenczy et al., 2011; Preston & Nicholl, 1997; Russell et al., 1987; Samaniego et al., 
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1998), for investigating the process of HCMV transfer into lytic infection from a quiescent 
state. The processes involved might have some relationship to reactivation of latent 
infections in vivo. The availability of HFT-IE1 and HFT-ICP0 cells enables studies on the 
potential roles of IE1 and ICP0 in reactivating quiescent HCMV genomes. In this part of 
the study, a re-activation assay was designed to mimic quiescent infection in the first 4 
days of infection by TNdlIE1 of uninduced HFT-IE1 and HFT-ICP0 cells, followed by 
induction of IE1 or ICP0 expression to potentially initiate lytic infection on the 4th day.  
4.6.1 IE1 reactivates IE1 null mutant HCMV infection 
TNdlIE1 was used to infect uninduced HFT.IE1 cells on the first day at MOI 1. After 4 
days of infection, the cell culture medium was changed to DMEM with 100 ng/ml 
doxycycline to trigger high level IE1 expression. After 4 days of induction, the cells were 
collected for IF analysis of viral gene expression and replication. The uninduced cells were 
analysed in parallel as controls. 
At 4 days post infection in the absence of induction, TNdlIE1 infected HFT.IE1 cells 
expressed IE2 (data not shown) in the same manner as TNdlIE1 infection on HFT cells 
(Figure 4.20). On the 2nd day after induction, the induced cells expressed more IE2 under 
the stimulation of IE1, but at this stage there was no significant reporter gene EGFP 
expression (Figure 4.22). After the accumulation of IE2 expression and other HCMV gene 
expression products, infected cells in the 4th day post infection expressed high levels of 
EGFP, whereas the uninduced cells had no expression of EGFP or any increase in IE2 
expression.  
In this assay, the lytic infection was controlled by the time of IE1 expression. During the 
first 4 days post infection, in the absence of induced IE1, the viral genome were held in a 
repressed state in host cell nucleus without expressing early or late genes. Even though a 
certain amount IE2 was expressed in the uninduced cells, it was not sufficient to initiate 
lytic infection. Following induction on the 4th day, doxycycline stimulated IE1 expression 
and released the genome from repression, therefore this increased IE2 expression and 
allowed the transfer of the viral infection into the lytic stage.  
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Figure 4.22 Confocal immunofluorescence images of TNdlIE1 re-activation assay on 
HFT.IE1 cells.  
HFT.IE1 cells were infected with TNdlIE1 at MOI 1 on day 1. On the 4th day, 
doxycycline containing medium was added to the cells for induction of IE1 expression. IF 
images were taken at 2 and 4 days post induction, after the cells were fixed and 
permeabilized for anti-IE2 mAb staining. The left side images in Figure 4.22 show the 
results at 2 days after induction and the right side shows the images at 4 days after 
induction. 
 
4.6.2 ICP0 cannot reactivate IE1 null HCMV infection but it does 
increase IE2 expression 
HTF.ICP0 cells were investigated in the same re-activation assay in parallel with HFT.IE1 
cells (Figure 4.23). As the previous complementation assays had shown, ICP0 was 
insufficient to stimulate IE1 null HCMV lytic infection, but it could increase IE2 
expression, probably by in part by substituting for the activities of pp71 (see Section 4.8 
below) but also in an analogous manner by which it re-activates expression from the MIEP 
when present in quiescent HSV-1 genomes (Baldick et al., 1997; Chau et al., 1999; Homer 
et al., 1999; Liu & Stinski, 1992; Preston & Nicholl, 2005; Samaniego et al., 1998) 
However, in this HCMV re-activation assay, ICP0 was still unable to stimulate TNdlIE1 
into full lytic infection. To summarise the TNdlIE1 complementation and re-activation 
assays, IE1 can be replaced by ICP0 on stimulating IE2 expression but is indispensible for 
efficient expression of other HCMV genes expression in a low MOI infection. This raises 
the possibility that IE1 is specifically required by IE2 to stimulate lytic infection. 
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Figure 4.23 Confocal immunofluorescence images of TNdlIE1 re-activation assay in 
HFT.ICP0 cells.  
HFT.ICP0 cells were infected with TNdlIE1 at MOI 1 on day 1, then on the 4th 
day, doxycycline containing medium was added to the cells to induce ICP0 expression. IF 
images were taken at 2 and 4 days post induction, the cells were fixed and permeabilized 
for anti-IE2 mAb staining. The left side images in Figure 4.23 show the results at 2 days 
after induction and the right side shows the 4 days post induction images. 
 
4.7 Analysis of sequences within IE1 that are important 
for its stimulation of HCMV infection 
4.7.1 Expression of IE1 mutants in HFT cells 
Chapter 3 described the construction and study of a series IE1 mutant for their interactions 
with PML, their effects on PML sumoylation and ND10 integrity, and their 
complementation of ICP0 null HSV-1. Two of these mutants identified motifs in IE1 that 
were indispensable for IE1 and PML interaction and the other functions, namely YL3 and 
YL4. Of the other mutants, YL1 and YL2 are located in the sequence shared by IE1 and 
IE2, YL7 and K450R were shown unable to be SUMO modified but could still de-
sumoylate PML and disperse it into nucleus. Furthermore, a previous report indicated the 
K450 site of IE1 is important for HCMV replication (Nevels et al., 2004a). Thus, the 
above IE1 mutants were inserted into the single inducible lentivirus vector and transduced 
HFT cells were produced for investigating their properties on complementing IE1 null 
HCMV infection. Figure 4.24 shows the mutation sites of IE1 YL1, YL2, YL3, YL4, 
K450R and YL7. 
163 
 
 
Figure 4.24 A schematic representation of the IE1 protein with its mutation locations.  
YL1 and YL2 located in exons2/3 which is the common sequence with IE2. YL3 
and YL4, located in exon 4, are located in the hydrophobic region of HCMV IE1 sequence. 
K450R is located in the acidic domain that is indispensable for IE1 SUMO modification. 
YL7 deletes the last 11 amino acids of IE1 sequence. Figure taken from (Everett et al., 
2013a). 
 
IE1 YL1-YL4, YL7 and K450R sequences were extracted from pLDT.IE1 YL1-YL4, YL7 
and K450R vectors using unique restriction enzyme digestion sites in the 3’ and 5’ ends 
and the fragments were used to replace the wt IE1 sequence in pLDT.IE1.TetR.IRES.P. 
HFT.IE1 YL1-YL4, IE1 K450R and IE1 YL7 cells were prepared with the same lentivirus 
transduction methods as introduced in section 4.2.1. The resulting cell lines were seeded in 
24-well plates at 1x105cells/ well and induced by doxycycline on the next day, then the 
induced cells were infected with TNdlIE1 at MOI 1. DMEM with doxycycline and 1% 
human serum replaced the infection medium after 4 h. At 10 days post infection, cell 
lysates were collected and resolved by 7.5% and 10% polyacrylamide gels and viral gene 
products were probed using antibodies to detect HCMV immediate early, early and late 
proteins (Figure 4.25).  
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Figure 4.25 WB analysis of TNdlIE1 infection on HFT.IE1 and HFT.IE1 mutant YL1, 
YL2, YL3, YL4, K450R and YL7 cell lines.  
Cells were induced by doxycycline 24 h before infection. The induced cells were 
infected by TNdlIE1 at MOI 1. After 10 days’ incubation, samples were collected and 
probed by anti-IE1 1B12, anti-IE1 E13, anti-UL44 mAb, anti-pp28 mAb and anti-Tubulin 
mAb as indicated. The positions of molecular weight standards (in thousands) are indicated 
to the right of each panel. 
 
Consistent with previous results, anti-IE1 (mAb E13) wasn’t able to detect IE1 YL1 
expression in HFT by WB (data not shown). To confirm IE1 YL1 expression, anti-IE1 
(mAb 1B12) (Zhu et al., 1995) was applied to detect IE1 mutant protein expression in WB. 
However, anti-IE1 (1B12) mAb could not detect IE1 YL7 in WB because the antibody was 
raised using a fragment of IE1 that is deleted in YL7. Thus, anti-IE1 (mAb E13) probing 
image is presented in Figure 4.25 as additional information for IE1 YL7 expression.  
As in the complementation assays of ICP0 null mutant HSV-1, IE1 mutants YL3 and YL4 
were unable to complement TNdlIE1 infection. They had been shown to be unable to de-
sumoylate PML in WB and disperse PML in IF in section 3.3. The functional analysis in 
TNdlIE1 complementation assay further confirmed that the sequences located in the YL3 
and YL4 regions are essential for IE1function and may be required for the stability of the 
whole protein. IE1 K450R and IE1 YL7 cannot be sumoylated (as shown in the anti-IE1 
antibody probed image), but they are still able to complement TNdlIE1 infection as 
indicated by anti-UL44 and anti-pp28 probing. Consistent with previous data, IE1 mutants 
YL1 and YL2 expressed in HFT cells were sumoylated. IE1 YL1 complemented TNdlIE1 
less efficiently than IE1 wt, indicated by lower UL44 and pp28 expression. The 
complementation assay of ICP0 null HSV-1 also indicated an attenuated activity of IE1 
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YL1 (Section 3.4). The expression of IE1 YL2 was less efficient than IE1 wt, but the 
sumoylated form of IE1 YL2 could also be detected. Surprisingly, the mutation in IE1 YL2 
completely abolished the ability to complement TNdlIE1 infection.  
To rule out the possibility that this abolishment was due to lower expression of IE1 YL2, 
the IE1 wt and IE1 YL2 proteins were expressed in HFT cells by the same double 
transduction lentivirus vector system described in Chapter 3.3 and the data are shown in 
the following section. 
4.7.2 Complementation of IE1 null mutant HCMV plaque formation 
by IE1 mutants 
To quantify the complementation activity of the IE1 mutants, the plaque formation 
efficiency of TNdlIE1 was performed on HFT.IE1 and the IE1 mutant cell lines. 
IE1 expression HFT cell lines were seeded in 24-well plates at 1x105cells/well. On the next 
day, the cells were induced by treatment with 100 ng/ml doxycycline for 24 h. Induced 
HFT.IE1 and HFT.IE1 mutant cell lines were infected with TNdlIE1 at sequential dilutions 
determined empirically to give countable numbers of plaques on each cell line. At 4 h post 
infection, infection medium was replaced by DMEM containing doxycycline and 1% 
human serum. At 7 days after infection, the infected cells were fixed and permeabilized for 
anti-UL44 mAb staining. The same experiment was performed three times to work out 
average data and standard deviation. Figure 4.26 shows the complementation assay of 
TNdlIE1 on HFT.IE1 and mutant cell lines.  
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Figure 4.26 Complementation assay of TNdlIE1 on HFT.IE1 and HFT.IE1 mutant cell 
lines.  
HFT.IE1, HFT.IE1 YL1, HFT.IE1 YL2, HFT.IE1 YL3, HFT.IE1 YL4, HFT.IE1 
K450R and HFT.IE1 YL7 cells were infected with TNdlIE1 at sequential dilutions 
determined empirically to give countable numbers of plaques on each cell line. At 7 days 
post infection, the cells were fixed and permeabilized for anti-UL44 mAb staining. The 
results are expressed as percentage in each cell type of the titre obtained in HFT.IE1 cells. 
 
The plaque assay shows that YL1 and YL7 complemented the TNdlIE1 at about 60% of 
the efficiency of IE1 wt. This was highly consistent with the ICP0 null HSV-1 
complementation assay on HepeRG-derived cells, indicating that the mutations in YL1 and 
YL7 cause only partial damage to IE1 activity. YL3 and YL4 were unable to complement 
TNdlIE1 even at high MOI, which was also consistent with the ICP0 null HSV-1 
complementation assay and the analysis by WB in section 4.7.1. IE1 K450R 
complemented TNdlIE1 infection as efficiently as IE1wt, which is consistent with the 
previous analysis of (Xu et al., 2001) but apparently different from the situation when the 
mutation is present within the viral genome (Nevels et al., 2004a). As seen in the WB 
assay, IE1 YL2 completely lost the ability to stimulate TNdlIE1 infection in this assay 
despite maintaining 20% activity in complementing ICP0 null HSV-1 infection in HA-IE1 
YL2 cells (Section 3.4). 
IE1 YL2 expression in HFT.IE1 YL2 cells was lower than IE1 wt in Figure 4.25, which 
could contribute to its reduced activity. In order to improve expression of IE1 YL2 in HFT 
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cells, HFT.TetR.IE1 and HFT.TetR.IE1 YL2 cell lines were generated by the double 
transduction method that was described in Section 2.2.3. Briefly, HFT cells were 
transduced with lentivirus stock derived from pLKOneo.CMV.EGFPnlsTetR. The 
resulting cell line was maintained in 0.5 mg/ml neomycin for selection. HFT.TetR cells 
selected from the above were transduced again by pLDT.IE1 and pLDT.IE1 YL2 derived 
lentiviruses respectively. The transduced cell lines were selected with 0.5 µg/ml 
puromycin. Selected cell lines were grown in DMEM containing 0.5 mg/ml neomycin and 
0.5 µg/ml puromycin. Western blot analysis of the resulting cell lines using antibodies 
against PML and IE1 indicated that the IE1 YL2 was expressed in HFT.TetR cells at levels 
much closer to those of the IE1 wt than from the single inducible vector, and it de-
sumoylated PML almost as efficiently as IE1 wt (Figure 4.27). There is a slight mobility 
difference between wt and YL2 forms of IE1, which is most likely due to the YL2 
mutations themselves as the complete IE1 open reading frame in pLDT.IE1 YL2 was 
confirmed by DNA sequence analysis. 
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Figure 4.27 WB analyses of HFT.TetR, HFT.TetR.IE1 and HFT.TetR.IE1 YL2 cell lines. 
Cells were induced with doxycycline for 24 h. The induced cell lysates were 
collected and probed by anti-IE1 1B12, anti-PML rAb and anti-actin mAb as indicated. 
The positions of molecular weight standards (in thousands) are indicated to the right of 
each panel. 
 
The above IE1 wt and IE1 YL2 expression cell lines were infected by TNdlIE1 in 
complementation assays. The infection protocols were the same as described in section 
4.7.2. Induced cells were infected by TNdlIE1 at different MOIs from 0.01 to 3 (TNdlIE1 
was titrated on HFT.IE1 cells), then HCMV plaque assays were performed as described in 
Chapter 2. An anti-UL44 mAb was used to detect the HCMV plaques. High MOI infection 
on HFT.TetR.IE1 cells formed large plaques and caused high cell death rate but no plaques 
were formed in HFT.TetR.IE1 YL2 cells (data not shown). To illustrate the 
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complementation assay clearly, the image of the MOI 0.1 infection is shown in Figure 
4.28. 
 
 
 
Figure 4.28 HCMV plaque assays of TNdlIE1 infection on HFT, HFT.TetR.IE1 and 
HFT.TetR.IE1 YL2 cells.  
Cells were induced with doxycycline 24 h before infection. The infected cells were 
incubated at 37℃ for 10 days then fixed and permeabilized for anti-UL44 mAb staining. 
The secondary antibody was sheep anti-mouse IgG hrp conjugated antibody A4416. 
 
Consistent with the data in Figure 4.26, IE1 YL2 did not complement TNdlIE1 infection 
even though the activity of the mutant protein on PML was only slightly reduced from that 
of IE1 wt (Figure 4.27).  
To further investigate the early and late stages of TNdlIE1 infection on HFT.TetR.IE1 wt 
and HFT.TetR.IE1 YL2 cells, both cell lines were infected by TNdlIE1 at MOI 1. At 10 
days post infection, the infected cells lysates were collected and resolved by 10% 
polyacrylamide gel electrophoresis and western blotting. The Early stage of infection was 
indicated by detection of UL44 expression and late stage was probed by anti-pp28 mAb 
(Figure 4.29). 
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Figure 4.29 Western blot analysis of TNdlIE1 infection on HFT, HFT.TetR.IE1 and 
HFT.TetR.IE1 YL2 cell lines.  
Cells were induced by doxycycline treatment 24 h before infection. The induced 
cells were infected with TNdlIE1 at MOI 1, then at 4 h post infection, cell medium was 
replaced with DMEM with 100 ng/ml doxycycline and 1% human serum. After 10 days of 
infection, samples were collected and probed by anti-PML rAb, anit-IE1 mAb, anti-UL44 
mAb, anti-pp28 mAb and anti-Tubulin mAb as indicated. The positions of molecular 
weight standards (in thousands) are indicated to the right of each panel. 
 
 
Western blot analysis indicated that at 10 days after infection, IE1 YL2 and IE1 wt were 
expressed at similar levels and IE1 YL2 de-sumoylated PML, albeit a little less efficiently 
than the wt protein. IE1 wt but not IE1 YL2 complemented TNdlIE1 as indicated by UL44 
and pp28 expression (Figure 4.29). This is consistent with the earlier experiments. This 
indicates that the amino acids sequence located in IE1 YL2 perform functions that are 
essential for IE1 activity during HCMV lytic infection. 
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4.7.3 IE1 YL2 maintains partial activity to enhance ICP0 null HSV-1 
infection on HFT cells 
The issue of the expression level and activity of IE1 YL2 arose at the very end of the time 
available for experimental work for this thesis. The experiments for the following two 
Figures were performed by Anne Orr after the deadline for finishing practical work had 
passed, but they are included here for completeness and because the issue of the potential 
activity of IE1 YL2 is important for the overall analysis. 
When IE1 and pp71 are expressed together in either HFT or HepaRG cells they 
complemented 50% of the ICP0 function in HSV-1 infection ((Everett et al., 2013a) and 
Section 4.3.3). The single expression of IE1 in HA.TetR cells can also rescue about 10% of 
the activity of ICP0 on complementing ICP0 null HSV-1 (Everett et al., 2013a). In this 
section, ICP0 null HSV-1 complementation assay was performed on HFT.TetR.IE1 wt/IE1 
YL2 cells and on HFT.TetR.myc-pp71.IE1 wt/IE1 YL2 cells to investigate any differences 
in activity between IE1 wt and IE1 YL2 (Figure 4.30).  
 
 
 
Figure 4.30 Complementation assay of ∆ICP0 HSV-1 on HFT.TetR.IE1 and 
HFT.TetR.IE1 YL2 cells.  
HFT.TetR.IE1 and HFT.TetR.IE1 YL2 cells were induced by doxycycline 
treatment 24 h before infection. The induced cells were infected with ∆ICP0 HSV-1 at an 
appropriate series of dilutions. At 4 h post infection, cell medium was changed to DMEM 
with 100 ng/ml of doxycycline and 1% human serum. At 24 h post infection, the infected 
cells were fixed and blue plaque assay were performed to collect the plaque formation 
efficiency data. The same experiment was performed twice, and the data presented show 
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the mean and range of the two values obtained. The results are expressed as fold-increase 
in absolute titre (PFU per ml) in each cell type over that in HFT.TetR cells. This 
experiment was performed by Anne Orr. 
 
Induced HFT.TetR.IE1 cells complemented ICP0 null HSV-1 infection at a similar level as 
that in HFT.IE1 cells (see Section 4.3.1). In this assay IE1 YL2 complemented ∆ICP0 
HSV-1 infection by about 6-fold, which was about 40% of the activity of IE1 wt. This 
figure was about twice that obtained in the HFT.IE1 YL2 cells produced by the single 
vector transduction (see Section 3.4), which may reflect the relatively greater expression 
level of YL2 in the HFT-TetR based cells. 
To compare IE1 YL2 with IE1 wt in more detail, both proteins were introduced into HFT 
cells together with pp71. HFT.TetR.myc-pp71.IE1 wt and HFT.TetR.myc-pp71.IE1 YL2 
were prepared by lentivirus transduction. HFT.TetR.IE1 and HFT.TetR.IE1 YL2 cells 
were infected by lentivirus derived from pLDT.myc-pp71 vector separately. Then the 
resulting cells were selected with 1 µg/ml blasticidin. The resulting cell lines were 
maintained in DMEM containing 1 µg/ml blasticidin, 0.5 mg/ml neomycin and 0.5µl/ml 
puromycin. HFT.TetR.myc-pp71.IE1 wt and HFT.TetR.myc-pp71.IE1 YL2 were analysed 
by WB to detect protein expression (Figure 4.31 A) and ∆ICP0 HSV-1 complementation 
assays were performed to test their activity (Figure 4.31 B). The three cell lines analysed in 
the WB expressed similar levels of myc-pp71 as indicated.  In the plaque assays, pp71 
cooperated with IE1 and complemented ∆ICP0 HSV-1 by about 700-fold over that in 
HFT.TetR.mycpp71 cells. Meanwhile, co-expression of IE1 YL2 with pp71 increased 
∆ICP0 HSV-1 infection 600-fold over that produced by pp71 alone. This assay indicated 
that IE1 YL2 was capable of achieving almost the same activity of the wt protein in the 
presence of pp71. Thus, these experiments demonstrate that the failure of IE1 YL2 to 
complement HCMV TNdlIE1 cannot be explained by reduced expression levels or 
complete disruption of the protein structure. Therefore, the amino acids located in the IE1 
YL2 region are essential specifically to mediate IE1 function in the context of HCMV 
infection.  
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Figure 4.31 Analysis of IE1 wt and IE1 YL2 by co-expression with pp71 in HFT cells.  
(A) Analysis of myc-pp71 expression in HFT.TetR.myc-pp71, HFT.TetR.myc-
pp71.IE1 and HFT.TetR.myc-pp71.IE1 YL2 cell lines. Cells were induced for 24 h then 
the induced cell lysates were collected and probed by anti-pp71 mAb and anti-actin mAb 
as indicated. (B) Analysis of ∆ICP0 HSV-1 complementation on HFT.TetR.myc-pp71, 
HFT.TetR.myc-pp71.IE1 and HFT.TetR.myc-pp71.IE1 YL2 cell lines. Cells were induced 
24 h before infection. The induced cells were infected with a range of multiplicities of 
∆ICP0-HSV-1, then at 4 h after infection, the medium was changed to DMEM containing 
doxycycline and 1% human serum. At 24 h post infection, blue plaque assays were 
performed to collect the plaque formation efficiency data. The results are expressed as 
fold-increase in absolute titre (PFU per ml) in each cell type over that in 
HFT.TetR.mycpp71 cells. The data show the mean and range of the two values of 
duplicate experiments. The experiments in Figure 4.31 were performed by Anne Orr. The 
positions of molecular weight standards (in thousands) are indicated to the right of each 
panel. 
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4.8 ICP0 complements pp71 null mutant HCMV infection 
Tegument protein pp71 is another ND10 interacting protein expressed by HCMV, which 
specifically interacts with hDaxx (Hofmann et al., 2002) and disrupts the hDaxx/ATRX 
complex (Lukashchuk et al., 2008). These functions are essential for pp71 to stimulate the 
HCMV MIEP and fulfil its function in immediate early infection stage. The shared 
property between ICP0 and pp71 is that although there is no evidence that ICP0 either 
interacts with or disrupts the hDaxx-ATRX complex (Lukashchuk & Everett, 2010), ICP0 
disperses hDaxx and ATRX from ND10 and inhibits their recruitment to HSV-1 genomes 
(Lukashchuk & Everett, 2010). The repressive effects of hDaxx and the hDaxx/ATRX 
complex contribute to cell mediated restriction of infection by both HCMV and HSV-1 
(Everett et al., 2009; Hofmann et al., 2002; Lukashchuk et al., 2008; Saffert & Kalejta, 
2006). In this section, HFT.ICP0 cells were used to investigate the possibility that arises 
from these observations that ICP0 might complement pp71 null mutant HCMV infection. 
4.8.1 Analysis of complementation of pp71 null mutant HCMV 
infection by ICP0 
A stock of the pp71 mutant ADsubUL82 (∆pp71 HCMV) (Bresnahan et al., 2000; 
Bresnahan & Shenk, 2000) was titrated on HFT.TetR.myc-pp71 cells, then induced 
HFT.ICP0 cells were infected with ∆pp71 HCMV at MOI 1. Within the next 4 days of 
infection, cell lysates were collected and analysed by WB (Figure 4.32). 
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Figure 4.32 WB analysis of ∆pp71 HCMV infection of induced and uninduced HFT.ICP0 
cells.  
Induced cells were treated with doxycycline for 24 h before infection. Induced and 
uninduced HFT.ICP0 cells were infected by ∆pp71 HCMV at MOI 1, then at 4 h post 
infection, the cell medium was replaced with routine cell culture medium with 100 ng/ml 
doxycycline and 1% human serum. Cell lysates were collected at 24 h, 48 h, 72 h and 96 h 
post infection and probed by anti-ICP0 mAb 11060, anti-IE1 mAb, anti-pp71 mAb, anti-
UL44 mAb and anti-Tubulin mAb as indicated. The secondary antibody was sheep anti-
mouse IgG hrp conjugated antibody A4416. The positions of molecular weight standards 
(in thousands) are indicated to the right of each panel. 
 
 
ICP0 stimulated ∆pp71 HCMV infection, increasing the expression of both IE1 and UL44, 
while the absence of pp71 detection (even on a long exposure) confirmed the mutant virus 
phenotype (Figure 4.32; see also Figure 4.34 for a control for the pp71 antibody). The 
parallel negative control infection on uninduced HFT.ICP0 cells detected no HCMV 
protein expression.  
To quantify the ∆pp71 HCMV complementation assay on HFT.ICP0 cells, plaque assays 
were performed on HFT, HFT.TetR.myc-pp71 and HFT.ICP0 cell lines that were infected 
by ∆pp71 HCMV at different MOIs. The complementation assay was performed as 
follows. HFT, HFT.TetR.myc-pp71 and HFT.ICP0 cells were seeded on 24-well plates at 
1x105cells/well. On the next day, cells were induced by treatment with 100 ng/ml 
doxycycline. The induced cells were infected by ∆pp71 HCMV at sequential dilutions 
determined empirically to give countable numbers of plaques on each cell line. The same 
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experiment was performed three times to work out an average figure and standard 
deviation. The data are shown in Figure 4.33. 
 
 
 
Figure 4.33 Complementation assay of ∆pp71 HCMV on HFT.TetR.myc-pp71 and 
HFT.ICP0 cells. 
HFT, HFT.TetR.myc-pp71 and HFT.ICP0 cells were induced by doxycycline 
treatment for 24 h before infection, then infected with ∆pp71 HCMV at a series MOIs to 
give countable numbers of plaques on each cell line (titrated on HFT.TetR.myc-pp71 
cells). At 4 h post infection, the cell medium was changed to DMEM with 100 ng/ml of 
doxycycline and 1% human serum. After 7 days of infection, the infected cells were fixed 
and permeabilized for anti-UL44 mAb staining. The results are expressed as fold-increase 
in absolute titre (PFU per ml) in each cell type over that in HFT cells. 
 
The results showed that myc-pp71 expression in HFT cells complemented the ∆pp71 
mutant HCMV about 1000-fold over HFT cells, whereas ICP0 increased the mutant virus 
titre by about 6000-fold. This result of ICP0 complementation to a greater extent than pp71 
is readily explained by the results in Section 4.4.2. In this scenario, ICP0 not only 
overcame the repression of the hDaxx-ATRX complex, but also provided a more 
convenient replication environment for ∆pp71 HCMV by degrading PML and Sp100.  
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To compare the complementation of ∆pp71 HCMV by ICP0 with wt HCMV infection, 
ADsubUL82 and the parental wt strain AD169 were titrated on HFT.ICP0 cells, as 
described in Section 2.2.5.5. ICP0 stimulated both wt HCMV and ∆pp71 HCMV plaque 
formation, which enabled visible plaque formation more rapidly than pp71. Thus the 
incubation time for plaque formation in infected HFT-ICP0 cells could be reduced to 5-7 
days. After calculating the virus titres, ∆pp71 HCMV and AD169 were adjust to MOI 1 for 
the infection of HFT.ICP0 cells. The infected cells were collected as cell lysates at 
different time points and analysed by WB. The data are shown in Figure 4.34. 
 
 
Figure 4.34 WB analysis of wt AD169 and ∆pp71 HCMV infection of HFT.ICP0 cells. 
HFT.ICP0 cells were seeded in 24-well plates. On the next day, the cells were 
induced for 24 h by treatment with DMEM with 100 ng/ml doxycycline. Induced cells 
were infected by AD169 and ∆pp71 HCMV at MOI 1, then at 4 h post infection, the 
infection medium was replaced by routine cell culture medium with 100 ng/ml doxycycline 
and 1% human serum. Cell lysate were collected at 24 h, 48 h, 72 h and 96 h post infection 
and probed using anti-ICP0 mAb 11060, anti-IE1 mAb, anti-IE2 maAb, anti-pp71 mAb, 
anti-UL44 mAb, anti-pp28 mAb and anti-Tubulin mAb as indicated. The secondary 
antibody was sheep anti-mouse IgG hrp conjugated antibody A4416. The positions of 
molecular weight standards (in thousands) are indicated to the right of each panel. 
 
 
As the MOI had been adjusted to 1, immediate early, early and late viral proteins were 
expressed in similar amounts in the AD169 and ∆pp71 HCMV infections (Figure 4.34). 
This indicated the function of pp71 can be replaced by ICP0 in HCMV infection.  
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4.8.2 Prior expression of pp71 does not increase plaque 
formation by wt HCMV 
In Section 4.4.2, IE1 was shown to increase wt HCMV plaque formation by about 20-fold 
over that in HFT cells. IE1 also stimulated the expression of other HCMV genes. 
Furthermore, the knock down of hDaxx has been demonstrated to increase wt HCMV 
(AD169) replication in previous publications (Glass & Everett, 2013; Tavalai et al., 
2008b). Thus, the question arose whether prior expression of pp71 could promote wt 
HCMV infection to levels in excess of those achieved by the pp71 provided in the 
tegument at the time of infection.  
In this section, HFT.TetR.myc-pp71 cells were infected by AD169 to investigate whether 
the extra pp71 expressed in HFT cells could increase the HCMV plaque formation. The 
same experiment was performed three times to work out an average figure and standard 
deviation. The data are shown in Figure 4.35. 
 
 
Figure 4.35 AD169 infections on HFT.TetR and HFT.TetR.myc-pp71 cells.  
HFT.TetR and HFT.TetR.myc-pp71 cells were induced for 24 h before infection. 
Induced cells were infected by AD169 at a series MOIs determined empirically to give 
countable numbers of plaques on each cell line. After 10 days of incubation, the infected 
cells were fixed and permeabilized for anti-UL44 mAb staining. The results are expressed 
as percentage in each cell type over that in HFT cells. 
 
Expression of myc-pp71 in HFT cells did not increase AD169 plaque formation, indicating 
that the pp71 in the AD169 particle is sufficient to overcome the hDaxx-ATRX repression 
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of the MIEP and the extra expressed pp71 in the host cells cannot further increase the 
infection. 
4.9 Conclusion and discussion  
Single inducible vectors expressed most viral genes efficiently in HFT cells. They 
provided a reliable and simple method for introducing modified genes into target cell lines. 
The inducible cell lines expressing relevant viral gene products were analysed by different 
biochemical and biological methods to investigate the protein properties.  
Previous studies demonstrated that IE1 and pp71 can complement ICP0 null HSV-1 
infection (Everett et al., 2013a) and simultaneous expression of these HCMV proteins can 
recover 50%  of the activity of ICP0. In this scenario the biochemical explanation of it was 
the antagonizing bioactivity of IE1 and pp71 on PML, Sp100 and hDaxx released the 
HSV-1 genome from the repression of ND10. ICP0 itself is more efficient on interacting 
with ND10 than IE1 or pp71 or both of them together. Considering the repression of ND10 
on HCMV infection, it seemed highly possible that ICP0 could replace IE1 or pp71 in 
HCMV infection. To investigate this hypothesis, the HFT.ICP0 cell line was prepared in 
this chapter, and the control cell lines, HFT.IE1, HFT.TetR.myc-pp71 and HFT.TetR.myc-
pp71.IE1, were also generated by the same methods. 
HCMV protein expression cell lines were analysed for their effects on PML and the 
complementation of ICP0 null HSV-1 infection. IE1 expressed in HFT cells de-SUMO 
modified PML efficiently and co-localized with then dispersed PML. Even though the IE1 
expressed in HFT cells complemented the ∆ICP0 HSV-1 less efficiently than the similar 
infection on HA-TetR-IE1 cells, the co-expression with pp71 increased the ∆ICP0 HSV-1 
infection about 1500-fold, which was 50% of ICP0 complementation. pp71 expression 
complemented ∆ICP0 HSV-1 at the same level as previously reported in HA-TetR-
myc.pp71 cells. Thus, the difference between HFT and HepaRG-based cell lines didn’t 
create significant variation on complementing ∆ICP0 HSV-1 infection, except for the 
reduced effect of IE1 by itself. 
IE1 was reported to be very important for HCMV infection on stimulating lytic infection 
and the mutant HCMV deleted of IE1 exon 4 was severely impaired at low MOI infection 
(Greaves & Mocarski, 1998). Even though the IE1 null HCMV infection and replication 
could be rescued at high MOI infection, it still doesn’t represent the infection in vivo. To 
180 
 
rescue IE1 null HCMV infection at low MOI, the expression of IE1 in host cells is 
necessary (Greaves & Mocarski, 1998; Mocarski et al., 1996). Alternatively, the revertant 
HCMV strains that insert IE1 exon 4 back into the HCMV genome could also rescue the 
mutant virus infection (Zalckvar et al., 2013). In this chapter, HFT.IE1 cells successfully 
complemented TNdlIE1 and TBdlIE1 infection. The HFT.IE1 cells were also applied in 
TNdlIE1 cultivation to prepare virus stocks. Infection of HFT cells with TNdlIE1 that had 
been cultivated from HFT.IE1 cells demonstrated the mutant virus didn’t insert IE1 genes 
from host cells into its genome, which confirmed that the rescue method of growing IE1 
null HCMV is reliable.  
In this chapter, both IE1 and ICP0 increased wt HCMV strain Towne infection by about 
20-fold. ICP0 creates a nuclear environment favourable for lytic virus infection, part of 
which is similar to the effects of PML and Sp100 depletion. Depletion of ND10 
components increased wt HCMV infection or IE gene expression in a number of previous 
studies (Adler et al., 2011; Glass & Everett, 2013; Tavalai et al., 2011; Tavalai et al., 
2008b). Thus, the increase caused by ICP0 was within expectation on the basis that ND10 
have repressive effect on HCMV gene expression. Pre-expressing IE1 in HFT cells before 
HCMV infection had a similar effect on HCMV plaque formation as that in induced 
HFT.ICP0 cells, therefore also creating a more convenient nuclear environment for wt 
HCMV infection. 
The HFT.ICP0 cell line was generated with the same inducible system used for HFT.IE1 
cells. Furthermore, the effects of ICP0 onND10 are more efficient and widespread than 
those of IE1, but the infection of TNdlIE1 and TBdlIE1 on induced HFT.ICP0 cells wasn’t 
complemented. The complementation results indicate that IE1 can specifically interact 
with the HCMV genome or HCMV gene products to stimulate viral replication. By 
analyzing HCMV gene expression, another immediate early gene product IE2 expression 
increase was noticed in HFT.ICP0 cells. It has been observed in previous reports that the 
deletion of IE1 specific sequence exon 4 completely abolished the IE1 expression but not 
IE2 (Greaves & Mocarski, 1998) and the deletion of ND10 components such as PML or 
hDaxx can increase IE2 expression (Tavalai et al., 2008b). IE2 expression is driven by the 
MIEP (Baldick et al., 1997; Chau et al., 1999; Homer et al., 1999; Liu & Stinski, 1992), 
which is activated by pp71 (Bresnahan & Shenk, 2000; Cantrell & Bresnahan, 2006; 
Lukashchuk et al., 2008). The presence of sumoylated PML is important for hDaxx 
recruitment to ND10 (Everett et al., 2013a; Lin et al., 2006), which represses IE2 
expression. ICP0 expression in HFT cells efficiently degraded PML that created similar 
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infection environment as PML depletion and disturbed the hDaxx recruitment to viral 
genomes (Lukashchuk & Everett, 2010). Thus the increase of IE2 expression might be due 
to the indirect effect of ICP0 on hDaxx.  
IE1 mutants introduced in chapter 3 were inserted into single inducible vectors in this 
chapter to prepare IE1 mutant expressing HFT cell lines. The IE1 mutants with reduced 
efficiency on complementing ICP0 null HSV-1 infection and those unable to be 
sumoylated were selected for further investigation in this chapter.  
IE1 YL1 and YL2 were located in the first 85 amino acids that is shared by IE1 and IE2. 
IE1 YL1 is located in a region of the protein that includes the nucleus localization signal 
(Lee et al., 2007). The IE1 null HCMV complementation assay demonstrated the amino 
acids located within IE1 YL1 were not important for IE1 bio-function or nuclear 
localisation in HFT-based cells. Furthermore, IF images of induced HA.TetR.IE1 YL1 
cells also indicated this mutation was not essential for IE1 nuclear localization (Chapter 3).  
Mutant IE1 YL2 expressed in HFT cells de-sumoylated PML almost as efficiently as IE1 
wt and increased ICP0 null HSV-1 plaque formation in both HFT (this chapter) and HA-
based cells (Chapter 3) (albeit less efficiently than IE1 wt). This evidence indicates that the 
amino acids located at IE1 YL2 are not essential for the IE1/PML interaction. In the 
presence of pp71, IE1 YL2 was almost as efficient as the wt protein in increasing ICP0 
null mutant plaque formation. In contrast, IE1 YL2 was completely incapable of 
complementing ∆IE1 HCMV infection. Thus, the 52nd, 54th and 55th  amino acids in the 
IE1 sequence are not responsible for the interaction with PML or IE1 sumoylation, but are 
required for stimulating HCMV lytic infection in host cells. Thus the YL2 mutations define 
a motif of IE1 that is specifically required for HCMV infection, but are at least partially 
dispensable for other IE1 functions. 
The sequences of the IE1 YL3 and YL4 mutations are located in the hydrophobic core of 
IE1 and both of these mutants are unable to interact with PML, be sumoylated or 
complement TNdlIE1 infection. This implies that the amino acid sequences located in IE1 
YL3 and YL4 are essential to maintain IE1 3D structure and the integrity of the IE1 
hydrophobic core is indispensable for IE1 bioactivity in HCMV infection and replication. 
Thus these mutants behave in a similar manner to the previously described L174P (Muller 
& Dejean, 1999; Xu et al., 2001). IE1 mutant K450R was shown to have an attenuated 
growth kinetic in HCMV infection (Nevels et al., 2004a). In this chapter using inducible 
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IE1 expression, the IE1 K450R mutant performed no differently from IE1 wt on 
complementing TNdlIE1 infection. Furthermore, HCMV gene expression in HFT.IE1 
K450R cells was also similar as in HFT.IE1 wt cells. This raised the possibility that IE1 
sumoylation is not essential for HCMV gene expression but important for the HCMV 
assembly process or viral particle release process. In the original study (Nevels et al., 
2004b), the growth defect of the IE1 K450R mutant viruses was attributed to a defect in 
IE2 expression although, consistent with the current study, UL44 expression was not 
affected. 
The C-terminal domain of IE1 is important for the association of IE1 with PML and 
STAT2, but not for viral replication (Reinhardt et al., 2005; Shin et al., 2012). In Chapter 
3, IE1 YL7 was shown unable to be sumoylated, but it performed similar to IE1 wt with 
regard to PML interaction and ∆ICP0 HSV-1 complementation. In this chapter, IE1 K450R 
was investigated for complementation of ∆IE1 HCMV infection and again it performed 
with similar efficiency as IE1 wt. This was consistent with previous studies illustrating that 
the deletion of the 12 amino acids (Reinhardt et al., 2005) or 16 amino acids (Shin et al., 
2012) in IE1 C terminal region has no negative effect on HCMV infection. In section 3.3.1 
and section 4.7.1, the sumoylation of IE1 YL7 was abolished. Previous reports made the 
conclusion that the viral replication was not impaired by the C-terminal deletion (Reinhardt 
et al., 2005; Shin et al., 2012), but on the other hand it was reported sumoylation of IE1 
contributes to viral replication (Nevels et al., 2004a). It is possible that sumoylation and 
the CTD affect HCMV infection in vivo or during reactivation from latency in a manner 
that is not recapitulated during infection of cultured cells. Thus, further studies are still 
required on IE1 YL7 and the role of IE1 sumoylation during HCMV infection.  
WB analysis of the IE1 mutant expressing HFT cell lines indicated that IE1 YL7 was 
incapable of being identified by the anti-IE1 1B12 antibody, indicating that the epitope 
recognised by this antibody is in the extreme C-terminus of the protein.   
The re-activation assays performed in this chapter demonstrated the IE1 null HCMV can 
enter into host cells efficiently. By IE2 antibody staining at 4 days post infection, infected 
cells were identified to express a certain amount of IE2 which indicates low level 
expression of the viral genome in host cells. In this scenario, pp71 assembled in IE1 null 
HCMV interacted with hDaxx and released the MIEP from the repression of the hDaxx-
ATRX complex. The MIEP then promoted IE2 expression, but not efficiently enough for 
stimulating viral infection into the lytic stage. Thus, in the first 4 days of ∆IE1 HCMV 
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quiescent infection, IE2 expression was maintained at a low level. The expression of IE1 
enhanced the expression of IE2 and allowed activation of later classes of viral genes and 
thus stimulated the HCMV lytic infection.  
IE2 is essential for HCMV infection which indicated by the study of IE2 deletion HCMV 
mutant which is severely impaired for viral infection and replication (White et al., 2004). 
Even though there has been no evidence of a direct interaction between IE1 and IE2 in 
previous research reports, some research investigations demonstrated that IE1 and IE2 
colocalize with ND10 (Ahn & Hayward, 1997; Korioth et al., 1996; Wilkinson et al., 1998) 
and immune-precipitation demonstrated a direct interaction between both IE1 and IE2 with 
HDAC3 (Nevels et al., 2004b). Furthermore, the expression of IE1 can dramatically 
increase the IE2 expression as indicated in this study and others (Castillo & Kowalik, 
2002). Thus, IE1 might perform as an enhancer on IE2 expression to fulfil the viral 
stimulation activity. Alternatively, it is also possible that an intermediate co-factor is 
responsible for IE1 and IE2 interaction, and thus explain why the region of IE1 identified 
by the YL2 mutation seems to be specifically required for efficient progression to later 
stages of HCMV infection. 
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5 Stimulation of ICP0-null HSV-1 and pp71 null 
HCMV infection by EBV proteins 
5.1 Introduction 
EBV is a member of the Gammaherpesvirinae family, which is one of the most common 
viruses which infect humans. As with HSV-1 and HCMV, EBV infection is separated into 
latent and lytic stages. Some components of ND10 have also been demonstrated to regulate 
or repress EBV infection in host cells (Echendu & Ling, 2008; Ling et al., 2005; 
Sivachandran et al., 2008; Tsai et al., 2011). The proteins that EBV expresses that 
modulate and may counter the repression of ND10 are EBNA1, BNRF1 and EBNA-LP, 
which have been implicated in interactions with or effects on PML, hDaxx/ATRX and 
Sp100 respectively. 
5.1.1 Similarities between EBV proteins and ICP0 from HSV-1 
ICP0 is a very efficient protein in terms of interacting with and disrupting ND10 by 
affecting multiple components of these structures simultaneously. Previous data have 
demonstrated that at least some ICP0 functions can be mediated by the separate effects of 
two HCMV proteins, IE1 and pp71. The effects of IE1 on sumoylated forms of PML and 
Sp100 and the dispersion of the hDaxx-ATRX complex by pp71 rescued 50% of the 
activity of ICP0 in ICP0 null HSV-1 complementation assays. Thus, the ND10 interaction 
proteins from EBV were selected and investigated for their potential to complement or 
enhance ICP0 null HSV-1 infection.  
EBV protein EBNA1 interacts with PML isoform IV then promotes the degradation of 
other PML isoforms (Sivachandran et al., 2008). EBNA-LP interacts with Sp100 in ND10 
and disperses it into the nucleoplasm (Echendu & Ling, 2008; Ling et al., 2005). EBV 
tegument protein BNRF1 has been shown to interact with hDaxx, disrupt the ATRX-
hDaxx complex and disperse hDaxx in the nucleus (Tsai et al., 2011). 
5.1.2 Similarities between BNRF-1 and pp71 
Both BNRF-1 and pp71 are viral tegument proteins. BNRF1 is composed of 1318 amino 
acid residues, whereas pp71 has 559 amino acid residues. Both proteins are important for 
stimulating the immediate early stage of infection of EBV and HCMV, respectively. In 
host cells, BNRF-1 and pp71 share one interaction target in ND10 which is the hDaxx-
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ATRX complex. They have been demonstrated to colocalize with hDaxx and then disperse 
the hDaxx-ATRX complex (Hofmann et al., 2002; Lukashchuk et al., 2008; Tsai et al., 
2011). Depletion of hDaxx allows greatly increased gene expression and replication by 
pp71 null mutant HCMV (Cantrell & Bresnahan, 2006; Kalejta & Shenk, 2003a; 
Lukashchuk et al., 2008; Saffert & Kalejta, 2006; 2007).  
5.2 Development of BNRF1, EBNA1 and EBNA-LP 
expression cell lines 
The EBNA-LP coding sequence was obtained from Dr. Paul D. Ling and it was attached to 
a FLAG tag at the C-terminal end. The BNRF1 coding sequence, also attached to a FLAG 
tag, was a gift from Dr. Paul Lieberman. The EBNA1 coding sequence was a gift from Dr. 
Joanna Wilson. By PCR modification, a myc tag was attached at the 5’ end of the EBNA1 
sequence and restriction enzyme sites were also designed in the 5’ PCR primer upstream of 
the myc-tag and also in the 3’ primer downstream of the C-terminal end of the coding 
sequence. The molecular weight difference between EBNA-LP and BNRF-1 was about 90 
kDa, which could be easily detected and separated by WB and therefore both proteins 
could be detected simultaneously with an anti-FLAG antibody when they were expressed 
in the same cell. 
To express three EBV proteins in single cell line, four EBV protein lentiviral vectors were 
designed and prepared. The vector plasmid pLDT.myc-EBNA1 was prepared by two steps. 
The first step used PCR to attach the myc tag at the N-terminal end of the EBNA-1 coding 
sequence. The PCR product was separated by DNA gel electrophoresis and purified using 
a commercial DNA extraction kit. This myc tagged EBNA-1 sequence was digested by 
restriction enzymes to generate ligation sites, then after isolation by DNA gel 
electrophoresis and purification, the myc-EBNA1 sequence was inserted into the plasmid 
pLDT.TetR.IRES.P vector that has the puromycin resistance sequence. For BNRF1, a 
FLAG tagged vector plasmid with the pLDT inducible expression backbone and the 
puromycin resistance gene (provided by Anne Orr) was used to prepare a blasticidin 
resistant version by swapping the drug resistance marker with that from 
pLDTbla.mycpp71. The FLAG-tagged EBNA-LP sequence was inserted into a pLDT 
vector with neomycin resistance. Thus, the single expression cell lines could be generated 
from each vector by lentivirus infection of HFT.TetR cells, and double and triple EBV 
proteins expression cell lines could also be prepared through use of different antibiotic 
selections, coupled with other modifications as described below.  
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5.2.1 BNRF 1 expression cell lines 
BNRF1 expressing cells were prepared by sequential transduction of HFT cells with 
pLKOneo.CMV.EGFPnlsTetR and pLDT.FLAG.BNRF1.puro vectors. HFT cells were 
firstly transduced with an EGFP-TetR expression vector with neomycin resistance. The 
resulting cells were transduced by pLDT.FLAG.BNRF1.puro vector and selected by 
puromycin. The doubly transduced cells were kept in DMEM with 500 µg/ml G418 and 1 
µg/ml puromycin for selection. Expression of BNRF1 was detected by probing for the 
FLAG tag in WB and IF (Figure 5.1).  
 
 
 
Figure 5.1 WB and confocal immunofluorescence analysis of HFT.TetR.FLAG-BNRF1 
cells. 
(A) WB analysis of the HFT.TetR.FLAG.BNRF1 cell line. Cells were induced by 
treatment with DMEM containing 100 ng/ml of doxycycline for 24 h, then the cell lysates 
were collected and probed by anti-FLAG mAb and anti-Tubulin mAb as indicated. (B) IF 
analysis of the HFT.TetR.FLAG.BNRF1 cell line. Cells were induced by treatment for 24 
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h with doxycycline, then the cells were fixed and permeabilised for anti-FLAG mAb 
staining. The secondary antibody was goat anti-mouse Alexa 555 conjugated antibody. 
 
Figure 5.1 (A) shows that the HFT.TetR.FLAG.BNRF1 cells expressed FLAG-BNRF1 
after the doxycycline induction, although some FLAG-BNRF1 leaky expression was 
detected in uninduced cells. The molecular weight of FLAG-BNRF1 was about 140 kDa. 
The IF analysis of HFT.TetR.FLAG.BNRF1 cells in Figure 5.1 (B) shows that, after a 24 h 
induction, the FLAG.BNRF1 protein was expressed in more than 80% of the cells, and the 
viral protein was spread in both nucleus and cytoplasm. The leaky expression of 
FLAG.BNRF1 was also observed in IF analysis as indicated by positive anti-FLAG mAb 
staining in a minority of uninduced cells.  
 
5.2.2 EBNA1 expression cell lines 
HFT.TetR.myc-EBNA1 cells that express myc-tagged EBNA1 by itself were generated by 
a similar protocol as HFT.TetR.FLAG-BNRF1 cells. The HFT.TetR cells were transduced 
by lentivirus made from the pLDT.myc.EBNA1 vector and selected with puromycin. The 
resulting cell line was grown in DMEM with 500 µg/ml G418 and 1 µg/ml puromycin, 
Then myc-EBNA1 expression was analysed by WB and IF (Figure 5.2 A, B). Meanwhile, 
any potential colocalization of EBNA1 with PML was also analysed by IF (Figure 5.2 
C,D) 
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Figure 5.2 WB and IF analysis of HFT.TetR.myc-EBNA1 cells 
 
(A) WB analysis of HFT.TetR.myc-EBNA1 cells. Cells were treated with DMEM 
containing 100 ng/ml of doxycycline for induction of myc.EBNA1 expression. After 24 h 
induction, cell lysates were collected and separated by SDS-PAGE using a 10% 
acrylamide gel. The proteins were transferred to a membrane which was probed using anti-
myc and anti-Tubulin mAbs as indicated. (B) IF analysis of the myc-EBNA1 expression in 
HFT.TetR.myc-EBNA1 cells. Induced and uninduced cells were fixed and permeabilized 
after 24 h induction for anti-myc mAb and anti-PML rAb staining as indicated. (C) IF 
images of a single induced cell expressing myc-EBNA1. (D) IF images of a single 
uninduced cell expressing myc-EBNA1 at a low level. The positions of molecular weight 
standards (in thousands) are indicated to the right of each panel. 
189 
 
 
 
In Figure 5.2 (A), myc-EBNA1 expression was triggered by doxycycline induction. The IF 
analysis in Figure 5.2 (B) provided the information about the expression rate of myc-
EBNA1. About 100% of the cells expressed myc-EBNA1 after treatment with doxycycline 
for 24 h. As with HFT.TetR.FLAG-BNRF1 cells, some expression of EBNA1 prior to 
induction was also observed by IF in this cell line, but this was not detectable by WB. It is 
possible that a longer exposure time for anti-myc mAb probing would show the leaky 
expression of the protein. The expression of myc-EBNA1 in uninduced cells was 
maintained at a much lower level compared with induced cells. Thus, this provided extra 
detail of any potential EBNA1 and PML interaction (Figure 5.2 C, D). Unlike the previous 
paper reported (Sivachandran et al., 2010; Sivachandran et al., 2008), co-localization of 
EBNA1 with PML was not observed in cells expressing either low or high amounts of the 
protein (Figure 5.2 C, D). Sivachandran et al.  also observed dispersal of PML and/or a 
reduction in ND10 number in EBNA1 expression cells, which was also not observed in 
HFT.TetR.myc-EBNA1 cells. These discrepancies could have been caused by differences 
in cell type, expression method and expression level. 
5.2.3 EBNA-LP expression cell lines 
The expression of EBNA-LP by itself in HFT cells was achieved by a slightly different 
approach than that used for the previous cell lines. The selection marker of the 
pLDT.FLAG-EBNA-LP.neo vector is neomycin which had been used to select the 
HFT.TetR cells used for HFT.TetR.FLAG-BNRF1 and HFT.TetR.myc-EBNA1 
preparation, and was therefore unavailable for this cell line. Vector 
pLDT.EYFP.TetR.IRES.P has puromycin resistance and expresses TetR together with 
inducible EYFP (see Materials and Methods). Previously, HFT.TetR.EYFP cells had been 
generated as a negative control for HCMV and HSV-1 infection experiments used in 
previous Chapters. In this chapter, HFT.TetR.EYFP cells were transduced by 
pLDT.FLAG-EBNA-LP.neo vector and the resulting cell line was selected by neomycin. 
HFT.TetR.FLAG-EBNA-LP cells were maintained in DMEM containing 500 µg/ml G418 
and 1 µg/ml puromycin. WB and IF analyses of HFT.TetR.FLAG-EBNA-LP cells are 
shown in Figure 5.3 A, B. Furthermore, the interaction between EBNA-LP with ND10 was 
also studied by IF and the images are shown in Figure 5.4. 
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Figure 5.3 WB and IF analysis of HFT.TetR.FLAG-EBNA-LP cells 
(A) WB analysis of HFT.TetR.FLAG-EBNA-LP cells. Induced cells were treated 
with DMEM containing 100 ng/ml doxycycline for 24 h. Then the cell lysates were 
collected and probed by anti-FLAG mAb and anti-Tubulin mAb as indicated. (B) IF 
analysis of induced and uninduced HFT.TetR.FLAG.EBNA-LP cells. Induced cells were 
treated by DMEM with 100 ng/ml doxycycline for 24 h. Then the induced and uninduced 
cells were fixed and permeabilized for anti-FLAG mAb and anti-PML rAb staining. The 
secondary antibodies were goat anti-mouse Alexa 555 conjugated antibody and goat anti-
rabbit Alexa 633 conjugated antibody. The positions of molecular weight standards (in 
thousands) are indicated to the right of each panel. 
 
 
As Figure 5.3 (A) shows, the expression of FLAG-EBNA-LP was relatively tightly 
regulated by the tetracycline inducible system that was constructed within the 
pLDT.EYFP.TetR.IRES.P vector. After induction, the expression of the viral protein was 
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as efficient as in the previous two EBV protein expression cell lines. This indicated that the 
TetR expressed by single inducible vector pLDT.EYFP.TetR.IRES.P was not only 
sufficient to control the EYFP expression but also efficient enough for FLAG-EBNA-LP 
expression. The IF analysis in Figure 3.52 (B) shows that about 70% of the cells expressed 
FLAG-EBNA-LP after 24 h induction with doxycycline, while in uninduced cells this was 
less than 1%. Furthermore, by observation of the low level expression of EBNA-LP in the 
small number of uninduced cells, and also the higher level of expression in the induced 
cells, the interaction between FLAG-EBNA-LP and ND10 was studied. (Figure 5.4 A,B)  
 
 
 
Figure 5.4 IF images of single cells expressing FLAG-EBNA-LP 
(A) IF images of uninduced single cell expressing FLAG-EBNA-LP at low level. 
(B) IF images of induced single cell that expressing FLAG-EBNA-LP at high level. 
 
The low level expression of EBNA-LP in HFT.TetR.FLAG.EBNA-LP cells provided 
detail of the interaction between EBNA-LP and ND10. Figure 5.4 (A) shows some 
evidence of co-localization between FLAG-EBNA-LP and PML when FLAG-EBNA-LP is 
expressed at a much lower level than in induced cells. A previous paper reported that 
EBNA-LP co-localizes with ND10 and disperses Sp100A in the nucleus (Ling et al., 
2005). The evidence of some co-localization between EBNA-LP and PML in Figure 5.4 A 
may represent the interaction between EBNA-LP and Sp100A. In Figure 5.4 (B), the 
expression of FLAG-EBNA-LP was induced by doxycycline for 24 h. In this case the 
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highly expressed EBNA-LP was more diffuse, which may reflect dispersal of Sp100A in 
the nucleus but there was insufficient time to test this possibility. Sp100A is dispensable 
for ND10 formation (Ishov et al., 1999). Thus, high level EBNA-LP expression might 
disperse Sp100A without further damage to ND10 structure which would be consistent 
with the normal PML foci in Figure 5.4 B. However, it must be borne in mind that 
sustained expression of a viral protein in transduced diploid fibroblasts, as in this study, 
does not always give the same results in this type of assay as the more common approach 
of plasmid transfection of transformed laboratory cell lines. Therefore, as with the EBNA-
1 and BNRF1 cell lines, a thorough IF analysis of all common ND10 proteins is required.  
 
5.2.4 Double and triple viral protein expression cell lines 
The TetR repressor expressed by the single inducible vector applied in HFT.TetR.EYFP 
cells had proved to be efficient for the control of the TetO sequence in another vector in 
the above experiments. The same method was used to prepare double and triple protein 
expression cell lines. HFT.BNRF1.EBNA-LP cells were prepared by sequential 
transduction of HFT.TetR.EYFP cells with pLDT.FLAG.EBNA-LP.neo and 
pLDT.FLAG.BNRF1.bla vectors. The resulting cell line was maintained in DMEM with 
500 µg/ml G418, 1 µg/ml blasticidin and 1 µg/ml puromycin. HFT.EBNA1.EBNA-LP 
cells were generated by two sequential transductions of HFT cells, firstly with lentivirus 
made from pLDT.myc.EBNA1.TetR.IRES.P to generate HFT.myc.EBNA1 single 
inducible cell line. The resulting cells were selected by puromycin and transduced by the 
second vector, made from pLDT.FLAG.EBNA-LP.neo. Transduced cells were selected 
using neomycin and kept in DMEM with 500 µg/ml G418 and 1 µg/ml puromycin. 
HFT.EBNA1.BNRF1 cells were also prepared by two transductions. The 
HFT.myc.EBNA1 cells described previously were transduced by lentivirus produced from 
the pLDT.FLAG.BNRF1.bla vector to express FLAG-BNRF1. The resulting cells were 
selected by neomycin and kept in DMEM with 1 µg/ml blasticidin and 1 µg/ml puromycin. 
HFT cells expressing BNRF1, EBNA1 and EBNA-LP simultaneously were transduced 
three times by lentiviruses made from pLDT.myc.EBNA1.TetR.IRES.P, 
pLDT.FLAG.EBNA-LP.neo and pLDT.FLAG.BNRF1.bla vectors. The resulting cells 
were selected using puromycin, blasticidin and neomycin. The cell lines prepared above 
were analysed by WB as shown in Figure 5.5. 
193 
 
 
 
Figure 5.5 WB analyses of EBV protein expression cell lines.  
HFT, HFT.BNRF1.EBNA-LP, HFT.EBNA1.EBNA-LP, HFT.BNRF1.EBNA1 and 
HFT.BNRF1.EBNA1.EBNA-LP cells were induced for 24 h by treatment with 
doxycycline. The uninduced cells were incubated within DMEM at the meantime. Cell 
lysates were collected and probed by anti-myc mAb, anti-FLAG mAb and anti-Tubulin 
mAb as indicated. The secondary antibody was sheep anti-mouse IgG hrp conjugated 
antibody A4416. The positions of molecular weight standards (in thousands) are indicated 
to the right of each panel. 
 
 
The expression of myc-EBNA1 in HFT.EBNA1.EBNA-LP, HFT.EBNA1.BNRF1 and 
HFT.EBNA1.EBNA-LP.BNRF1 cells as indicated in Figure 5.5 was controlled by TetR 
protein expressed by the pLDT.myc.EBNA1.TetR.IRES.P vector. Furthermore, the TetR 
repressor also controlled FLAG-BNRF1 and FLAG-EBNA-LP expression in the above cell 
lines. These results indicate that the regulatory system provided by TetR expression from 
the pLDT.myc.EBNA1.TetR.IRES.P vector and the presence of TetO sequences in the 
additional vectors were efficient in controlling EBV protein expression.   
BNRF1 of EBV and pp71 of HCMV are both tegument proteins and they share the ND10 
hDaxx-ATRX complex interaction target. This raises the possibility that BNRF1 could 
replace pp71 in HCMV infection. To investigate the functional interchange between pp71 
and BNRF1, HFT.EBNA1.EBNA-LP.pp71 and HFT.BNRF1.IE1 cell lines were 
generated. The HFT.EBNA1.EBNA-LP.pp71 cells were also used in comparison with 
HFT.EBNA1.EBNA-LP.BNRF1 cells in the ICP0 null HSV-1 complementation assay. 
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Meanwhile, HFT.BNRF1.IE1 cells were compared with HFT.ICP0 cells in the same 
complementation assay. 
HFT.EBNA1.EBNA-LP.pp71 cells were prepared by transducing the 
HFT.EBNA1.EBNA-LP cells with lentivirus made from the pLDT.myc.pp71 vector which 
expresses blasticidin resistance for the resulting cell line selection. HFT.IE1 cells were 
transduced by pLDT.FLAG.BNRF1.bla to construct HFT.IE1.BNRF1 cells. WB analysis 
of protein expression in HFT.EBNA1.EBNA-LP.pp71 and HFT.BNRF1.IE1 cell lines is 
shown in Figure 5.6. 
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Figure 5.6 WB analyses of HFT.EBNA1.EBNA-LP.pp71 and HFT.BNRF1.IE1 cells 
(A) WB analysis of HFT.EBNA1.EBNA-LP.pp71 cells. Induced cells were treated 
with DMEM containing 100 ng/ml doxycycline for 24 h and the uninduced cells were 
incubated in DMEM at the meantime. Cell lysates were collected and probed by anti-
FLAG mAb, anti-myc mAb, anti-pp71 mAb and anti-Tubulin mAb as indicated. (B) WB 
analysis of HFT.BNRF1.IE1 cells. Cell lysates were probed by anti-FLAG mAb, anti-IE1 
mAb and anti-Tubulin mAb as indicated. The secondary antibody was sheep anti-mouse 
IgG antibody A4416. The positions of molecular weight standards (in thousands) are 
indicated to the right of each panel. 
 
Expression of pp71 in HFT.EBNA1.EBNA-LP.pp71 cells was triggered by doxycycline 
induction as indicated in Figure 5.6 A. The expression of IE1 in HFT.BNRF1.IE1 cells was 
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also efficient as shown in Figure 5.6 B. Those cell lines were investigated in the ICP0 null 
HSV-1 complementation assay to study the properties of the EBV proteins. 
 
5.3 EBV proteins stimulate ICP0-null HSV-1 infection 
The EBV proteins under study in this chapter have been reported to interact with ND10 
components in the nucleus during latent and lytic infection. For example, EBNA1 disrupts 
ND10 and associates with PML through an interaction with PML IV (Sivachandran et al., 
2008), BNRF1 binds to hDaxx and disrupts the hDaxx-ATRX complex to stimulate early 
viral gene expression (Tsai et al., 2011), and EBNA-LP interacts with and displaces Sp100 
from ND10 in the nucleus (Ling et al., 2005). These proteins therefore share some 
similarities to the functions of ICP0 in HSV-1, which degrades sumoylated PML and 
Sp100 and disperses hDaxx and ATRX complex in the nucleus (Everett et al., 2009; 
Lukashchuk & Everett, 2010). The complementation assay of ∆ICP0 HSV-1 by EBV 
protein expression in HFT cells was investigated in this section. The investigation was also 
extended to compare the abilities of pp71 and BNRF1 to complement ICP0 null HSV-1. 
Thus, HFT.EBNA-LP.EBNA1.pp71 cells were infected by ∆ICP0 HSV-1 in parallel with 
HFT.EBNA-LP.EBNA1.BNRF1 in the same experiment.  
This study was performed in a similar manner as the complementation assay of ∆ICP0 
HSV-1 in HFT.IE1 cells (Chapter 4.3). Briefly, HFT cells expressing the different EBV 
proteins were seeded in 24-well plates at 1x105 cells/well and induced for 24 h to express 
viral proteins. The induced cells were infected with ∆ICP0 HSV-1 and blue plaque assays 
were performed at 24 h post infection to collect the plaque formation efficiency data. The 
same experiments were performed three times to work out an average figure and standard 
deviation. The results are shown in Figure 5.7. 
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Figure 5.7 Complementation assay of ΔICP0 HSV-1 in EBV protein expression cell lines. 
(A) Complementation assay of ∆ICP0 HSV-1 in HFT.myc.EBNA1, 
HFT.FLAG.BNRF1 and HFT.FLAG.EBNA-LP cells. Cells were induced by treatment 
with 100 ng/ml doxycycline for 24 h before infection. Induced cells were infected by 
∆ICP0 HSV-1 at different MOIs. After 4 h of infection, the cell medium was changed to 
DMEM with 100 ng/ml doxycycline and 1% human serum. At 24 h post infection, the 
infected cells were fixed and blue plaque assays were performed. Plaque formation 
efficiency data are expressed as fold-increase in absolute titre (PFU per ml) in each cell 
type over that in HFT cells. (B) Complementation assay of ∆ICP0 HSV-1 in 
HFT.EBNA1.EBNA-LP, HFT.EBNA1.BNRF1, HFT.EBNA-LP.BNRF1, HFT.EBNA-
LP.EBNA1.BNRF1 and HFT.EBNA-LP.EBNA1.pp71 cell lines. The infection protocols 
were as same as Figure 5.7 (A). The fold increases in plaque formation were measured 
against HFT cells. 
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Figure 5.7 (A) shows that expression of single EBV proteins stimulated ∆ICP0 HSV-1 
infection in each case. The mutant virus infections were only very slightly increased by 
expression of EBNA1 and to a greater but still relatively small degree by EBNA-LP. 
Meanwhile, BNRF1 increased the ∆ICP0 HSV-1 infection about 25-fold. These data 
indicate that the expression of EBV proteins can complement ∆ICP0 HSV-1 infection, but 
not as efficiently as ICP0. In Figure 5.7 (B), double EBV protein expression cell lines 
complemented ICP0 null HSV-1 infection to a greater degree. HFT.EBNA-LP.BNRF1 and 
HFT.EBNA1.BNRF1 cells complemented ∆ICP0 HSV-1 infection about 50-fold whereas 
simultaneously expressing EBNA1 and EBNA-LP increased ∆ICP0 HSV-1 infection only 
about 4-fold. Meanwhile, ∆ICP0 HSV-1 infection was substantially increased in induced 
HFT.EBNA-LP.EBNA1.BNRF1 cells. These results indicate that EBNA1, EBNA-LP and 
BNRF1 can cooperatively release at least some of the repression of ∆ICP0 HSV-1. These 
data are consistent with the hypothesis that the increased plaque formation of the ICP0 
mutant are due to the combined effects of these EBV proteins on ND10 components, but 
further work is required to confirm that these proteins have the reported ND10-related 
functions in these cell lines.  
The effect of substituting BNRF1 by pp71 was studied in the same complementation study. 
The HFT.EBNA-LP.EBNA1.pp71 cells increased the ∆ICP0 HSV-1 infection by about 
250-fold, which was very close to the 230-fold increase observed in HFT.EBNA-
LP.BNRF1.EBNA1cells. This observation indicates the possibility of interchangeable 
activity between BNRF1 and pp71 and is consistent with the prediction in section 5.1.2. 
Previously studies demonstrated the simultaneous expression of IE1 and pp71 in HFT cells 
can largely complement ∆ICP0 HSV-1 infection (Figure 4.9). The data in Figure 5.7 B also 
indicate that BNRF1 can be replaced by pp71 in complementing ICP0 null HSV-1 
infection. To further investigate the interchangeable role between pp71 and BNRF1, 
HFT.IE1.BNRF1 cells were constructed. The same complementation assay in Figure 5.7 
was performed on HFT.IE1.BNRF1 and HFT.ICP0 cells, and the results are shown in 
Figure 5.8. 
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Figure 5.8 Complementation assay on HFT, HFT.IE1.BNRF1 and HFT.ICP0 cells.  
Cells were treated with DMEM with 100 ng/ml doxycycline 24 h for induction. 
Induced cells were infected by ΔICP0 HSV-1 at sequential dilutions determined 
empirically to give countable numbers of plaques on each cell line. At 4 h post infection, 
cell medium was changed to DMEM with 100 ng/ml doxycycline and 1% human serum. 
After 24 h infection, the cells were fixed and blue plaque assays were performed for 
collecting the complementation efficiency data. This experiment was performed three 
times to obtain an average complementation data and standard deviation. The results are 
expressed as fold-increase in absolute titre (PFU per ml) in each cell type over that in HFT 
cells. 
 
IE1 and BNRF1 together increased the ∆ICP0 HSV-1 infection about 500-fold, which is 
about 20% of the activity of ICP0 in HFT.ICP0 cells. The previous data presented in 
section 4.3.3 showed that IE1 and pp71 together reached 50% of the activity of ICP0 in 
this assay. The above comparison analysis between pp71 and BNRF1 indicates the 
possibility that those two proteins might be interchangeable in HCMV infection. Thus, in 
the next section, BNRF1 expression cells were infected by pp71 null HCMV to further 
investigate the hypothesis in section 5.1.2. 
5.4 BNRF-1 complements pp71 null HCMV infection 
The hDaxx-ATRX complex represses the MIEP in the early stages of HCMV infection, 
and this repression can be overcome by HCMV tegument protein pp71 (Cantrell & 
Bresnahan, 2006; Lukashchuk et al., 2008; Saffert & Kalejta, 2006). BNRF1, the most 
abundant tegument protein in EBV (Johannsen et al., 2004), also interacts with hDaxx and 
disrupts the hDaxx-ATRX complex in the nucleus (Tsai et al., 2011). The 
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complementation assay in section 5.3 indicated the interchangeable function between pp71 
and BNRF1. Thus, it was interesting to investigate the potential of BNRF1 to substitute for 
the function of pp71 in HCMV infection to further compare these two tegument proteins. 
A complementation assay of ∆pp71 HCMV was performed on HFT, HFT.FLAG-BNRF1 
and HFT.TetR.myc-pp71 cells. The infection protocols and methods were similar to those 
described in section 4.8. Briefly, HFT.TetR, HFT.FLAG-BNRF1 and HFT.TetR.myc-pp71 
cells were induced and infected by pp71 null HCMV at different MOIs. The infected cells 
were incubated for 10 days to allow the formation of HCMV plaques. Then the HCMV 
plaque assay was performed using histochemical staining for UL44 and the plaque 
formation efficiency data were collected. The results are shown in Figure 5.9. 
 
 
Figure 5.9 Complementation assay of Δpp71 HCMV on HFT.FLAG-BNRF1 and 
HFT.TetR.myc-pp71 cell lines.  
Cells were induced with DMEM with 100 ng/ml doxycycline for 24 h before 
infection. Induced cells were infected at a series of MOIs. At 12 h post infection, the cell 
medium was changed to DMEM with 100 ng/ml doxycycline and 1% human serum. After 
10 days of infection, the infected cells were fixed and permeabilized for HCMV plaque 
assays. The results were firstly calculated as fold-increases in absolute titre (PFU per ml) 
in each cell type over that in HFT cells. In this experiment, the plaque forming efficiency 
of the mutant virus was increased by about 200-fold in pp71-expressing cells compared to 
HFT cells. Complementation efficiency by myc-pp71 was set as 100% and the relative 
complementing efficiency of BNRF1 was worked out against myc-pp71. The same 
experiment was performed three times to calculate the average and standard deviation. 
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BNRF1 complemented the ∆pp71 HCMV infection as efficiently as pp71 in Figure 5.9. 
The slightly increase of BNRF1 over that of pp71 might due to the different protein 
expression efficiency. The above complementation data was based on the plaque forming 
efficiency, which cannot provide direct information about HCMV gene expression. To 
investigate in more detail about the properties of BNRF1 in ∆pp71 HCMV infection, 
infected cell lysates were analysed by WB (Figure 5.10). 
 
 
Figure 5.10 WB analysis of ∆pp71 HCMV infection in HFT.FLAG-BNRF1 and 
HFT.TetR.myc-pp71 cell lines. 
Cells were induced by doxycycline treatment for 24 h, then the induced cells were 
infected by ∆pp71 HCMV at MOI 1 (titrated on HFT.TetR.myc-pp71 cells) for 12 h. Then 
the cell medium was changed to DMEM with 100 ng/ml doxycycline and 1% human 
serum. On consecutive days up to 4 days post infection, cell lysates were collected and 
probed by anti-pp71 mAb, anti-FLAG mAb, anti-IE1 mAb, anti-UL44 mAb and anti-
Tubulin mAb as indicated. The positions of molecular weight standards (in thousands) are 
indicated to the right of each panel. 
 
The WB analysis further confirmed that BNRF1 can complement ∆pp71 HCMV infection 
in HFT cells. Consistent with the HCMV plaque assays, expression of both IE1 and UL44 
in HFT.FLAG-BNRF1 cells was more efficient than in HFT.pp71 cells. The same 
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phenomenon was also noticed by observing the size of anti-UL44 mAb stained HCMV 
plaques that formed in pp71 and BNRF1 expression HFT cells (data not shown). 
5.5 Conclusion and discussion 
Previous data in chapter 3 found that expression of HCMV proteins IE1 and pp71 can 
recover about 50% of ICP0-null mutant HSV-1 infection, which indicates that β-herpes 
virus proteins can functionally replace an α-herpes virus protein. Chapter 4 investigated 
the properties of ICP0 in HCMV infection and demonstrated that ICP0 can complement 
pp71 null HCMV infection. Thus, ND10 interacting proteins from α-herpes virus and β-
herpes virus can be functionally interchangeable. Then, an interesting question is whether 
γ-herpes virus proteins that interact with ND10 can replace their counterparts in HSV-1 
and HCMV. 
The study in this chapter demonstrated the possibility of using EBV proteins that interact 
with ND10 to replace HCMV proteins and partially rescue ICP0 null HSV-1 infection. 
Three EBV proteins investigated in this study performed different functions in viral 
infection. EBNA-LP and BNRF1 are relevant to EBV latent infection and expressed in 
lytic stage, further more BNRF1 is also demonstrated to be important for lytic infection 
(Feederle et al., 2006; Finke et al., 1987). EBNA1 is important during EBV infection and 
replication, but is also commonly expressed during latency to enable genome replication 
and partition of EBV genomes during cell division (Raab-Traub, 2002). Those EBV 
proteins expressed to interact with ND10 members increased ICP0 null HSV-1 infection at 
different levels. Single expression of EBNA1, EBNA-LP or BNRF1 complemented ∆ICP0 
HSV-1 less efficiently than double and triple proteins expression. Thus, it is possible that 
the EBV proteins cooperatively interact with ND10 for complementing ∆ICP0 HSV-1 
infection.  
HFT.TetR.EBNA1 cells express EBNA1 efficiently but cannot disperse PML in this study. 
This was not consistent with a previous study that demonstrated that EBNA1 could 
degrade PML through an interaction with PML.IV (Sivachandran et al., 2010; 
Sivachandran et al., 2008). This might due to the difference between the expression cell 
lines that were used in these studies, or the expression of EBNA1 was insufficient for PML 
degradation in this study. Thus, that HFT cells expressing EBNA1 increased ∆ICP0 HSV-1 
infection only about 2-fold was within expectation. The other two EBV proteins, EBNA-
LP and BNRF1, were investigated and demonstrated to interact with Sp100 and hDaxx 
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respectively (Echendu & Ling, 2008; Ling et al., 2005; Tsai et al., 2011). Single 
expression of EBNA-LP or BNRF1 achieved better complementation efficiency of ICP0 
null HSV-1 than EBNA1. Co-expression of EBNA1 with EBNA-LP or BNRF1 increased 
∆ICP0 HSV-1 infection about 5- and 30-fold respectively, which are higher than each 
single EBV protein expression cell lines. Furthermore, simultaneous expression of EBNA-
LP and BNRF1complemented ∆ICP0 HSV-1 infection about 80-fold, which was the most 
efficient combination within the double EBV proteins expression cell lines. This might be 
related to the ND10 interaction efficiency of EBNA-LP and BNRF1, but due to the time 
limitation for these studies, further detail could not be provided at this stage. HFT cells 
expressing EBNA-LP, EBNA1 and BNRF1 complemented ICP0 null HSV-1 about 220-
fold that was about 10% to the ICP0 complementation in Figure 5.8. The previous 
investigation of HFT.TetR.myc-EBNA1 cells indicating the expressed myc-EBNA1 was 
insufficient for PML degradation and dispersion, which might contribute less than EBNA-
LP and BNRF1 in de-repression of ICP0 null HSV-1 infection. As introduced previously, 
more detail about the EBNA-LP and BNRF1 that was expressed in HFT.EBNA-
LP.EBNA1.BNRF1 cells is required for making further conclusions from this 
complementation study. But, a brief conclusion that could be generated in this stage is that 
the EBV ND10 interacting proteins could enhance or complement ICP0 null HSV-1 
infection by a considerable degree. 
Previous studies demonstrated that HCMV proteins pp71 and IE1 together can largely 
complement ICP0 null HSV-1 infection (Everett et al., 2013a). Therefore, to compare 
BNRF1 with pp71, the HCMV protein was co-expressed with EBV proteins in this study. 
The combinations examined were expression of BNRF1 with IE1, and EBNA1 and 
EBNA-LP with pp71. Due to the time limitations, there was no direct comparison 
performed between HFT.IE1.BNRF1 and HFT.IE1.pp71 in ∆ICP0 HSV-1 
complementation assays. HFT.EBNA-LP.EBNA1.pp71 cells were compared with 
HFT.EBNA-LP.EBNA1.BNRF1 cells directly on complementing ∆ICP0 HSV-1 infection. 
Plaque formation efficiencies were similar in these triple proteins expression cell lines and 
the results demonstrated that pp71 and BNRF1 are interchangeable in complementing 
∆ICP0 HSV-1 infection. Furthermore, that HFT.IE1.BNRF1 cells rescued 20% activity of 
ICP0 in ∆ICP0 HSV-1 complementation assays indicated the possibility of a similar 
cooperation mechanism between IE1/BNRF1 with IE1/pp71 to increase ∆ICP0 HSV-1 
infection. 
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A direct comparison assay was performed on HFT.FLAG-BNRF1 and HFT.myc-pp71 
cells in the complementation of ∆pp71 HCMV infection. The results demonstrated that the 
plaque formation efficiencies on HFT.FLAG-BNRF1 and HFT.myc-pp71 cells were 
similar. WB analysis of HCMV gene expression further confirmed the observation in the 
∆pp71 HCMV complementation study. Thus, with the data above, a brief conclusion that 
BNRF1 and pp71 are interchangeable could be made. 
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6 Summary, Discussion and Future Prospects 
6.1 Summary 
Intrinsic resistance of host cells to viral infection plays an important role in virus infection 
defence processes (Bieniasz, 2004).  The studies presented in this thesis aimed to 
contribute more detail to the understanding of the intrinsic resistance mechanisms. By 
cross interchange of viral proteins from different herpes virus, the interchangeable role of 
ICP0, pp71, IE1, BNRF1, EBNA1 and EBNA-LP was partially demonstrated. Those viral 
proteins from different herpes viruses that belong to α, β and γ herpes virus families have 
all been demonstrated to interact with ND10 (Ahn et al., 1998; Echendu & Ling, 2008; 
Everett et al., 2006; Hofmann et al., 2002; Sivachandran et al., 2010; Tsai et al., 2011). 
Previous work had indicated that IE1 and pp71 of HCMV can largely complement ∆ICP0 
HSV-1 infection (Everett et al., 2013a). Thus, to extend this investigation, ICP0 was 
investigated in ∆IE1 HCMV and ∆pp71 HCMV complementation assays. Furthermore, 
recent publications identified several EBV proteins that target ND10 during viral infection 
(Ling et al., 2005; Sivachandran et al., 2010; Tsai et al., 2011). Those proteins were also 
introduced into the ∆IE1 HCMV and ∆pp71 HCMV complementation assays to study the 
properties of EBV proteins in α and β herpes virus infections. With brief investigation, 
EBNA-LP, EBNA1 and BNRF1 were identified to stimulate ∆ICP0 HSV-1 infection and 
BNRF1 was demonstrated to complement ∆pp71 HCMV infection. These investigations 
indicated that herpes viruses could benefit from each other to de-repress gene expression, 
and in many cases it seems likely that this is related to their effects on ND10. This raises 
the possibility of developing a common anti-herpes virus treatment by interfering with the 
anti-ND10 functions of different herpes virus proteins. 
6.2 Discussion 
6.2.1 ND10 interacting proteins from different herpes virus 
families are Interchangeable 
Previous work indicated that functions of ICP0 from HSV-1 that counteract ND10 can be 
viewed as being functionally separated into two proteins in HCMV, IE1 and pp71 (Everett 
et al., 2013a). Tegument protein pp71 interacts with the hDaxx-ATRX complex and causes 
the degradation of hDaxx (Hwang & Kalejta, 2007; Saffert & Kalejta, 2006; 2007). 
Immediate early protein IE1 de-sumoylates and disperses PML and Sp100 during HCMV 
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infection and stimulates lytic infection (Ahn et al., 1998; Greaves & Mocarski, 1998; 
Korioth et al., 1996). The expression of IE1 and pp71 together rescued 50% of the activity 
of ICP0 in complementing ∆ICP0 HSV-1 infection (Everett et al., 2013a). In the reverse 
experiment, ICP0 was unable to complement ∆IE1 HCMV infection but successfully 
complemented ∆pp71 HCMV infection in human fibroblast cells. The above investigation 
demonstrated that there are HCMV specific functions of IE1 for stimulating HCMV lytic 
infection. Meanwhile, it was demonstrated that pp71 can be replaced by ICP0 during 
HCMV infection. Furthermore, the results also predicted that in vivo infection, at least in 
principle, HCMV and HSV-1 might benefit from each other for stimulating lytic infection.  
PML and Daxx depletion has been reported to improve IE1 null HCMV infection (Tavalai 
et al., 2008b). This previous publication collected the complementation data by monitoring 
IE2 expression efficiency in infected cells (Tavalai et al., 2008b). The paper suggested that 
∆IE1 HCMV infection is repressed by PML and Daxx and the repression can be overcome 
by depletion of PML or Daxx or both of them. However, no further information about 
early or late viral gene expression and viral particle generation was provided to support the 
conclusion. Thus, the knock down of ND10 components may stimulate IE2 expression but 
not complete HCMV replication. The data presented in section 4.5 provided more detail 
about IE1 null HCMV early and late gene expression in infected human fibroblast cells. It 
was confirmed that the absence (degradation of PML and Sp100 in induced HFT.ICP0 
cells) of PML and Sp100 increased IE2 expression but this was not sufficient for 
stimulation of abundant early and late gene expression. In other words, IE1 was still 
required for efficient HCMV infection and replication. Therefore, the IE1 must specifically 
interact with other HCMV proteins or genes to stimulate viral infection and this function is 
not replaceable by ICP0. 
EBV tegument protein BNRF1 interacts with the hDaxx-ATRX complex to stimulate viral 
infection (Tsai et al., 2011). It thus shares some of the same properties with pp71 such as 
interacting with the hDaxx-ATRX complex and being an abundant tegument protein in the 
viral structure (Hofmann et al., 2002; Lukashchuk et al., 2008; Tsai et al., 2014; Tsai et al., 
2011). The complementation assay of ∆pp71 HCMV indicated that BNRF1 can stimulate 
∆pp71 HCMV infection as efficiently as pp71, and the increases in ∆pp71 HCMV gene 
expression stimulated by BNRF1 and pp71 were also in the same scale. This further 
confirmed the interchangeable role of BNRF1 and pp71. Thus, hDaxx-ATRX complex 
interacting viral proteins from different herpes viruses are interchangeable for each other.  
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6.2.2 The integrity of ND10 is important for HSV-1 infection 
resistance  
Previous observations on ND10 interaction proteins from HCMV that stimulated ICP0 null 
HSV-1 infection (Everett et al., 2013a) indicated that antagonizing the major components 
of ND10 can contribute to the de-repression of ∆ICP0 HSV-1 infection. Chicken 
Adenovirus Gam1 protein was also reported to enhance ∆ICP0 HSV-1 infection through 
ND10 disruption (Everett et al., 2014), which further enhanced the notion that ND10 are 
important for resistance to HSV-1 infection at the cellular level. Thus, the ND10 
interaction proteins from EBV were introduced into the ∆ICP0 HSV-1 complementation 
assay to investigate the above notion and to study these EBV proteins’ properties. EBNA1 
was reported to interact with PML IV to disrupt ND10 and lower PML levels 
(Sivachandran et al., 2008). EBNA-LP is responsible for Sp100 displacement from ND10 
during EBV infection (Echendu & Ling, 2008). EBV tegument protein BNRF1 interacts 
with the hDaxx-ATRX complex to stimulate early gene expression (Tsai et al., 2011). 
Those EBV proteins were all involved in de-stabilizing ND10 during EBV infection and 
contribute to EBV lytic infection. Therefore, EBV proteins were single, double and triple 
expressed in HFT cells. HFT.EBNA1.EBNA-LP.BNRF1 cells complemented ∆ICP0 
HSV-1 infection about 220-fold over HFT cells, which is the highest increase among the 
EBV protein expression cell lines prepared in this study. This observation further 
confirmed that the ND10 components cooperatively repress HSV-1 infection. Due to the 
time limitation, further investigation cannot be performed at this stage. Furthermore, the 
intrinsic resistance mechanism of ND10 on EBV is not yet well studied. Thus, it is still 
possible that more EBV proteins are involved in the interaction with ND10 and de-repress 
the viral genome expression by interfering with intrinsic resistance. Whether those 
potential candidates could contribute to HSV-1 infection still needs to be investigated. 
6.2.3 IE1 and IE2 are essential for abundant HCMV gene 
expression 
In this study, the investigation on ICP0 complementation and re-activation of IE1 null 
HCMV infection indicated that IE2 requires IE1 to initiate abundant HCMV early and late 
gene expression. Previous research work had observed a similar phenomenon indicating 
that IE1 cooperates with IE2 to synergistically activate many viral promoters (Klucher et 
al., 1993; Malone et al., 1990; Stenberg et al., 1990). Other studies also indicated that 
neither IE1 nor IE2 are dispensable for efficient HCMV gene expression at low MOI 
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infection (Bresnahan & Shenk, 2000; Mocarski et al., 1996; White & Spector, 2005). 
Furthermore, a study of quiescent infection of ∆pp71 HCMV at low MOI on human 
fibroblast cells revealed expression of IE1 but not IE2 (Bresnahan & Shenk, 2000). The 
investigation of the YL series of IE1 mutants identified the amino acids located in the IE1 
YL2 region as being specifically and absolutely required for IE1 functions in stimulating 
HCMV infection. Previous research reported by White and Spector introduced a HCMV 
mutant virus that deleted 48 amino acids in exon 3 and that was impaired at low and high 
MOI infection (White & Spector, 2005). These authors also applied IE1 expression human 
fibroblast cells to rescue this mutant virus infection but this failed to overcome the 
complete defect of the virus, which further enhanced the notion that both IE1 and IE2 are 
required for lytic infection, and that the same mutation within the IE2 sequence might also 
impair HCMV infection. Unlike the use of mutant viruses, the inducible cell line system 
allows the effects of such mutations on IE1 functions to be studied in the presence of wt 
IE2. 
6.2.4 The mechanism by which herpes virus proteins that interact 
with the hDaxx-ATRX complex release viral gene expression 
A previous paper reported that the HCMV IE1 protein stimulates viral gene expression by 
antagonizing histone deacetylation (HDAC) (Nevels et al., 2004b). Tegument protein pp71 
was reported to induce the degradation of hDaxx, which recruits HDAC enzymes to 
repress target gene repression (Hollenbach et al., 2002; Li et al., 2000), to stimulate 
HCMV gene expression (Saffert & Kalejta, 2006). This indicated that the invaded viral 
DNA becomes tightly wrapped by nucleosomes with repressive chromatin marks through 
the activity of histone deacetylase enzymes that repress viral gene expression. The 
presence of hDaxx-ATRX within ND10, and the observation that quiescent HSV-1 
genomes are sequestered within ND10 (Everett et al., 2007) suggests a linkage between 
ND10 sequestration and histone deacetylation of viral genomes. By adding TSA (histone 
deacetylase inhibitor) during the IE1 null HCMV infection, viral gene expression was 
increased and viral production was rescued to wt HCMV levels, but this treatment did not 
affect wt HCMV infection (Nevels et al., 2004b). This phenomenon is consistent with the 
observation in section 4.8.2 that expressing pp71 in HFT cells prior to wt HCMV infection 
didn’t further increase the infection. Thus, the intrinsic repression from HDACs could be 
efficiently antagonized by IE1 and pp71 expressed by wt HCMV, whereas additional 
inhibition of HDACs cannot contribute to further gene expression stimulation. In this 
study, expression of IE1 before infection created a more convenient host environment for 
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HCMV infection by targeting sumoylated PML and Sp100. How this might relate to 
inhibition of HDACs remains to be determined. In the scenario of IE1 null HCMV infected 
HFT.ICP0 cells, there is evidence that ICP0 also interacts with HDAC enzymes, although 
it did not apparently inhibit their activity (Lomonte et al., 2004). There is considerable 
evidence that ICP0 promotes an open chromatin structure with acetylated histones 
(Ferenczy & DeLuca, 2009; 2011; Knipe & Cliffe, 2008), but it appears that TSA cannot 
substitute for ICP0 in the case of HSV-1 in HFs or HepaRG cells (Everett et al., 2008; 
Preston & Nicholl, 2006), although it can have ICP0-like effects in Vero cells and 
neurones (Scherer et al., 2014; Terry-Allison et al., 2007).  
One potential hypothesis that might explain some of these complex observations is to 
propose that stimulation by TSA can occur when repression is not complete. For example, 
in HFs and HepaRG cells, in absence of ICP0, HSV-1 genomes are highly repressed, but 
this is less true in Vero cells and neurones. Thus the chromatin structure might be more 
open in these, allowing TSA to work. In IE1 deficient HCMV, there is more IE gene 
expression than in ICP0 null HSV, so initial repression is not absolute (probably because 
of pp71). Thus TSA might stimulate IE1 deficient HCMV more efficiently than ICP0 null 
HSV-1. A testable prediction from this hypothesis is that TSA would increase ICP0 null 
HSV-1 infection more in pp71 expressing cells than in controls. 
IE1 and pp71 were reported to interfere with HDAC function during the immediate early 
stage of viral infection (Nevels et al., 2004b; Saffert & Kalejta, 2006). Furthermore 
hDaxx-ATRX complex interacting protein BNRF1 was reported to replace ATRX in 
ATRX-hDaxx-Histone H3.3 to facilitate EBV early infection (Tsai et al., 2014). The above 
observations indicate that herpes virus genomes are wrapped into a repressive chromatin 
structure and the ATRX-hDaxx complex plays a role in this process in host cells. The 
mutant viruses that deleted IE1, pp71 or ICP0 are unable to proceed to lytic infection at 
low MOI infection, but the infection could be rescued at high MOI (Bresnahan & Shenk, 
2000; Greaves & Mocarski, 1998; Stow & Stow, 1986). At low MOI infection, the viral 
genomes lack the proteins to open the viral genome into linear DNA for transcription and 
are sequestered within ND10. The expression of ND10 interacting proteins antagonizes the 
repression from ND10 and releases the viral genome into an open form for transcription. 
Whereas during high MOI infection, due to the large amount viral genomes released into 
nucleus, the cellular defence system that relies on ND10 is overloaded and some viral 
genomes overcome the intrinsic resistance of host cells to proceed to viral gene expression.  
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hDaxx co-localizes with PML by interaction with sumoylated PML via its SIM (Lin et al., 
2006). In IE1 expressing HepaRG cells, PML and Sp100 are desumoylated and dispersed 
and therefore negatively regulate hDaxx co-localization with ND10 (Everett et al., 2013a). 
Thus, the question is whether hDaxx can recruit ATRX in the cells that PML and Sp100 
are depleted or dispersed? If so, can this hDaxx-ATRX complex repress HCMV infection? 
A single experiment in this study answered part of the above questions. HFT.IE1 cells 
were infected with pp71 null HCMV in parallel with HFT.TetR.myc-pp71 cells. The 
HCMV plaque assay indicated that the induced HFT.IE1 cells cannot complement pp71-
null HCMV infection (data not shown). A previous investigation from the Thomas Shenk 
lab found expression of both IE2 and IE1 is severely depressed in ADsubUL82 infected 
cells at low MOI infection (Bresnahan & Shenk, 2000). IE1 expression de-sumoylated and 
dispersed PML and Sp100 and dispersed hDaxx in induced HFT.IE1 cells before 
ADsubUL82 infection. But it appears that the dispersed hDaxx can still recruit ATRX and 
repress the MIEP during ADsubUL82 infection. Thus, the IE2 gene was still poorly 
expressed. As the investigation demonstrated in section 4.5 and section 4.6, IE2 requires 
IE1 to stimulate early and late gene expression at low MOI HCMV infection. Furthermore, 
pp71 null HCMV infected HFT.IE1 cells cannot de-repress the MIEP from hDaxx-ATRX 
complex without pp71. Thus the IE2 was not expressed in the absence of pp71 and IE1 
was not capable of enhancing viral gene expression. From the above discussion, it 
indicates that IE1 and IE2 cooperatively stimulate HCMV gene expression and neither of 
them is dispensable for HCMV infection at low MOIs. 
6.3 Future Prospects 
6.3.1 Is the sequence located in IE1 YL2 important for IE2?  
The previous discussion indicated the possibility that IE1 and IE2 might interact or in some 
way act in concert through intermediate co-factors (section 4.9). The data in section 4.7.3 
identified the amino acids located at IE1 YL2 as essential for IE1 stimulating HCMV lytic 
infection but not important for IE1 sumoylation and desumoylating PML. Mutation sites of 
IE1 YL2 are also shared with IE2. Thus, the function of these amino acids in IE2 sequence 
is worth investigating.  
The investigation in this thesis demonstrated that pp71 is replaceable by ICP0 and BNRF1. 
Other reports also indicated that the depletion of ATRX or hDaxx can improve ∆pp71 
HCMV infection (Cantrell & Bresnahan, 2006; Lukashchuk et al., 2008; Tavalai et al., 
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2008b). Therefore, the interaction with the hDaxx-ATRX complex is an important property 
for pp71 during HCMV infection. Previous research data observed low levels of IE1 
expression during ∆pp71 HCMV low MOI infection but no IE2 was expressed (Bresnahan 
& Shenk, 2000). The accumulating data has demonstrated that IE2 expression is enhanced 
by the MIEP which is repressed by the hDaxx-ATRX complex (Baldick et al., 1997; Chau 
et al., 1999; Homer et al., 1999; Liu & Stinski, 1992). This repression could be released by 
pp71 (or ICP0 and BNRF1 in this study) through the interaction with hDaxx-ATRX 
complex, but not by IE1 in this study. Thus, expressing IE2 before ∆pp71 HCMV infection 
may possibly rescue the mutant virus infection, as the co-expression of IE1 and IE2 could 
create a scenario for maintaining expression of the HCMV genome even in the absence of 
pp71, where viral genes could be stimulated for expression before being repressed by the 
hDaxx-ATRX complex.  
6.3.2 ND10 interaction proteins from HSV-1 and HCMV are 
potentially interchangeable with their counterparts in EBV 
Chapter 6 demonstrated that ND10 interacting proteins from EBV can increase ∆ICP0 
HSV-1 infection and complement ∆pp71 HCMV infection. Furthermore, deletion of ND10 
components contributes to increased HCMV infection (Cantrell & Bresnahan, 2006; Glass 
& Everett, 2013; Lukashchuk et al., 2008; Tavalai et al., 2008b) and ICP0 expression 
achieved a similar increase in this study. Therefore there is accumulating evidence 
indicating the importance of ND10 integrity for intrinsic resistance to HCMV infection. 
Therefore, introducing ND10 interacting proteins into cells prior to EBV infection is likely 
to enhance the lytic viral infection and reduce the proportion of cells entering latent 
infection.  
BNRF1 was investigated in terms of replacing pp71 in HCMV infection in this study and 
this achieved very promising results. Both pp71 and BNRF1 are tegument proteins and 
interact with the hDaxx-ATRX complex. A recent publication indicates that BNRF1 
replaces ATRX in the ATRX-hDaxx-Histone 3.3 complex to remodel the hDaxx-Histone 
3.3 chaperone for stimulating EBV early infection (Tsai et al., 2014). Investigations on the 
very early stages of HCMV infection found that pp71 colocalizes with the ATRX-hDaxx 
complex and disperses ATRX earlier than hDaxx from ND10 (Lukashchuk et al., 2008). 
Thus, it is reasonable to predict similar interaction mechanisms between pp71 and BNRF1 
and the ATRX-hDaxx complex. Thus pp71 might initially replace the ATRX in the 
ATRX-hDaxx complex at a very early time of HCMV infection and then disperse the 
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hDaxx later through forming pp71-hDaxx complex. Furthermore, these similar properties 
between pp71 and BNRF1 make it worthwhile to investigate whether pp71 can replace 
BNRF1 in EBV infection, and this result could contribute to future efforts to target their 
inhibitory effects on the ATRX-hDaxx complex for developing more efficient anti-herpes 
virus medicinal treatments. 
6.3.3 Further analysis of the effects of EBV proteins on ND10 
Due to time limitations, it was not possible to investigate thoroughly the potential effects 
of EBV protein expression on specific ND10 components to clarify whether their reported 
roles in this context are reproduced in the cell lines constructed here. It is also possible that 
these proteins might affect the response of ND10 components to herpesvirus infection and 
their recruitment to the viral genomes. These studies will be necessary to indicate whether 
their abilities to stimulate ICP0 null mutant HSV-1 infection, in cell expressing EBNA-1, 
EBNA-LP and BNRF1 simultaneously, for example, are connected to ND10 dynamics or 
to some other function. 
6.3.4 A common anti-herpes virus infection target  
ICP0 and pp71 were demonstrated to be interchangeable in the context of HCMV infection 
this thesis. Furthermore, BNRF1 was also confirmed to replace pp71 in complementing 
∆pp71 HCMV and increasing plaque formation by ∆ICP0 HSV-1. These investigations 
indicate the possibility that HSV-1, HCMV and EBV are subject to the same cellular 
intrinsic resistance mechanisms caused by the hDaxx-ATRX complex and other ND10-
related events. Despite the fact that the various viral proteins show no sequence similarity, 
they have nonetheless evolved to target the same group of cellular proteins. This suggests 
that interference with the mechanisms of targeting the hDaxx-ATRX could be a potential 
drug design target for developing new treatment for broad anti-herpes virus infections. On 
the same theme, the region identified in mutant YL2 forms a specific structural loop region 
on the IE1 surface (Scherer et al., 2014)  which the results presented here strongly suggest 
is essential for IE1 activity. Thus assays that screen for small molecules that interact with 
this loop region might provide leads towards a novel HCMV therapeutic approach. 
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